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ABSTRACT  
For many years, it has been suggested that drugs that interfere with 
dopamine (DA) transmission alter the “rewarding” impact of primary reinforcers 
such as food.  Research and theory related to the functions of mesolimbic DA 
are undergoing a substantial conceptual restructuring, with the traditional 
emphasis on hedonia and primary reward yielding to other concepts and lines of 
inquiry.  The present research is focused upon the involvement of nucleus 
accumbens DA in effort-related choice behavior. Viewed from the framework of 
behavioral economics, the effects of accumbens DA depletions and antagonism 
on food-reinforced behavior are highly dependent upon the work requirements 
of the instrumental task, and DA depleted rats show a heightened sensitivity to 
response costs, especially ratio requirements. Moreover, interference with 
accumbens DA transmission exerts a powerful influence over effort-related 
choice behavior. Rats with accumbens DA depletions or antagonism reallocate 
their instrumental behavior away from food-reinforced tasks that have high 
response requirements, and show increased selection of low reinforcement/low 
cost options. Nucleus accumbens DA and adenosine interact in the regulation of 
effort-related functions, and other brain structures (anterior cingulate cortex, 
amygdala, ventral pallidum) also are involved. Studies of the brain systems 
regulating effort-based processes may have implications for understanding drug 
abuse, as well as symptoms such as psychomotor slowing, fatigue or anergia in 
depression and other neurological disorders. 
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RESUMEN 
Durante muchos años, se ha sugerido que drogas que interfieren con la 
transmisión de dopamina (DA) estarían alterando el impacto "gratificante" de los 
reforzadores primarios como la comida. Investigación experimental y 
aproximaciones teóricas respecto al estudio de las funciones de la DA en la vía 
mesolímbica están dando lugar a una restructuración conceptual sustancial en 
este campo, de manera que el énfasis tradicional en la hedonia y en el 
reforzamiento primario han quedado apartados dado paso a una nueva 
conceptualización y renovadas líneas de investigación.  
La presente investigación se centra en la implicación de la DA en el núcleo 
accumbens (Nacb) en tareas de elección basadas en el esfuerzo. Abordando esta 
cuestión desde el marco conceptual de la economía comportamental, los efectos 
de la depleción de DA en el Nacb y el antagonismo DAérgico sobre la conducta 
reforzada por comida dependen en gran medida de los requisitos de trabajo de la 
tarea. La depleción DAérgica en ratas ha demostrado causar una mayor 
sensibilidad a los costes de respuesta, en especial en tareas de elección con 
diferentes requerimientos de respuesta. Por otra parte, la alteración de la 
transmisión Daérgica en el Nacb ejerce una poderoso efecto sobre la conducta de 
elección basada en el esfuerzo. Las ratas con antagonismo o depleción DAérgica 
en el Nacb redirigen su conducta instrumental lejos de los alimentos percibidos 
como reforzantes pero que van asociados a las tareas que implican altos 
requerimientos de respuesta, mostrando mayor selección sobre opciones con 
menor requerimiento o coste de respuesta. Además de la implicación de otras 
estructuras cerebrales (corteza cingulada anterior, la amígdala, el área tegmental 
ventral) en estas funciones, la DA en el Nacb y el neuromodulador adenosina 
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interactúan en la regulación de las funciones relacionadas con el esfuerzo. Los 
estudios de los sistemas cerebrales que regulan los procesos de elección basado 
en el esfuerzo, pueden tener implicaciones para mejorar la comprensión del 
abuso de drogas, así como síntomas tales como retardo psicomotor, fatiga o 
anergia presentes en la depresión y otros trastornos neurológicos. 
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GENERAL INTRODUCTION 
In order to survive, organisms must gain access to significant stimuli 
such as food, water, sex and other conditions.  The processes involved in such 
behavioral activities are varied and complex, and the brain mechanism related to 
these processes are a subject of considerable research activity.  Instrumental 
learning processes involving reinforcement and punishment lead to the 
acquisition of behaviors that regulate the probability, proximity and availability 
of significant stimuli.  But even when such responses are already acquired, 
multiple factors contribute to the selection of particular instrumental behaviors 
in a given environmental context.  For example, in a complex environment, 
organisms typically have access to multiple reinforcers, which can vary in 
regards to their quality, quantity, and temporal characteristics.  In addition, 
distinct instrumental actions can be associated with particular reinforcers, and 
these actions can vary widely in topography, and in terms of the quantitative 
features of the response requirements.  Several areas of inquiry in behavioral 
science, including research on response-reinforcement matching, optimal 
foraging theory, and behavioral economics, have emerged in order to 
characterize the choice behavior observed in these complex environments 
(Baum, 1974; Allison, 1981, 1993; Salamone, 1987; Williams, 1988; Hursh et 
al., Tustin, 1995; 1988; Aparicio, 2001, 2007; Vuchinich and Heather, 2003; 
Hengeveld et al., 2009).  This research has provided approaches for 
understanding how reinforcement value, as well as response requirements, 
influence the relative allocation of instrumental behavior across multiple 
options.     
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This perspectives article will provide an overview of recent research on 
the behavioral pharmacology of a specific aspect of these broader issues.  One 
response-related factor that profoundly influences instrumental behavior is 
work-related response costs (Staddon 1979; Kaufman 1980; Kaufman et al. 
1980; Salamone, 1986, 1987, 1992; Hursh et al., 1988; Foltin 1991; Tustin, 
1995).  The present review will focus upon the effects of drugs and 
neurochemical manipulations that affect dopamine (DA) transmission, and how 
these effects interact with the response requirements, particularly ratio 
requirements, imposed upon food-reinforced instrumental behavior.  In addition, 
the article will review the literature on the role of DA in effort-related choice 
behavior, with a particular emphasis upon DA in a brain area known as the 
nucleus accumbens.  Finally, the interactions between nucleus accumbens DA 
and other neurotransmitters and brain areas will be discussed, and the broader 
relevance of these findings will be considered.  
HYPOTHESIZED ACTIONS OF DA ANTAGONISTS: THE 
“REWARD” HYPOTHESIS OF DA FUNCTION 
There have been substantial theoretical developments in the last few 
years related to the hypothesized behavioral functions of DA, particularly 
nucleus accumbens DA.  In order to consider the involvement of DA in work-
related aspects of instrumental response allocation, one should place these ideas 
into a historical context relative to other hypothesized functions of DA.  A few 
decades ago, it became common in the behavioral neuroscience literature to 
label DA as a “reward” transmitter, which was said to produce feelings of 
subjective pleasure or motivational appetites that mediate or drive positive 
reinforcement phenomena. However, it has become evident to many 
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investigators that there are conceptual limitations and empirical problems with 
the traditional DA hypothesis of “reward” (Salamone et al. 1997; 2005, 2007, 
2009, 2010; Barbano & Cador 2007; Baldo & Kelley 2007), not the least of 
which is the use of the term “reward” itself (Cannon & Bseikri 2004; Salamone 
et al. 2005; Salamone 2006; Sanchis-Segura & Spanagel 2006; Yin et al. 2008). 
The term “reward” is rarely defined by researchers when they are using it to 
describe a behavioral process. Some use the term as though it were a synonym 
for “reinforcement”, while others use it in reference to “appetite” or “primary 
motivation”.  Still others employ this term as a thinly veiled label for “pleasure”.  
In many cases, the word “reward” seems to be used as a rather monolithic, all-
encompassing term that refers globally to all aspects of reinforcement learning, 
motivation and emotion, whether conditioned or unconditioned.  If used in this 
manner, the term reward is so broad as to be practically meaningless.  It should 
be evident that it is difficult to test a hypothesis which maintains that a 
neurotransmitter mediates such an ill-defined set of functions. Thus, it has been 
suggested that it is advantageous to maintain the distinction between the terms 
reward and reinforcement; with this usage, reinforcement refers more directly to 
instrumental learning mechanisms (Wise 2004; Sanchis-Segura and Spanagel 
2006), while reward tends to connote the primary motivational and emotional 
effects of reinforcing stimuli (Salamone & Correa, 2002; Salamone et al. 2005, 
2007; Everitt & Robbins 2005). 
In addition to these lexicographical and conceptual issues, there also is a 
substantial body of empirical evidence that has been accumulated in recent 
years, which fails to support the various forms of the DA hypothesis of 
“reward”.  One ironic observation is that the processes most directly linked to 
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the use of the term reward (i.e., subjective pleasure, primary motivation) are 
ones that have been demonstrated to be most problematic in terms of 
demonstrating the involvement of DA systems (Salamone et al. 2007).  For 
example, the idea that nucleus accumbens DA mediates the subjectively reported 
pleasure associated with positive reinforcers has been strongly challenged 
(Salamone et al. 2007; Berridge 2007; Berridge & Kringlebach 2008). 
Interference with accumbens DA transmission does not impair appetitive taste 
reactivity for sucrose (Berridge 2007; Berridge & Kringlebach 2008), which is a 
frequently used behavioral marker of hedonic reactivity in rodents. Human 
studies have reported that DA antagonists failed to blunt the subjectively rated 
euphoria produced by drugs of abuse (Gawin 1986; Brauer & De Wit 1997; 
Haney et al. 2001; Nann-Vernotica et al. 2001; Wachtel et al. 2002).  Moreover, 
the potential role of DA systems in instrumental behavior or learning is not 
limited to situations involving positive reinforcement. There is considerable 
evidence that striatal mechanisms in general, and nucleus accumbens DA in 
particular, also participate in aspects of aversive learning, punishment, and 
responsiveness to aversive stimuli (Salamone 1994; Munro & Kokkinidis 1997; 
Blazquez et al. 2002; Pezze & Feldon, 2004; Delgado et al. 2008; Faure et al. 
2008; Martinez et al. 2008).  Although human imaging studies often are used to 
support the idea that nucleus accumbens mediates subjective pleasure (e.g. 
Sarchiapone et al.2006; Wacker et al. 2009), this is grossly oversimplified; 
indeed, research employing various imaging methods has demonstrated that the 
human nucleus accumbens also responds to stress, aversion and 
hyperarousal/irritability (Liberzon et al. 1999; Pavic 2003; Jensen et al. 2003; 
Phan et al. 2004; Pruessner et al., 2004; Levita et al. 2009; Delgado et al., 2008, 
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2011). Neurochemical and physiological studies in animals clearly indicate that 
DA neuron activity is not simply tied to the delivery of primary positive 
reinforcers. Rather, DA neuron activity and DA release can be activated by a 
number of different aversive (e.g. footshock, tailshock, tail pinch, restraint 
stress, aversive conditioned stimuli, aversive drugs, social defeat stress) and 
appetitive conditions (McCullough & Salamone 1992; McCullough et al. 1993; 
Guarraci and Kapp 1999; Young, 2004; Marinelli et al. 2005; Anstrom & 
Woodward 2005; Broom & Yamamoto 2005; Schultz 2007a, 2007b; Brischoux 
et al. 2009). These neurochemical changes are seen across varying time horizons 
(including tonic, slow phasic and fast phasic changes; Salamone 1996; Roitman 
et al., 2004; Schultz 2007a, 2007b; Salamone et al. 2007; Hauber 2010; Segovia 
et al., 2011).  Studies involving learning indicate that DA systems in general and 
nucleus accumbens in particular are not only involved in learning related to 
reinforcement (e.g. Wise, 2004), but also are involved in learning related to 
punishment (Shoenbaum and Setlow, 2003; Salamone et al., 2007). Thus, it has 
been suggested that the term “instrumental learning” would be more broadly 
applicable than “reinforcement learning” for describing the hypothesized role of 
DA in learning processes (Salamone et al., 2007).      
If DA antagonism is actually interfering with the fundamental 
characteristics of reinforcing stimuli, this prompts one to inquire as to what those 
characteristics are. Of course, reinforcement refers to behavioral contingencies 
that act to strengthen a particular behavior; positive reinforcement refers to a 
process by which a response is followed by the presentation of stimulus that 
typically is contingent upon that response, and these events are followed by an 
increase in the probability of the occurrence of that response in the future.  
 16 
However, it is worthwhile to consider what properties enable a stimulus to act as 
a reinforcer. As is often noted, Skinner did not often discuss the critical 
characteristics of stimuli that allow them to act as reinforcers. Nevertheless, 
Skinner did, on occasion, consider the role of motivational variables such as 
food deprivation in the process of reinforcement. For example, Skinner (1953, p 
149) stated "Reinforcement thus brings behavior under the control of an 
appropriate deprivation. After we have conditioned a pigeon to stretch its neck 
by reinforcing with food, the variable which controls the neck-stretching is food 
deprivation."  Many other investigators have offered their own perspectives on 
this issue, and it has been argued that there are some common characteristics that 
are evident across different researchers (Salamone & Correa, 2002).  A large 
number of investigators who have written about the fundamental characteristics 
of reinforcing stimuli have arrived at the conclusion that stimuli that act as 
positive reinforcers tend to be relatively preferred, or to elicit approach behavior, 
and that these effects are a fundamental aspect of positive reinforcement. For 
example, Tapp (1969; p 173) stated "At the simplest level, reinforcers have the 
capacity to direct an organism's behavior. Those stimuli that are approached are 
regarded as positively reinforcing".  Reinforcers have been described as a 
commodity that is in demand, or a stimulus that is being approached, self-
administered, attained or preserved; they also have been described as activities 
that are preferred, deprived or in some way being regulated (Premack, 1959; Lea 
1978; Hursh, 1988; Staddon & Ettinger, 1989; Timberlake, 1993; Dickenson and 
Balleine, 1994; Tustin, 1995; Salamone & Correa, 2002). According to the 
behavioral economic analysis offered by Hursh (1993; p 166) “responding is 
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regarded as a secondary dependent variable that is important because it is 
instrumental in controlling consumption”. 
For these reasons, it is important to note that low doses of DA 
antagonists that suppress food-reinforced instrumental behavior typically have 
been shown to leave behavior directed towards the acquisition and consumption 
of food (Salamone et al., 1991); these manipulations have little effect on food 
intake (Rolls et al., 1974; Fibiger et al., 1976; Salamone et al., 1991; Rusk & 
Cooper, 1994; Ikemoto & Panksepp, 1996), discrimination and preference based 
upon food reinforcement magnitude (Martin-Iversen et al., 1987; Salamone et 
al., 1994), and simple approach responses reinforced by food delivery (Ettenberg 
et al. 1981; Salamone 1986; Mekarski 1988). Although it is well known that 
whole forebrain DA depletions can produce aphagia (i.e., lack of eating), it is 
DA depletions in sensorimotor and motor-related areas of the lateral or 
ventrolateral caudate/putamen that have been most conclusively linked to this 
effect, rather than the nucleus accumbens (Ungerstedt 1971; Dunnett & Iversen 
1982; Salamone et al. 1993a). In contrast, nucleus accumbens DA depletion and 
antagonism have been shown repeatedly not to substantially impair food intake 
(Ungerstedt 1971; Koob et al. 1978; Bakshi & Kelley 1991; Salamone et al. 
1993a; Baldo et al., 2002; Kelley et al., 2005).  Moreover, the effects of DA 
antagonists or accumbens DA depletions on food-reinforced instrumental 
behavior do not closely resemble the effects of pre-feeding or appetite 
suppressant drugs (Salamone et al., 1991, 2002; Aberman & Salamone 1999; 
Sink et al., 2008).   
Although it has been suggested that the “reward-related” actions of low 
doses of DA antagonists or nucleus accumbens DA depletions should produce 
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effects that closely resemble extinction, this has not generally been observed in 
the literature (Faustman & Fowler, 1981, 1982; Gramling et al., 1984, 1987; 
Evenden & Robbins, 1983; Asin & Fibiger, 1984; Salamone 1986; Wirtschafter 
& Asin, 1985; Spivak and Amit, 1986; Willner et al., 1988; Feldon and Winer, 
1991; Salamone et al. 1995, 1997; Rick et al. 2006).  One example from this 
literature is Salamone (1986).  Although 0.1 mg/kg of the DA antagonist 
haloperidol severely reduced responding on a fixed ratio (FR) 20 schedule of 
lever pressing, a dose 4 times that size had no effect on the reinforced response 
of simply being in proximity to the food dish on a fixed interval 30 sec schedule 
(Salamone 1986).  The lack of effect of DA antagonism on this simple food-
reinforced response stands in marked contrast to the effect of extinction, which 
substantially suppressed the instrumental response (see Figure 1).  In this 
experiment (Salamone 1986), schedule-induced locomotor activity also was 
recorded in parallel with the instrumental response of being in proximity to the 
food dish.  Despite the fact that 0.4 mg/kg haloperidol did not affect the 
reinforced response, it did suppress the motor activity induced by scheduled 
presentation of food.  In combination with other studies, these results highlight 
several important features of the effects of DA antagonism.  First, the effects of 
DA antagonism do not closely resemble the effects of extinction across a broad 
range of conditions (Salamone et al., 1997). Second, DA antagonism suppressed 
schedule-induced motor activity, which is consistent with other studies focusing 
on the effects of DA antagonism or accumbens DA depletions (Robbins & 
Koob, 1980; Robbins et al., 1983; Wallace et al., 1983; Salamone 1988; 
McCullough & Salamone, 1992; Robbins & Everitt, 2007).  Finally, these results 
were consistent with the growing body of evidence indicating that the effects of 
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DA antagonists on instrumental behavior interact powerfully with the 
instrumental response requirement (Ettenberg et al., 1981; Mekarski, 1989).   
THE EFFECTS OF DA ANTAGONISM AND ACCUMBENS DA 
DEPLETION INTERACT WITH THE INSTRUMENTAL RESPONSE 
REQUIREMENTS 
In parallel with the historical developments described above, during the 
1970s to the 1990s there was an emerging emphasis in the behavioral literature 
on effort, response costs or constraints, and economic models of operant 
behavior.  Several investigators emphasized how response costs or constraints 
affected operant response output (Staddon 1979; Kaufman 1980; Kaufman et al. 
1980; Foltin 1991; Tustin, 1995).  Work requirements, such as the number of 
lever presses necessary for obtaining food, were shown to act as determinants of 
instrumental response output, and also to affect food consumption (Collier & 
Jennings, 1969; Johnson & Collier 1987).  Behavioral economic models stress 
how a number of factors, including not only reinforcement value, but also 
conditions related to the characteristics of the instrumental response, can 
determine behavioral output (Lea, 1978; Allison, 1981, 1993; Bickel et al., 
2000). Hursh et al. (1988) suggested that the price of food reinforcement as a 
commodity is a cost/benefit ratio expressed as the effort expended per unit of 
food value consumed.   
Several lines of evidence have served to strengthen support for the 
hypothesis that the effects of interference with DA transmission interact 
powerfully with the instrumental response requirement.  One of the ways of 
controlling work requirements in an operant schedule is to use various ratio 
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schedules.  Caul & Brindle (2001) observed that the effects of the DA antagonist 
haloperidol on food-reinforced behavior were dependent upon the ratio 
requirement, with a FR1 schedule being less sensitive than a progressive ratio. 
One can deplete accumbens DA by local injections of a neurotoxic substance 
such as 6-hydroxydopamine, and several studies have used this approach.  
Aberman & Salamone (1999) employed a range of ratio schedules (FR1, 4, 16 
and 64) to assess the effects of accumbens DA depletions.  While FR1 
performance was not affected by DA depletion (see also Ishiwari et al., 2004), 
and FR4 responding showed only a mild and transient suppression, the FR16 and 
FR64 schedules were much more impaired.  This pattern indicated that 
accumbens DA depletions promoted the induction of ratio strain, i.e., rats with 
accumbens DA depletions were much more sensitive to the size of the ratio 
requirement.  This pattern can be described as reflecting an increase in the 
elasticity of demand for food reinforcement (Salamone et al. 1997, 2009; 
Aberman & Salamone 1999). If the ratio requirement is analogous to the price of 
the commodity (reinforcement pellets), it appears that rats with accumbens DA 
depletions are more sensitive than control animals to the price of the food 
reinforcers.  Needless to say, rats do not use currency to purchase operant 
pellets. Instead, it has been suggested that an operant procedure is more of a 
barter system, in which the rat trades its work (or reductions in leisure) for a 
commodity (Tustin, 1995; Rachlin 2003). Thus, rats with accumbens DA 
depletions are more sensitive than control animals to work-related response 
costs, and less likely to trade high levels of ratio output for food.  In a 
subsequent experiment, Salamone et al., (2001) reported that increased 
sensitivity to larger ratio requirements in rats with accumbens DA depletions 
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were observed when rats were tested across a broader range of ratio schedules as 
high as FR300, even when the overall relation between lever pressing and food 
delivered per lever press was kept constant (i.e., an FR50 density of 
reinforcement, with 1 pellet every 50 responses; 2 pellets every 100 responses on 
the FR100; 4 pellets for every 200 responses on the FR200; and 6 pellets every 
300 responses for the FR300). These results showed that both the magnitude and 
the organization of the ratio requirement appear to be critical determinants of the 
sensitivity of an operant schedule to the effects of accumbens DA depletions.  
Additional experiments examined the effects of accumbens DA 
depletions on tandem schedules, in which a ratio requirement was attached to an 
interval requirement. This was done in order to ensure that the results by 
Aberman & Salamone (1999) and Salamone et al. (2001) reflected the influence 
of ratio size, as opposed to other variables such as time.  Research employing 
tandem VI/FR schedules with varying combinations (e.g. VI 30 sec/FR5, VI 60 
sec/FR10, VI 120 sec/FR10) has yielded a consistent pattern; accumbens DA 
depletions did not suppress overall response output in rats responding on the 
conventional VI schedules (i.e., those requiring only one response after the 
interval), but did substantially reduce responding on the corresponding VI 
schedule with the higher ratio requirement attached (Correa et al. 2002; Mingote 
et al. 2005). These findings are consistent with research showing that accumbens 
DA antagonism did not impair performance on a progressive interval task 
(Wakabayashi et al. 2004), and suggest that interval requirements per se do not 
pose a severe constraint to rats with compromised DA transmission in nucleus 
accumbens. These studies emphasize that, over and above any effect of 
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intermittence or time, ratio requirements provide a work-related challenge that is 
very disruptive to rats with accumbens DA depletions or antagonism.  
Taking all these results together, nucleus accumbens DA depletions 
appear to have two major effects on ratio responding: 1) they reduce the 
response-enhancing effects that moderate-size ratio requirements have on 
operant responding (i.e., the ascending limb of the inverted-u-shaped function 
relating ratio requirement to response output), and 2) they enhance the response-
suppressing effects that very large ratios have on operant respnding (i.e., the 
descending limb of the function; enhancement of ratio strain; Salamone & 
Correa 2002; Salamone et al., 2007, 2009).  In addition, more molecular 
behavioral analyses indicate that accumbens DA depletions produce a slight 
reduction in the local rate of responding, as indicated by the distribution of 
interresponse times (Salamone et al. 1993b, 1999; Mingote et al. 2005), as well 
as an increase in pausing (Salamone et al. 1993b; Mingote et al. 2005; see also 
Nicola, 2010).   Computational approaches have been used to characterize these 
effects of accumbens DA depletions on response rate on ratio schedules (e.g. 
Niv et al. 2007; Phillips et al. 2007). According to Phillips et al., (2007), DA 
release in nucleus accumbens appears to provide a window of opportunistic 
drive during which the threshold cost expenditure to obtain the reward is 
decreased (Phillips et al. 2007). 
In the context of this discussion of the effects of dopaminergic drugs on 
ratio performance, it is useful to consider the term “reinforcement efficacy”, 
which is sometimes used to describe the effects of drug manipulations on ratio 
performance. With progressive ratio schedules, the ratio requirement increases 
as successive ratios are completed, and the “break point” is said to occur at the 
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point at which the animal stops responding.   One can operationally define 
reinforcement efficacy in terms of the break point in a progressive ratio 
schedule, or by measuring ratio strain in rats responding across different FR 
schedules.  The determination of reinforcement efficacy can be a very useful tool 
for characterizing the actions of drugs that are self-administered, and for 
comparing self-administration behavior across different substances or drug 
classes (e.g., Marinelli et al. 1998; Woolverton and Rinaldi, 2002; Morgan et al., 
2002; Ward et al., 2005).  Nevertheless, given the terminological difficulties 
discussed above, it is useful to stress that the term “reinforcement efficacy” 
should not be used simply as a replacement for “reward”, and that progressive 
ratio breakpoints should not be viewed as necessarily providing some direct and 
unambiguous measure related to the subjective pleasure produced by the 
stimulus (Salamone, 2006; Salamone et al., 2009).  Drug-induced changes in 
progressive ratio break points can reflect actions on several different behavioral 
and neurochemical processes (Arnold & Roberts, 1997; Hamill et al., 1998; 
Lack et al., 2008).  For example, changing the response requirements by 
increasing the height of the lever decreased progressive ratio break points 
(Skjoldager et al., 1993; Schmelzeis & Mittleman 1996).  Although some 
researchers have maintained that the break point provides a direct measure of the 
appetitive motivational characteristics of a stimulus, it is, as stated in a landmark 
review by Stewart (1974), more directly a measure of how much work the 
organism will do in order to obtain that stimulus.  The animal is making a 
cost/benefit choice about whether or not to continue to respond, based partly on 
factors related to the reinforcer itself, but also upon the work-related response 
costs and time constraints imposed by the ratio schedule.  For these reasons, 
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interpretations of the actions of drugs or lesions on progressive ratio break points 
should be done with caution, as should be the case for any individual task.  A 
drug that alters the break point could do so for many different reasons. For 
example, recent studies have shown that the DA antagonist haloperidol can 
suppress food-reinforced progressive ratio responding, and lower break points, 
but nevertheless leave intact the consumption of a concurrently available but less 
preferred food source (Randall et al. 2011b; Pardo et al., 2011).  These actions of 
haloperidol on this task differed markedly from those produced by pre-feeding 
and appetite suppressant drugs (Randall et al. 2011b; Pardo et al., 2011). 
DA ANTAGONISM AND NUCLEUS ACCUMBENS DA 
DEPLETIONS AFFECT THE RELATIVE ALLOCATION OF 
INSTRUMENTAL RESPONDING IN EFFORT-RELATED CHOICE 
TASKS 
As noted above, animals must make choices in complex environments 
that present multiple opportunities for obtaining significant stimuli, and several 
paths for accessing them (Williams, 1988; Aparicio, 2001, 2007). The variables 
that influence these choices are complex and multidimensional, and they include 
not only reinforcement value, but also response-related factors. Among the most 
important are those factors involving cost/benefit interactions based upon effort 
and reinforcement value (Neill & Justice, 1981; Hursh et al., 1988; Salamone & 
Correa 2002; Salamone et al. 2003, 2005, 2007; van den Bos et al. 2006; Walton 
et al. 2006; Salamone, 2010).  Considerable evidence indicates that low systemic 
doses of DA antagonists, as well as local disruption of nucleus accumbens DA 
transmission, affect the relative allocation of behavior in animals responding on 
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tasks that assess effort-based choice behavior (Salamone et al. 2003, 2005, 2007; 
Floresco et al. 2008a,b; Hauber & Sommer 2009).   
One task that has been used to assess the effects of dopaminergic 
manipulations on response allocation is a procedure that offers rats the option of 
lever pressing reinforced by delivery of a relatively preferred food (e.g. Bioserve 
pellets; usually obtained on a FR5 schedule), or approaching and consuming a 
less preferred food (lab chow) that is concurrently available in the chamber 
(Salamone et al., 1991). Trained rats under baseline or control conditions get 
most of their food by lever pressing, and consume only small quantities of chow.  
Low-to-moderate doses of DA antagonists, which block either D1 or D2 family 
receptor subtypes (cis-flupenthixol, haloperidol, raclopride, eticlopride, SCH 
23390, SKF83566, ecopipam), produce a substantial alteration of response 
allocation in rats performing on this task; they decrease food-reinforced lever 
pressing but substantially increase intake of the concurrently available chow 
(Salamone et al. 1991, 1996, 2002; Cousins et al., 1994; Koch et al., 2000; Sink 
et al. 2008; Worden et al. 2009).  The use of this task for assessing effort-related 
choice behavior has been validated in many ways.  Doses of DA antagonists that 
produce the shift from lever pressing to chow intake do not affect total food 
intake or alter preference between these two specific foods in free-feeding 
choice tests (Salamone et al. 1991; Koch et al., 2000).  In contrast, appetite 
suppressants from different classes, including amphetamine (Cousins et al. 
1994), fenfluramine (Salamone et al., 2002) and cannabinoid CB1 antagonists 
(Sink et al. 2008), failed to increase chow intake at doses that suppressed lever 
pressing. Similarly, pre-feeding reduced both lever pressing and chow intake 
(Salamone et al. 1991).  Furthermore, with higher ratio requirements (up to FR 
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20, or progressive ratios), animals that are not drug treated shift from lever 
pressing to chow intake 
 (Salamone et al. 1997; Randall et al., 2011b; Pardo et al., 2011), 
indicating that this task is sensitive to work load. These results indicate that 
interference with DA transmission does not simply reduce food intake, but 
instead acts to alter response allocation between alternative sources of food that 
can be obtained through different instrumental responses.  
The shift from lever pressing to chow intake in rats performing on this 
task is associated with DA depletions in nucleus accumbens; decreases in lever 
pressing and increases in chow intake occur as a result of accumbens DA 
depletions, as well as local injections of D1 or D2 family antagonists into either 
the core or shell subregions of nucleus accumbens (Salamone et al. 1991; 
Cousins et al. 1993; Cousins & Salamone 1994; Sokolowski & Salamone 1998; 
Koch et al. 2000; Nowend et al., 2001; Farrar et al., 2010). Thus, although lever 
pressing is decreased by accumbens DA antagonism or depletions, these rats 
show a compensatory reallocation of behavior and select a new path to an 
alternative food source.   
Salamone et al. (1994) also developed a T-maze procedure, in which the 
two choice arms of the maze lead to different reinforcement densities (e.g. 4 vs. 
2 food pellets, or 4 vs. 0); under some conditions, a barrier can be placed in the 
arm with the higher density of food reinforcement to present an effort-related 
challenge.  When the high density arm has the barrier in place, and the arm 
without the barrier contains fewer reinforcers, DA depletions or antagonism 
decrease choice for the high density arm, and increase selection of the low 
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density arm with no barrier (Salamone et al., 1994; Cousins et al., 1996; Denk et 
al. 2005; Mott et al., 2009; Pardo et al., 2012).  Like the operant concurrent 
choice task, this T-maze task also has undergone considerable behavioral 
validation and evaluation (Salamone et al., 1994; Cousins et al., 1996; van den 
Bos et al., 2006; Pardo et al., 2012). For example, when there is no barrier in the 
maze, rodents overwhelmingly prefer the high reinforcement density arm, and 
neither haloperidol nor accumbens DA depletion alters their response choice 
(Salamone et al., 1994).  When the arm with the barrier contained 4 pellets, but 
the other arm contained no pellets, rats with accumbens DA depletions still 
managed to choose the high density arm, climb the barrier, and consume the 
pellets (Cousins et al., 1996). In a recent T-maze study with mice, while 
haloperidol reduced choice of the arm with the barrier, this drug had no effect on 
choice when both arms had a barrier in place (Pardo et al., 2012).  Thus, 
dopaminergic manipulations do not alter the preference for the high density of 
food reward over the low density, and did not affect discrimination, memory or 
instrumental learning processes related to arm preference. The results of the T-
maze studies in rodents, together with the findings from the FR5/chow 
concurrent choice studies reviewed above, indicate that low doses of DA 
antagonists and accumbens DA depletions cause animals to reallocate their 
instrumental response selection based upon the response requirements of the 
task, and select lower cost alternatives for obtaining reinforcers (see reviews by 
Salamone et al., 2003, 2005, 2007; Floresco et al. 2008a). 
Effort discounting procedures also have been employed to study the 
effects of dopaminergic manipulations.  Floresco et al. (2008b) demonstrated 
that the DA antagonist haloperidol altered effort discounting even when the 
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effects of time delay were controlled for (Floresco et al. 2008b).  Bardgett et al. 
(2009) recently developed a T-maze effort discounting task, in which the amount 
of food in the high density arm of the maze was diminished each trial on which 
the rats selected that arm (i.e., an “adjusting-amount” discounting variant of the 
T-maze procedures, which allows for the determination an indifference point for 
each rat).  Effort discounting was altered by the D1 family antagonist SCH23390 
and the D2 family antagonist haloperidol; these drugs made it more likely that 
rats would choose the low reinforcement/low cost arm.  Increasing DA 
transmission by administration of amphetamine blocked the effects of 
SCH23390 and haloperidol, and also biased rats towards choosing the high 
reinforcement/high cost arm, which is consistent with operant choice studies 
using DA transporter knockdown mice (Cagniard et al., 2006).  Together with 
other results, the findings reported by Bardgett et al. (2009) and Floresco et al. 
(2008b) support the suggestion that, across a variety of conditions, DA 
transmission exerts a bidirectional influence over effort-related choice behavior. 
DA INTERACTS WITH OTHER TRANSMITTERS TO 
INFLUENCE EFFORT-RELATED CHOICE BEHAVIOR 
As reviewed above, DA antagonists and accumbens DA depletions affect 
instrumental response output, response allocation, and effort-related choice 
behavior.  Obviously, no single brain area or neurotransmitter participates in a 
behavioral process in isolation to other structures or chemicals; for that reason it 
is important to review how other brain areas and neurotransmitters interact with 
dopaminergic mechanisms.  Over the last several years, several laboratories have 
begun to characterize the role that multiple brain structures (e.g. amygdala, 
anterior cingulate cortex, ventral pallidum) and neurotransmitters (adenosine, 
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GABA) play in effort-related choice behavior (Walton et al., 2002, 2003; Denk 
et al., 2005; Schweimer and Hauber, 2006; van den Bos et al. 2006; Floresco and 
Ghods-Sharifi 2007; Floresco et al., 2008a; Hauber & Sommer 2009; Farrar et 
al., 2008; Mott et al. 2009; Pardo et al., 2012). 
Within the last few years, considerable emphasis has been placed upon 
DA/adenosine interactions.  Caffeine and other methylxanthines, which are 
nonselective adenosine antagonists, act as minor stimulants (Ferré et al. 2008; 
Randall et al., 2011a).  DA-rich brain areas, including the neostriatum and the 
nucleus accumbens, have a very high degree of adenosine A2A receptor 
expression (Schiffmann et al. 1991; DeMet and Chicz-DeMet, 2002; Ferré et al. 
2004). There is considerable evidence of cellular interactions between DA D2 
and adenosine A2A receptors (Fink et al. 1992; Ferré 1997; Hillion et al. 2002; 
Fuxe et al. 2003).  This interaction frequently has been studied in regard to 
neostriatal motor functions related to Parkinsonism (Ferré et al. 1997, 2001; 
Hauber & Munkel 1997; Svenningsson 1999; Hauber et al. 2001; Wardas et al. 
2001; Morelli and Pinna 2002; Correa et al. 2004; Pinna et al. 2005; Ishiwari et 
al. 2007; Salamone et al. 2008a, 2008b).  However, several reports also have 
characterized aspects of adenosine A2A receptor function related to learning 
(Takahashi et al. 2008), anxiety (Correa and Font 2008), and instrumental 
responding (Font et al., 2008; Mingote et al. 2008).   
Drugs that act upon adenosine A2A receptors profoundly affect 
instrumental response output and effort-related choice behavior (Farrar et al. 
2007, 2010; Mingote et al. 2008; Font et al. 2008; Worden et al. 2009; Mott et 
al. 2009; Pardo et al. 2012). Intra-accumbens injections of the adenosine A2A 
agonist CGS 21680 reduced responding on a variable interval 60 sec schedule 
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with a FR10 requirement attached, but did not impair performance on a 
conventional variable interval 60 sec schedule (Mingote et al. 2008), a pattern 
similar to that previously shown with accumbens DA depletions (Mingote et al. 
2005).  In rats responding on the FR5/chow feeding concurrent choice 
procedure, injections of CGS 21680 into the accumbens decreased lever pressing 
and increased chow intake (Font et al. 2008).  This effect was site specific, 
because injections of CGS 21680 into a control site dorsal to the accumbens had 
no effect.   
It also has been demonstrated that adenosine A2A receptor antagonists 
can reverse the effects of systemically administered DA D2 antagonists in rats 
tested on the FR5/chow feeding concurrent choice task (Farrar et al. 2007; 
Worden et al. 2009; Salamone et al. 2009; Nunes et al., 2010).  Moreover, 
systemic or intra-accumbens injections of the adenosine A2A antagonist MSX-3 
were able to block the effects of intra-accumbens injections of the D2 antagonist 
eticlopride in rats responding on the FR5/chow concurrent choice task (Farrar et 
al., 2010).  In studies using the T-maze barrier procedure, adenosine A2A 
antagonists have been shown to reverse the effects of DA D2 antagonism in rats 
(Mott et al., 2009) and mice (Pardo et al., 2012). Furthermore, adenosine A2A 
receptor knockout mice are resistant to the effects of haloperidol on selection of 
the high reinforcement/high cost arm of the T-maze (Pardo et al., 2012).  
The pattern of effects seen in these studies depends upon which specific 
receptor subtypes are being acted upon by the drugs being administered. 
Although the adenosine A2A receptor antagonists MSX-3 and KW 6002 reliably 
and substantially attenuate the effects of D2 antagonists such as haloperidol and 
eticlopride in rats responding on the FR5/chow concurrent choice procedure 
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(Farrar et al. 2007; Worden et al. 2009; Salamone et al. 2009; Nunes et al., 
2010), they produce only a mild reversal of the effects of the D1 antagonist 
ecopipam (SCH 39166; Worden et al. 2009; Nunes et al., 2010).  In addition, the 
highly selective adenosine A1 receptor antagonist was completely ineffective at 
reversing the effects of DA D1 or D2 antagonism (Salamone et al. 2009; Nunes et 
al., 2010). Similar results were obtained with rats and mice responding on the T-
maze barrier choice task; while MSX-3 was able to reverse the effect of the D2 
antagonist haloperidol on selection of the high reinforcement/high cost arm, the 
A1 antagonists DPCPX and CPT were not (Mott et al. 2009; Pardo et al., 2012). 
These results indicate that there is a relatively selective interaction between 
drugs that act upon DA D2 and adenosine A2A receptor subtypes.  Based upon 
anatomical studies, it appears that this is likely to be due to the pattern of cellular 
localization of adenosine A1 and A2A receptors in striatal areas, including the 
nucleus accumbens (Fink et al. 1992; Ferré 1997; Svenningsson et al. 1999; 
Hillion et al. 2002; Fuxe et al. 2003). Adenosine A2A receptors are typically co-
localized on striatal and accumbens enkephalin-positive medium spiny neurons 
with DA D2 family receptors, and both receptors converge onto the same 
intracellular signaling pathways.  Thus, adenosine A2A receptor antagonists may 
be so effective in reversing the actions of D2 antagonists because of direct 
interactions between DA D2 and adenosine A2A receptors located on the same 
neurons (Farrar et al., 2010; Salamone et al., 2009, 2010). 
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FIGURE 2 | Anatomical diagram depicting the pattern of DA and adenosine 
receptor localization in nucleus accumbens. See text for details (see also Ferré, 
1997; Hillion et al., 2002; Fuxe et al., 2003). mGP, medial globus pallidus; epn, 
entopeduncular nucleus; s. nigra, substantia nigra; VTA, ventral tegmental area. 
 
SUMMARY AND CONCLUSIONS: IMPLICATIONS FOR 
BEHAVIOR ANALYSIS AND PSYCHOPATHOLOGY 
One possible contribution that the fields of psychopharmacology and 
behavioral neuroscience can make to behavioral analysis and theory is to use 
manipulations, such as drugs and lesions, in order to dissociate complex 
behavioral processes into components (Salamone et al. 2007, 2009).  A measure 
derived from observations of behavior, or a parameter that is generated from 
curve-fitting analyses has many factors that contribute to it, and pharmacological 
research often can dissociate between these factors, because a drug can severely 
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affect one while leaving another basically intact. A useful example of this 
principle is the progressive ratio break point, which, as discussed above, is 
influenced by several factors (Randall et al., 2011b; Pardo et al., 2011).  Another 
case in which this point is highly relevant is the measurement of intracranial 
self-stimulation thresholds.  Such measures often are viewed as providing “rate-
free” indices of “reward”, or even “hedonia”, nevertheless, they are influenced 
by lever pressing ratio requirements as well as the electrical current level 
(Fouriezos et al. 1990).  Recent studies with intracranial self-stimulation 
thresholds indicate that dopaminergic modulation of self-stimulation thresholds 
does not affect reward value per se, but instead alters the tendency to pay 
response costs (Hernandez et al. 2010).  Response-reinforcement matching also 
has been used in some research related to behavioral economics, reinforcer 
value, and the functions of DA systems (e.g. Heyman & Monaghan 1987; 
Aparicio 2007).  Matching equations have been employed to describe the results 
of studies with both conventional and concurrent VI schedules, and one of the 
parameters (Re) can be used to represent reinforcement value (e.g., Herrnstein 
1974; see equation below for single-lever conventional VI schedules, in which B 
represents response rate, R represents reinforcement density, k is the constant for 
maximal responding, and Re represents the reinforcement level that generates 
50% of maximum responding; B = k R/(R + Re)). However, used in this way, Re 
does not selectively represent the reinforcement value of food per se; actually, it 
reflects the relative value of entire activity of lever pressing for and consuming 
the food reinforcer compared to the reinforcing value of all other stimuli and 
responses available (Williams, 1988; Salamone et al. 1997, 2009).  Several 
factors can contribute to this composite measure, which is one of the reasons 
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why other matching equations have been developed that account for deviations 
from matching by allowing for estimates of reinforcer sensitivity, as well as 
response preference or bias (Baum 1974; Williams 1988; Aparicio 2001).  
Clearly, a drug or lesion manipulation could yield apparent effects on 
“reinforcement value” that actually reflect changes in response-related factors 
(Salamone 1987; Salamone et al. 1997, 2009).   
In view of these points, it is useful to consider how terms such as value 
are used in behavioral economics and neuroeconomics research.  The aggregate 
reinforcement value of an instrumental activity (e.g. lever pressing for and 
consuming food) should probably be viewed as a composite measure that 
includes both the reinforcing value of the reinforcer itself, and also any net value 
or costs associated with the instrumental response that is required to obtain the 
reinforcer. Viewed in this manner, the effects of DA antagonists or depletions on 
effort-related choice behavior could be described in terms of actions upon the 
response costs associated with the particular instrumental response, rather than 
the reinforcing value of the food stimulus itself.  Although the effects of 
haloperidol on bias may be minimal when two levers that are relatively similar 
are used (e.g. Aparicio 2007), they may be much larger when substantially 
different responses are compared (e.g. lever pressing vs. nose poking or sniffing; 
lever pressing vs. unrestricted access to food; barrier climbing vs. locomotion to 
a location containing food).  
In addition to providing insights into aspects of instrumental behavior 
seen in the laboratory, research on effort-related choice behavior also has 
clinical implications.  Addiction is characterized by a re-organization of the 
preference structure of the person, and also by a dramatic change in the 
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allocation of behavioral resources towards the addictive substance. Typically, 
there is a heightened tendency to engage in drug-reinforced instrumental 
behavior, and drug consumption, often at the expense of other behavioral 
activities.  Thus, drug –reinforced instrumental behavior in humans involves 
many processes, including exertion of effort.  Addicts will go to great lengths to 
obtain their preferred drug, overcoming numerous obstacles and constraints. 
As well as being related to aspects of drug taking and addiction, research 
on effort-related choice behavior has implications for understanding the neural 
basis of psychiatric symptoms such as psychomotor slowing, anergia, fatigue 
and apathy, which are seen in depression as well as other psychiatric or 
neurological conditions (Salamone et al. 2006, 2007).  These symptoms, which 
can have devastating behavioral manifestations (Stahl 2002; Demyttenaere et al. 
2005), essentially represent impairments in aspects of instrumental behavior, 
exertion of effort and effort-related choice, which can lead to difficulties in the 
workplace, as well as limitations in terms of life function, interaction with the 
environment, and responsiveness to treatment.  There is considerable overlap 
between the neural circuitry involved in effort-related functions in animals and 
the brain systems that have been implicated in psychomotor slowing and anergia 
in depression (Salamone et al. 2006, 2007, 2009, 2010).  Thus, research on 
effort-related behavioral processes, and their neural regulation, could have 
substantial impact on clinical research related to addiction, depression, and other 
disorders.  
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GENERAL HYPOTHESIS 
DA is implicated in effort-related processes, and is essential for the 
activational aspect of motivation. We hypothesize that DA antagonism or DA 
depletion would affect effort based decision making to obtain a reward, as well 
as the activational effects of conditioned stimuli associated to a reinforcer while, 
leaving intact the consummatory or directional aspect of motivation, such as the 
intake of different reinforcers with no effort demands.    
Furthermore, adenosine has been described as a new target for the 
treatment of the symptoms seen on these processes due to its co-localization 
with DA. We hypothesize that antagonists acting on adenosine receptors would 
be able to attenuate DA antagonist effects on behavioral activation, and effort 
based decision making. More specifically, A2A receptor antagonism would 
reverse the effects of DA D2 receptor antagonism.  
Lastly, as Nacb has been described as an important brain area directly 
related to the regulation of some aspects of motivation and motor control, we 
hypothesized that DA antagonists would increase the signal of different cellular 
markers on this area and, adenosine antagonists would be able to attenuate or 
reverse those effects.  
 
SPECIFIC HYPOTHESIS: 
The specific hypothesis for each group of experiments in the present 
work, were the following: 
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Chapter 1: Selection of sucrose concentration after DA depletion and 
selective DA antagonists depends on the effort required by the instrumental 
response: studies using tetrabenazine and D1, D2 and D3 antagonists. 
- DA antagonists impair effort expenditure depending on the particular 
subtype of DA that is antagonized. Lever pressing for 5% sucrose is expected to 
be decreased after DA antagonism, producing a shift towards the intake of free 
0.3% sucrose. However, no effect of DA antagonism is expected if no effort 
demand is required to obtain sucrose. 
- It is expected that DA antagonism does not resemble the effect of pre-
exposing animals to both sucrose solutions. 
- It is expected that non selective adenosine antagonists reverse DA 
antagonism effects on behavior due to DA/adenosine receptor interactions.  
- On behavioral activation, it is expected that DA antagonists decrease 
horizontal and vertical locomotion. Furthermore, non selective adenosine 
antagonists are expected to increase locomotion due to their psychostimulant 
properties.  
  
Chapter 2: Individual differences in work output relate to DA 
dependent signal transduction mechanisms in Nacb: Studies of DA D2 
antagonism, adenosine A2A antagonism, cannabinoid CB1 antagonism and 
pre-feeding on effort-related choice behavior as assessed by a progressive 
ratio/chow feeding choice task. 
- It is expected that under a novel variant procedure that utilizes a 
progressive ratio (PROG15)/chow feeding task, normal animals will press the 
lever to obtain the more preferred pellets, to a certain break point.  
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- Haloperidol would affect PROG responding in a manner that was not 
dependent upon decreases in primary food motivation or appetite, and thus 
would decrease PROG lever pressing but leave chow intake intact.  
-  MSX-3, an A2A adenosine antagonist, would produce a behavioral 
effect that is generally opposite to that produced by haloperidol; it is expected to 
increase lever presses and highest ratio achieved, decreasing chow consumption.  
- DA antagonism is not expected to resemble effects of the appetite 
suppressants and the effects of the reinforcer devaluation provided by pre-
feeding. Due to the putative appetite suppressant effects of interfering with 
cannabinoid CB1 receptor transmission, it was expected that AM251, as well as 
pre-feeding, would decrease both lever pressing and chow consumption.  
- Due to the increasing work requirements and individual differences on 
this tasks, DARPP-32 immunoreactivity in Nacb would be greater in animals 
with high baseline levels of lever pressing (i.e., “high responders”) than in rats 
with low levels of lever pressing. 
  
Chapter 3: Effect of subtype-selective adenosine receptor antagonists 
on basal or haloperidol-regulated striatal function: studies of c-Fos 
expression and motor activities in outbred and A2AR KO mice. 
- D2 antagonist haloperidol is expected to decrease locomotion. 
- Adenosine antagonists are expected to attenuate the effects of DA 
antagonism. Theophylline, a non selective adenosine antagonist, is expected to 
reverse haloperidol effects due to its action on A2A receptors. CPT, a selective 
A1 antagonist, is not expected to attenuate D2 antagonism effects while A2A 
selective antagonism, using MSX-3, is expected to reverse it. 
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- KO mice for the A2A receptor are expected to be resistant to haloperidol 
effects.  
- On c-Fos expression, A2A receptor antagonists are expected to reverse 
c-Fos induction after D2 antagonism.  
 
 Chapter 4: Adenosine A2A receptor antagonism and genetic deletion 
attenuate the effects of dopamine D2 antagonism on effort-based decision 
making in mice: Studies using a T-maze with barrier. 
- The D2 antagonist haloperidol is expected to produce a shift on the 
behavior towards the option with lower effort demands.  
- Haloperidol effects are expected to be different compared devaluation 
of the reinforcer by pre-feeding. Satiated animals are expected to decrease the 
number of HD arm selection, increasing the number of omissions.  
-Adenosine antagonists are expected to reverse DA antagonism 
depending on the adenosine receptor. Theophylline is expected to reverse 
haloperidol effects due to its action on A2A receptors, increasing HD arm 
selections. CPT, a selective A1 antagonist, is not expected to attenuate D2 
antagonism, while A2A selective antagonism, using MSX-3, is expected to 
redirect the behavior towards the HD arm. 
- A2A receptor KO mice are expected to be resistant to D2 antagonist 
haloperidol effect on this task.  
-On c-Fos expression, the same pattern of adenosine-Da interactions are 
expected; theophylline and MSX-3 are expected to decrease c-Fos induction 
after D2 antagonism.  
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Chapter 5: Dopamine D2 receptor antagonism modulates the 
preference for primary reinforcers based on their effort requirements: 
studies using running wheels and sucrose consumption in mice. 
- D2 antagonism at medium doses is expected to decrease counts in the 
running wheel. 
-  In a maze where two reinforcers with different effort demands attached 
are present, control animals are expected to spend more time running on the 
wheel, exerting an effort instead of consuming sucrose.  
- Haloperidol, a D2 selective antagonist, is expected to produce a shift on 
behavior towards the less demanding reinforcer option. Animals are expected to 
increase their interaction with the reinforcer that implies lower effort demands.  
- Haloperidol effects are expected not to be similar to the devaluation of 
the reinforcer, differing then from the condition of pre-exposure. 
  
Chapter 6: Impact of DA D2 receptor antagonism on the activational 
effects produced by olfactory conditioned stimuli associated to voluntary 
sucrose consumption. 
- Neutral stimuli such as an odor, are expected to acquire similar 
activational properties after been pairing with a natural reinforcer such as 10% 
sucrose solution.  
- The D2 antagonist, haloperidol, is expected not to have an effect on 
direct sucrose intake, but is expected to dose dependently affect locomotion.   
- Conditioned stimuli associated to sucrose are expected to enhance 
locomotion on a novel environment that does not have the unconditioned stimuli 
present, effect that is expected to be blocked by low doses of haloperidol.  
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CHAPTER 1: 
 
SELECTION OF SUCROSE CONCENTRATION AFTER 
DOPAMINE DEPLETION AND SELECTIVE DOPAMINE RECEPTOR 
ANTAGONISTS DEPENDS ON THE EFFORT REQUIRED BY THE 
INSTRUMENTAL RESPONSE: STUDIES USING TETRABENAZINE 
AND D1, D2 AND D3 ANTAGONISTS. 
 
Abstract 
Mesolimbic dopamine (DA) is involved in behavioral activation and 
effort-related processes.  Rats with impaired DA transmission reallocate their 
instrumental behavior away from food-reinforced tasks with high response 
requirements, and instead select less effortful food-seeking behaviors. The 
present experiments were undertaken to study the impact of DA depletion and 
the individual contribution of different DA receptors on effort-based decision 
making. Because studies in the literature argued for a reduction in the
 
hedonic 
value of sucrose after DA antagonism, the present experiments study the impact 
of DA antagonism on the activational and directional components of motivated 
behaviors using sucrose as the reinforcer. The present work systematically 
compared the effect of DA depletion with tetrabenozine, as well as DA D1, D2 
and D3 antagonists on a concurrent lever pressing/drinking choice task and on a 
free choice-non operant task. In the operant procedure, rats can choose between 
responding on a fixed ratio (FR) 7 lever-pressing schedule for a high sucrose 
concentration (i.e., 5%) vs. approaching and consuming a less concentrated one 
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(0.3%). DA depletion produced by tetrabenazine (0.75 and 1.0 mg/kg) decreased 
lever pressing for 5% sucrose but increased free 0.3% sucrose intake, thus 
inducing a shift in the choice towards a less effortful behavior. The D1 
antagonist ecopipam (0.2 mg/kg IP) and the D2 antagonist haloperidol (0.1 
mg/kg IP) altered choice behavior, reducing lever pressing and increasing free 
sucrose intake. D3 antagonism did not produce any effect. The same 
pharmacological manipulations in rats choosing between these two solutions 
under free access conditions do not change preference for the high sucrose 
concentration and do not reduce total sucrose intake. Functional interaction 
between adenosine and DA receptors in the regulation of effort-based decision 
making was studied because they play an integral part in the regulation of striatal 
areas, including Nacb. Co-administration of the adenosine non-selective receptor 
antagonist theophylline (20 mg/kg IP) reversed the effects of the D2 antagonist 
but not the D1 antagonist. Caffeine was not able to reverse D1 antagonism either. 
These results may have implications for understanding phenomena related to 
motivation and energy-related disorders such as psychomotor slowing or anergia 
in depression.  
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INTRODUCTION 
Organisms are capable of making vigorous instrumental responses in 
order to gain access to significant stimuli. The behavior of animals can reflect a 
selection process, in which the value of a stimulus (e.g. taste of a food) relative 
to the cost of obtaining it (e.g. nature of the instrumental response) is an 
important determinant of behavioral output. According to that, it has been 
accepted the differentiation of at least two major functions in motivated 
behaviors; the directional aspect that guides behavior to specific ends and the 
activational aspect making emphasis in the vigor or persistence to obtain it 
(Cofer and Appley, 1964; Duffy, 1963; Salamone, 1988, 1991, 1992; Salamone 
et al., 1997).  
There is increasing evidence showing that interference with dopamine 
(DA) transmission alters some of these aspects of motivated behavior leaving 
others unaffected (Ungerstedt 1971; Rolls et al., 1974, Fibiger et al., 1976; Koob 
et al. 1978; Salamone et al., 1991, 1993, Baldo et al. 2002). Several lines of 
evidence implicate DA, particularly in nucleus accumbens (Nacb), as a critical 
component of the brain circuitry regulating behavioral activation and effort-
related processes (Salamone et al., 1991, 2003, 2005, 2007; Vezina et al., 2002; 
Zhang et al., 2003; Wakabayashi et al., 2004; Barbano and Cador, 2006, 2007; 
Cagniard et al., 2006; Phillips et al., 2007; Floresco et al., 2008; Salamone, 
2010). Thus, in operant tasks, under control conditions when animals need to 
press a lever to obtain preferred food there is release and metabolism of DA in 
Nacb and striatum (Church et al. 1987; Salamone et al. 1989; McCullough et al. 
1993; Segovia et al., 2011). On the contrary, rats with Nacb DA depletions or 
DA receptor blockade reduce lever pressing for food and show alterations in 
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response allocation on tasks that measure effort-related choice behavior 
(Salamone et al. 1991, 1997, 2003, 2005, 2006, 2007).  
Studies of effort-related choice behavior typically offer animals 
alternative paths to obtain reinforcement, which involve cost/benefit trade-offs 
related to the work requirements for obtaining the reinforcer.  The concurrent 
lever-pressing/chow-feeding procedure has been widely used for the study of 
DA implication in effort-based decision-making (Salamone et al., 1991). Under 
a fixed-ratio 5 (FR5) schedule, animals learn how to press the lever to obtain 
high amounts of preferred food instead of consuming the no-cost available lab 
chow (Salamone et al., 1991). Previous work has shown that, lesions of Nacb by 
6-hydroxidopamine (6-OHDA), peripherally or intra-Nacb non selective DA 
receptor antagonists, as well as D1 and D2 -family receptor antagonists (Cousins 
et al. 1994; Nowend et al. 2001; Sink et al., 2008; Worden et al., 2009; Nunes et 
al., 2010; Salamone et al. 1991, 1996, 2002; 2009; Cousins et al. 1994; Koch et 
al. 2000), decrease lever pressing and increase chow consumption on the food 
concurrent choice task. However, by reducing food motivation after prefeeding 
the animals or administering appetite suppressant drugs a different pattern of 
response was seen; lever pressing and chow intake were both suppressed 
(Salamone et al., 1991). 
Natural palatable rewards such as food and fluids as well as drugs of 
abuse have been used to study the DArgic response in the Nacb (Westerink et 
al., 1997; Roitman et al., 2004). Many studies have shown that sweet taste 
stimulation can act as a potent natural reward (Levine et al., 2003; Yamamoto, 
2003). Thus, by using fluids containing different sucrose or saccharine 
concentrations researchers have assessed the role of DA in motivational and 
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emotional processes (Ikemoto and Panksepp, 1996; Treit and Berridge, 1990; 
Cannon and Palmiter, 2003; Cannon and Bseikri, 2004). Taste reactivity after 
oral administration of sucrose is a widely used measure of the emotional 
reactions to sucrose (Treit and Berridge, 1990; Peciña et al., 1997; see also 
Berridge and Robinson, 1998), and numerous studies have demonstrated that 
Nacb DA is not involved in the regulation of these emotional reactions (Ikemoto 
and Panksepp, 1996; Baldo et al., 2002; Treit and Berridge, 1990; Cannon and 
Palmiter, 2003; Cannon and Bseikri, 2004; Martinez-Hernandez et al., 2012). 
The directional or consummatory component in motivated behaviors also 
involves emotional aspects, but the nature of the measurements in these tasks is 
not pure measures of emotion. Thus, behavioral variables such as preference 
between solutions and amount of sucrose consumed can indicate if animals are 
oriented towards the reinforcer, but also can be influenced by the instrumental 
task that is required. This particular aspect of motivation has demonstrated not to 
be dependent on Nacb DA, but is influenced by manipulations of other neural 
systems (such as GABA/benzodiazepine systems in the brainstem, ventral 
pallidal systems where lesions produce aversion, or opioid systems in the Nacb 
shell (Berridge, 1996; Berridge and Peciña, 1995; Cromwell and Berridge, 1994; 
Peciña and Berridge, 1996a,b).  
Although mesolimbic DA is a critical component of the brain circuitry 
regulating effort-related choice behavior (Salamone and Correa 2002; Salamone 
et al. 2003, 2005, 2006), other transmitters also are involved (Salamone et al. 
2007; Farrar et al. 2008; Hauber and Sommer, 2009). The purine nucleoside 
adenosine has been involved in this type of function (Salamone and Correa 
2009; Mingote et al., 2008; Font et al., 2008). Striatal areas, including 
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neostriatum as well as Nacb, have a high concentration of adenosine A2A 
receptors (Jarvis and Williams 1989; Schiffmann et al. 1991; DeMet and Chicz-
DeMet 2002; Ferré et al. 2004), and there is a functional interaction between DA 
D2 and adenosine A2A receptors, which are co-localized on enkephalin-
containing medium spiny neurons (Fink et al. 1992; Ferré 1997; Ferré et al., 
1997, 2008b; Hillion et al. 2002; Fuxe et al. 2003). Furthermore, adenosine A1 
and DA D1 receptors tend to be co-localized on the same substance P- containing 
striatal neurons (Ferré 1997, 2008; Ferré et al. 1997, 2005). Thus, non receptor 
selective adenosine antagonists such as caffeine and theophylline can act on both 
subpopulations of neurons (Armentero et al., 2011). 
The present work was undertaken to examine the role of DA in effort-
related choice behavior using an adaptation of the concurrent lever pressing/ 
chow food procedure originally developed by Salamone et al., (1991). Most of 
the previous research has been focused on food as the reinforcer. However, in 
the present set of experiments we evaluated selection of palatable fluid 
concentrations of sucrose (5% versus 0.3% w/v). In the present conditions, 
animals need to press the lever under a FR7 schedule to have access to the 5% 
sucrose solution while having free access to the 0.3% sucrose solution during the 
session. The same sucrose concentrations were also used in parallel experiments 
in which both solutions were given to animals under free access-no lever 
pressing requirements. These free access experiments are a way to evaluate DA 
involvement in the directional aspect of motivation under minimal or no effort 
demanding conditions and can provide information about possible palatability 
alterations after DA antagonism. On these two different tasks we evaluated the 
effect of the DA depleting agent tetrabenazine, a selective vesicular monoamine 
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transporter-inhibitor for VMAT-2 (Zheng et al., 2006; Fasano and Bentivoglio, 
2009). The following experiments evaluated DA selective antagonists with 
different affinity profiles for the DA receptors subtypes; D1, D2 and D3 receptors. 
Previous research has focused mostly on D1 and D2 receptors, but less is known 
about the D3 role in effort based decision making. As control experiments we 
evaluated the impact of letting animals to satiate of both sucrose solutions before 
the experimental sessions started. Furthermore, two experiments were also 
conducted to determine the ability of non-selective adenosine antagonists to 
reverse DA antagonism effects on choice. Thus, theophylline and caffeine were 
used to reverse the behavioral effects of D1 and D2 antagonists.  
 
MATERIALS AND METHODS 
Animals 
Adult male, Sprague-Dawley rats (Janvier, France) were housed in pairs 
in a colony maintained at 23ºC with 12-h light/dark cycles (lights on at 8:00 h). 
Rats (N=256) weighed 190-240 g at the beginning of the study. Rats were 
initially water restricted, after the first day of training and then, they were fed 
supplemental water to maintain the water restriction throughout the study (20 
ml/day/rat), with chow available ad libitum in the home cages. Despite water 
restriction, rats gained weight normally throughout the experiment. All animals 
were under a protocol approved by the Institutional Animal Care and Use 
Committee of Universitat Jaume I, and all experimental procedures complied 
with European Community Council directive (86/609/EEC). All efforts were 
made to minimize animal suffering, and to reduce the number of animals used.  
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Pharmacological agents  
Sucrose (Sigma Quimica C.O) solutions were dissolved in tap water for 
oral consumption. All drugs were administered intraperitoneally (IP). 
Tetrabenazine (Tocris Bioscience) was dissolved and sonicated in 20% DMSO 
which was dissolved in 0.9% saline (pH=4.5). SCH39166 (ecopipam; (6aS-
trans)-11-Chloro-6,6a,7,8,9, 13b-hexahydro-7-methyl-5H-benzo[d] aphtha[2,1-
b]azepin- 12-ol hydrobromide), (Tocris Bioscience), a highly selective D1 
receptors antagonist (Alburgues et al., 1992), was dissolved in a 0.2% tartaric 
acid solution (pH=4.0), which was also used as the vehicle control. Haloperidol 
(Sigma Quimica C.O), a relatively selective DA D2 receptor antagonist, was 
dissolved in 0.2% tartaric acid solution (pH=4.0), which also was used as the 
vehicle control. GR103691 (Tocris Bioscience), a DA antagonist with high 
affinity to D3 receptor (Audinot et al, 1998), was dissolved and sonicated in 20% 
DMSO which was dissolved in 0.9% saline (pH=4.5). Theophylline and 
Caffeine (Tocris Bioscience), nonselective adenosine antagonists, were 
dissolved in distilled water (pH=7.4).  
Doses of tetrabenozine, ecopipam, haloperidol, theophylline and caffeine 
used for the experiments were based upon previous research (Sink et al., 2008; 
Worden et al., 2009; Randall et al., 2011) and on pilot studies. The specific 
doses of each drug were selected in order to be high enough to produce a robust 
shift from lever pressing to free intake, but low enough not to produce a general 
disruption of behavior. The dose range chosen for D3 antagonist was based upon 
doses listed in published behavioral studies involving IP administration in rats 
(Gerlach et al., 2011; Clifford and Waddington, 1998) and higher doses.  
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Apparatus and testing procedures 
Operant chambers (28 cm x 23 cm x 23 cm; Med Associates Inc., St. 
Albans, VT) were used for the concurrent FR7/free sucrose procedure 
experiments. These chambers were equipped with a retractable lever that was 
located on the right side of the wall (2 cm above the floor), which triggered the 
entry of a retractable graduated cylinder tube with rubber stopper and a stainless 
steel sipper spout with double ball bearings to prevent leakage, on the same wall 
(5 cm above the grid floor) when pressed. This tube contained 5% w/v sucrose. 
Lever pressing also activated an interior chamber light during retractable 
drinking disposal. The opposite wall contained a drinking spout (0.3% w/v 
sucrose), not retractable. All chambers were housed in sound attenuated 
enclosures with exhaust fans that masked external noise. Electrical 
inputs/outputs of each chamber were controlled by an IBM compatible PC 
(Med-Associates software).  
 
Locomotion chamber. The open field was 80 cm x 60 cm x 52 cm. The 
behavioral test room was illuminated with a soft light, and external noise was 
attenuated. Animals were habituated to the open field during 10 minutes 24 
hours before the test session.  Locomotor activity was registered manually. For 
horizontal locomotion an activity count was registered each time the animal 
crossed from a quadrant to another with all four legs. A count of vertical 
locomotion was registered each time the animal raised its forepaws in the air 
higher than its back, or rested them on the wall.  
Concurrent FR7/free sucrose. Operant sessions occurred once a day for 5 
days/week. Animals were trained to lever press for access to a 5% sucrose (g/l) 
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solution. Rats were initially trained during 4 days to lever press on a FR1 
reinforcement schedule: during 3 days sessions lasted 30-min with the 5% 
sucrose dispenser available during 30, 15 and 5 seconds progressively every 
time a ration was completed. On the 4rth day the session was reduced for the rest 
of the experiment to 15 minutes and the 5% sucrose dispenser was available for 
5 seconds. On the second phase rats were shifted for 2 days to a FR5 schedule. 
Finally rats were shifted to FR7 (5 days/week, 2 weeks). Rats were then trained 
on the concurrent FR7/sucrose 0.3% procedure. With this task, 0.3% sucrose 
was freely available on the opposite side of the chamber during the FR7 
sessions. At the end of the session, rats were immediately removed from the 
chamber, and sucrose intake was determined by measuring the remaining fluids. 
Rats were trained until they attained stable levels of baseline lever pressing and 
free 0.3% sucrose intake (i.e consistent responding over 200 lever presses per 15 
min during the last 5 days), after which drug testing began. Every day rats 
received supplemental water (20 ml /animal) in the home cage.  
Free two-bottle sucrose drinking paradigm. Animals were individually 
placed during 15 minutes in new home cages (20 cm x 45 cm x 25 cm) where 
two bottles containing 0.3% and 5% sucrose drinking solutions were placed 
separated 10 cm apart for 5 days/week. To control for possible side preferences, 
the left-right positions of the bottles were randomly assigned to different rats. In 
order to train these groups in a similar way to the operant groups, rats were 
initially exposed to the 5% sucrose concentration (30 min, for 3 days) after 
which 0.3% and 5% sucrose were concurrently present during 15 minutes 
sessions for 3 weeks before testing started. At the end of the session, rats were 
immediately removed from the chamber, and sucrose intake was determined by 
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measuring the remaining fluid. Rats received supplemental water (20 ml/day/rat) 
in the home cage.  
For the pre-exposure condition, animals were trained as described above, 
and the day before test, they had ad libitum access to 5%, 0.3% sucrose and 
water, for 24 hours in their home cage. Then, animals were exposed to an 
operant session where sucrose intake and lever presses were registered. 
Additional groups were exposed to free two-bottles sessions. 
Locomotion experiment. Different groups of animals were tested with the 
higher dose of every drug used in the drinking experiments. 
Experiments 
Each rat received all drug doses in their particular experiment in a 
randomly varied order (one treatment per week, with none of the treatment 
sequences repeated across different animals in the same experiment). Baseline 
(i.e. non-drug) sessions were conducted 4 additional days per week. The specific 
treatments and testing times for each experiment are listed below.  
Experiment 1: Effect of introducing free low sucrose concentration 
concurrently available in the operant chamber on lever pressing behavior. As 
described above, animals were trained under a FR7 schedule until a stable 
baseline on lever pressing was achieved. The low free access sucrose 0.3% 
concentration was introduced and training proceeded. Lever pressing for the 5% 
concentration was registered before and after introducing the alternative fluid 
(N= 30, same animals as in experiments 3, 4 and 8B).  
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Experiment 2: Effect of the DA depleting agent tetrabenazine on 
selection of different sucrose concentrations in operant and free intake 
procedures.  
A). Effect of tetrabenazine on concurrent FR7/free sucrose choice. On 
the test day, trained rats (N=9) received the following tetrabenazine doses: 0.0, 
0.5, 0.75 and 1.0 mg/kg (90 minutes before testing) and lever pressing and 
sucrose intake of 5% or 0.3% concentration were assessed. 
B). Effect of tetrabenazine on free access two-bottle sucrose choice. On 
the test day, trained rats (N=10) received the following tetrabenazine doses: 0.0, 
0.5, 0.75 and 1.0 mg/kg (90 minutes before testing) and free sucrose intake of 
5% or 0.3% concentration were assessed. 
Experiment 3: Effect of the D1 antagonist ecopipam (SCH 39166) on 
selection of different sucrose concentrations in operant and free intake 
procedures.  
A). Effect of different doses of the D1 antagonist ecopipam (SCH-39166) 
on concurrent FR7/free sucrose choice. On the test day, trained rats (N=10) 
received the following ecopipam doses: 0.0, 0.05, 0.1 and 0.2 mg/kg (30 minutes 
before testing).  
B). Effect of different doses of the D1 antagonist ecopipam (SCH-39166) 
on free access two-bottle sucrose choice. On the test day, trained rats (N=10) 
received the following ecopipam doses: 0.0, 0.05, 0.1 and 0.2 mg/kg (30 minutes 
before testing). 
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Experiment 4: Effect of the D2 antagonist haloperidol on selection of 
different sucrose concentrations in operant and free intake procedures. 
A). Effect of different doses of the D2 antagonist haloperidol on FR7/free 
sucrose choice. On the test day, trained rats (N=10) received the following 
haloperidol doses: 0.0, 0.025, 0.05 and 0.1 mg/kg (50 minutes before testing). 
B). Effect of different doses of the D2 antagonist haloperidol on free 
access two-bottle sucrose choice. On the test day, trained rats (N=10) received 
the following haloperidol doses: 0.0, 0.025, 0.05 and 0.1 mg/kg (50 minutes 
before testing). 
Experiment 5: Effect of the D3 antagonist GR103691 on selection of 
different sucrose concentrations in operant and free intake procedures. 
A). Effect of different doses of the D3 antagonist GR103691 on FR7/free 
sucrose choice. On the test day, trained rats (N=10) received the following 
GR103691 doses: 0.0, 0.5, 1.0 and 2.0 mg/kg (30 minutes before testing). 
B). Effect of different doses of the D3 antagonist GR103691 on free 
access two-bottle sucrose choice. On the test day, trained rats (N=10) received 
the following GR103691 doses: 0.0, 0.5, 1.0 and 2.0 mg/kg (30 minutes before 
testing). 
Experiment 6: Effect of pre-exposure to sucrose solutions on selection of 
different sucrose concentrations in operant and free intake procedures. 
A). Effect of pre-exposure to sucrose on FR7/free sucrose choice. 
Animals (N=8) had ad libitum water, 5% and 0.3% sucrose in their home cages 
during 24 hours previous to being tested in the FR7/free sucrose choice. After 
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the operant session, lever pressing and sucrose intake of 5% or 0.3% 
concentration were assessed. 
B). Effect of pre-exposure to sucrose on free access two-bottle sucrose 
choice. Animals (N=9) had ad libitum water, 5% and 0.3% sucrose in their home 
cages during 24 hours previous to being tested in the free choice paradigm. 
Sucrose intake of 5% or 0.3% concentration were assessed after the session 
ended. 
Experiment 7: Effect of reducing sucrose concentration of the free fluid 
in the operant choice procedure: study using the D2 antagonist haloperidol. 
Initial experiments on free consumption demonstrated that animals (N=20) did 
not differentiated between 0.1 and 0.2% (t (1,18)=1.03, n.s.), but they did 
differentiated between 0.2 and 0.3% sucrose solutions (t (1,18)=43.59, p<0.01) 
(see table 1). Thus, in the present experiment we assessed the impact of 
haloperidol when the free access solution concurrently available on the operant 
choice procedure was lower than the one used for all previous experiments. 
Animals were trained as described above and the free access sucrose solution 
was 0.2% rather than 0.3%. On the test day, trained rats (N=10) received the 
following haloperidol doses: 0.0, 0.025, 0.05 and 0.1 mg/kg (50 minutes before 
testing), and lever pressing and sucrose intake of 5% or 0.2% concentration were 
assessed. 
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Table 1. Preference for two different concentrations of sucrose in different 
groups of animals under a free choice paradigm. Mean (±SEM) ml consumed in 
15 min.  
 
Experiment 8: Ability of non-selective adenosine antagonists theophylline 
and caffeine to reverse the effects of D1 and D2 antagonists on selection of 
different sucrose concentrations in operant and free intake procedures.  
A). Effect of theophylline and caffeine after ecopipam (SCH39166) 
administration on FR7/free sucrose choice. Different groups of animals were 
used for the present experiments (N=60). On the test day, trained rats received 
the following treatments: 0.0 or 0.2 mg/kg ecopipam (30 minutes before testing) 
plus 0 or 20 mg/kg theophylline or 0 or 20 mg/kg caffeine (20 minutes before 
testing). Lever pressing and sucrose intake of 5% or 0.3% concentration were 
assessed at the end of the session. 
B). Effect of theophylline after haloperidol administration on FR7/free 
sucrose choice. For this experiment, we used animals that had a baseline level 
below the criterion established for the operant experiments (over 200 lever 
presses for 5 days before testing started) to see if theophylline improved the 
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response of the low performers. On the test day, trained rats (N=10) received the 
following treatments: 0 or 0.1 mg/kg haloperidol (50 minutes before testing) 
plus 0 or 20 mg/kg theophylline (20 minutes before testing). Lever pressing and 
sucrose intake of 5% or 0.3% concentration were assessed at the end of the 
session. 
C). Effect of theophylline and caffeine on two-bottle sucrose drinking 
paradigm. Different groups of animals were used for the present experiments 
(N=30). On the test day, trained rats received the following treatments: 0.0 or 20 
mg/kg theophylline or 20 mg/kg caffeine (20 minutes before test). Sucrose 
intake of 5% or 0.3% concentration was assessed at the end of the session. 
Experiment 9: Effect of tetrabenazine, ecopipam, haloperidol, 
GR103691, theophylline and caffeine on locomotor activity. Different groups of 
animals were used for the present experiments (N=40). The different vehicles 
used in the previous experiments were used for the locomotion experiment. 
Because there were no differences between them in locomotion (data not 
shown), all these data were considered the vehicle group. On the test day, rats 
received vehicle or one of the following treatments: 1.0 mg/kg of tetrabenazine, 
0.2 mg/kg ecopipam, 0.1 mg/kg haloperidol, 2.0 mg/kg GR103691, 20 mg/kg 
theophylline or 20 mg/kg caffeine. Horizontal and vertical locomotion were 
simultaneously recorded during 10 minutes. 
Statistical analyses 
The dependent variables total number of lever presses and ml of sucrose 
intake from the 15 min sessions were analyzed with repeated measures of 
analysis of variance (ANOVA) except for experiments 8 A and C on which a 2 
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way-factorial ANOVA was applied. When the overall ANOVA was significant, 
non-orthogonal planned comparisons using the overall error term were used to 
compare each treatment with the vehicle control group (Keppel, 1991). For these 
comparisons,  level was kept at 0.05 because the number of comparisons was 
restricted to the number of treatments minus one. Locomotion data were 
analyzed using between-groups ANOVA. STATISTICA 7 software was used for 
statistical analysis of the data. All data were expressed as mean ±SEM, and 
significance was set at p<0.05. 
 
RESULTS 
Experiment 1: Effect of introducing free low sucrose concentration 
concurrently available in the operant chamber on lever pressing behavior. 
Repeated measures ANOVA for the factor day of training showed a significant 
effect on lever pressing (F(10,290)=7.33, p<0.01). Planned comparisons yield 
significant differences between the last day of FR7 alone and the following two 
days of free 0.3% sucrose concurrently available (p<0.01) (see Fig. 1). As 
expected, repeated measures ANOVA for the factor day of training on 5% 
sucrose intake was also significant (F(10,290)=4.1, p<0.01). Planned 
comparisons showed significant differences between last day of FR7 alone and 
the following two days of free 0.3% sucrose introduction (p<0.05). Thus, the 
presence of a new sucrose source in the operant cage produced a temporal shift 
in behavior that disappeared by the third day. 
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Fig. 1. Effect of introducing a spout providing free sucrose on the operant 
performance. Mean (±SEM) number of lever presses in 15 min. **p<0.01 
significantly different from the last day with no concurrent 0.3% sucrose 
available.  
 
Experiment 2: Effect of the DA depleting agent tetrabenazine on 
selection of different sucrose concentrations in operant and free intake 
procedures.  
A). Effects of tetrabenazine in the operant procedure are shown in figure 
2A, 2B and 2C. The ANOVA for repeated meassures indicated that 
tetrabenazine produced a significant effect on lever pressing (F(3, 24)=5.15, 
p<0.01), on 5% sucrose intake (F(3, 24)=6.88, p<0.05) and on 0.3% sucrose 
intake (F(3,24)=6.79, p<0.01). Planned comparisons showed that tetrabenazine 
significantly reduced lever pressing at the two highest doses, 0.75 mg/kg 
(p<0.05) and 1 mg/kg (p<0.01) compared to vehicle, as well as reducing 5% 
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sucrose intake (0.75 mg/kg, p<0.05, and 1 mg/kg, p<0.01) compared to vehicle, 
and significantly increased 0.3% sucrose intake at all doses tested (p<0.01).  
B).The effect of tetrabenazine on free access sucrose intake is shown in 
fig. 2D and 2E. Repeated measures ANOVA yielded no effect of the factor dose 
on 5% sucrose intake (F(3,27)=1.11, n.s.) or 0.3% sucrose intake (F(3,27)=0.09, 
n.s.).  
 
Fig. 2. Effect of tetrabenazine (0.0, 0.5, 0.75 and 1 mg/kg) in the operant choice 
paradigm A) lever presses, B) 5% sucrose intake, and C) 0.3% sucrose intake, 
and in the free choice paradigm D) 5% free sucrose intake, and E) 0.3 free 
sucrose intake. Mean (±SEM) number of lever presses or ml consumed in 15 
min. *p<0.05 **p<0.01 significantly different from vehicle. 
 
 76 
Experiment 3: Effect of the D1 antagonist ecopipam (SCH 39166) on 
selection of different sucrose concentrations in operant and free intake 
procedures. 
A). The effect of ecopipam in the operant task is shown in fig. 3A, 3B and 
3C. The repeated measures ANOVA indicated that ecopipam produced a 
significant effect on lever pressing (F (3, 27)=10.05, p<0.01), on 5% sucrose 
intake (F (3,27)= 15.04, p<0.01) and on 0.3% sucrose intake (F (3, 27)= 6.22, 
p<0.01). Planned comparisons showed that ecopipam significantly reduced lever 
pressing at the doses of 0.1 mg/kg (p<0.05) and 0.2 mg/kg (p<0.01) compared to 
vehicle, as well as reducing 5% sucrose intake at the same doses (p<0.01) 
compared to vehicle and, significantly increased 0.3% sucrose intake at the 
doses of 0.1 and 0.2 mg/kg (p<0.01).  
B). Figures 3D and 3E show the effect of ecopipam on free access sucrose 
intake. Repeated measures ANOVA yielded no effect on 5% sucrose intake (F 
(3,27)=0.40, n.s.) or 0.3% sucrose intake (F (3,27)=0.40, n.s.). 
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Fig. 3. Effect of ecopipam (0.0, 0.05, 0.1 and 0.2 mg/kg) in the operant choice 
paradigm A) lever presses, B) 5% sucrose intake, C) 0.3% sucrose intake, and in 
the free choice paradigm D) 5% free sucrose intake, and E) 0.3% free sucrose 
intake. *p<0.05 **p<0.01 significantly different from vehicle. Mean (±SEM) 
number of lever presses or ml consumed in 15 min. 
 
Experiment 4: Effect of the D2 antagonist haloperidol on selection of 
different sucrose concentrations in operant and free intake procedures. 
A). Effects of haloperidol in the operant procedure are shown in fig. 4A, 
4B and 4C. The ANOVA for the main factor haloperidol showed that this drug 
produced a significant effect on lever pressing (F(3, 27)=17.98, p<0.01), on 5% 
sucrose intake (F(3,27)=16.35, p<0.01) and on 0.3% sucrose intake (F(3, 
27)=6.22, p<0.01). Planned comparisons revealed significant differences 
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between 0.0 mg/kg and the two highest doses of haloperidol (0.05 and 0.1 
mg/kg, p<0.01) on lever pressing, on 5% sucrose intake (p<0.05 and p<0.01 
respectively), and a significant difference between 0.0 mg/kg and 0.1 mg/kg 
(p<0.01) on 0.3% sucrose intake.   
B). Figures 4D and 4E show the effects of haloperidol on free access 
sucrose intake. Repeated measures ANOVA yielded no effect of the factor dose 
on free access 5% sucrose intake (F(3,27)=0.41, n.s.), 0.3% sucrose intake 
(F(3,27)=0.64, n.s.). 
 
Fig. 4. Effect of haloperidol (0.0, 0.025, 0.05 and 0.1 mg/kg) in the operant 
choice paradigm A) lever presses, B) 5% sucrose intake, and C) 0.3% sucrose 
intake, and in the free choice paradigm, D) 5% free sucrose intake, and E) 0.3% 
free sucrose intake. Mean (±SEM) number of lever presses or ml consumed in 
15 min. *p<0.05 **p<0.01 significantly different from vehicle. 
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Experiment 5: Effect of the D3 antagonist GR103691 on selection of 
different sucrose concentrations in operant and free intake procedures. 
A). The effect of different doses of the D3 antagonist GR103691 on the 
operant procedure are shown in fig. 5A, 5B and 5C. Repeated measures 
ANOVA for the factor GR103691 dose yielded no significant effect on lever 
pressing (F(3,27)=1.98, n.s.), on 5% sucrose intake (F(3,27)=1.21, n.s.) and on 
0.3% sucrose intake (F(3,27)=2.19, n.s.). 
B). The effect of GR103691 on free sucrose intake is shown in fig. 5D and 
5E. Repeated measures ANOVA yielded no effect of the factor dose on 5% 
sucrose intake (F(3,27)=0.91, n.s.) or 0.3% sucrose intake (F(3,27)=0.42, n.s.).  
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Fig. 5. Effect of GR103691 (0.0, 0.5 1 and 2 mg/kg) in the operant choice 
paradigm,  A) lever presses, B) 5% sucrose intake, and C) 0.3% sucrose intake, 
and in the free choice paradigm, D) 5% free sucrose intake, and E) 0.3% free 
sucrose intake. Mean (±SEM) number of lever presses or ml consumed in 15 
min. 
 
Experiment 6: Effect of pre-exposure to sucrose solutions on selection of 
different sucrose concentrations in operant and free intake procedures. 
A). Figures 6A, 6B and 6C show the effect of pre-exposing animals to 
both concentrations of sucrose 24 hours before the test was performed. The 
repeated measures ANOVA indicated that to pre-expose the animals produced a 
significant effect on lever pressing (F(1,7)=10.63, p<0.05), and on 5% sucrose 
intake (F(1,7)= 18.40, p<0.01). Although the significance was close 
(F(1,7)=4.84, p=0.064), 0.3% sucrose intake was not affected.  
B). The effect of pre-exposing the animals to reduce sucrose motivation, 
on free access sucrose intake is shown in fig. 6D and 6E. The ANOVA indicated 
that to pre-expose the animals produced a significant effect on 5% sucrose intake 
(F(1,8)= 64, p<0.01), and no effect on 0.3% sucrose intake (F(1,8)=0.00, n.s.) 
since the level of intake was already very low.  
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Fig. 6. Effect of sucrose pre-exposure in the operant choice paradigm, A) lever 
presses, B) 5% sucrose intake, and C) 0.3% sucrose intake, and in the free 
choice paradigm. D) 5% free sucrose intake and E) 0.3% free sucrose intake. 
Mean (±SEM) number of lever presses or ml consumed in 15 min. *p<0.05, 
**p<0.01 significantly different from control condition. 
 
Experiment 7: Effect of reducing sucrose concentration of the free fluid in 
the operant choice procedure: study using the D2 antagonist haloperidol. 
The effects of haloperidol in the operant procedure when the free fluid is a 
concentration of 0.2% sucrose are shown in fig. 7A, 7B and 7C. The ANOVA 
indicated that haloperidol produced a significant effect on lever pressing (F(3, 
27)=4.46, p<0.05), on 5% sucrose intake (F(3,27)=5.87, p<0.01), but no effect 
on 0.2% sucrose intake (F(3,27)=0.20, n.s.). Planned comparisons revealed that 
haloperidol significantly reduced lever pressing at the highest dose compared to 
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vehicle (p<0.05) as well as reducing 5% sucrose intake (p<0.05) compared to 
vehicle. These data indicate that the compensation in sucrose intake towards the 
low concentration fluid is only produced when the animals perceived the fluid as 
sweet but not because there was a fluid intake deficiency. 
 
Fig. 7. Effect of haloperidol (0.0, 0.025, 0.05 and 0.1 mg/kg) in the operant 
choice paradigm, A) lever presses, B) 5% sucrose intake, and C) 0.2% sucrose 
intake. Mean (±SEM) number of lever presses or ml consumed in 15 min. 
*p<0.05 significantly different from vehicle. 
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Experiment 8: Ability of non-selective adenosine antagonists, theophylline 
and caffeine to reverse the effects of D1 and D2 antagonists on selection of 
different sucrose concentrations in operant and free intake procedures.  
A). A two-way (ecopipam dose x xantine treatment) factorial ANOVA 
was performed. Figure 8A shows the effects on lever pressing. There was a 
significant effect of ecopipam (F(1,54)=17.04, p<0.01), but no significant effect 
of the factor xantines (F(2,54)=2.18, n.s.) and no significant ecopipam x xantine 
interaction (F(2,54)=0.22, n.s.). The same pattern was observed for 5% sucrose 
intake (Fig. 8B). There was a significant effect of ecopipam (F(1,54)=28.55, 
p<0.01), but no significant effect of xantines (F(2,54)=1.93, n.s.) and no 
significant ecopipam x xantine interaction (F(2,54)=0.46, n.s.). Finally in figure 
8C is shown the effect on 0.3% free sucrose intake. There was a significant 
effect of ecopipam dose (F(1,54)=7.17, p<0.01), a significant effect of xantine 
dose (F(2,54)= 10.28, p<0.01), but no significant ecopipam x xantine interaction 
(F(2,54)=1.71, n.s.). Thus, neither theophylline nor caffeine was able to reverse 
the impact of ecopipam on operant performance and shift in sucrose 
consumption towards the free available fluid. 
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Fig. 8. Effect of nonselective adenosine antagonists caffeine and theophylline (0 
and 20 mg/kg) in ecopipam (0 and 0.2 mg/kg) treated animals in the operant 
choice paradigm. A) lever presses B) 5% sucrose intake, and C) 0.3% sucrose 
intake. Mean (±SEM) number of lever presses or ml consumed in 15 min.  
 
B). Figure 9A, 9B and 9C depict the effects of theophylline on 
haloperidol actions in the operant procedures in animals that had a low baseline 
level of lever pressing before the testing phase started. Repeated measures 
ANOVA across conditions indicated a significant overall treatment effect on 
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lever pressing (F(3, 27)=15.04, p<0.01), on 5% sucrose intake (F(3, 27)=15.88, 
p<0.01) and on 0.3% sucrose intake (F(3,27)= 5.00, p<0.01. Planned 
comparisons showed that HP/Veh was significantly different from the Veh/Veh 
control condition (p<0.01) for all the dependent variables. In addition, co-
administration of theophylline and haloperidol (HP/T) significantly increased 
lever presses and 5% sucrose intake as well as decreasing free 0.3% sucrose 
intake (p<0.01) compared to the HP/Veh condition, indicating an attenuation of 
the haloperidol effects. Thus, although theophylline on its own did not produce 
significant changes it did produced a significant reversal of the effects of 
haloperidol on all measures. 
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Fig. 9. Effect of the nonselective adenosine antagonist theophylline (0 and 20 
mg/kg) in haloperidol (0 and 0.1 mg/kg) treated animals in the operant choice 
paradigm. A) lever presses B) 5% sucrose intake, and C) 0.3% sucrose intake. 
Mean (±SEM) number of lever presses or ml consumed in 15 min. **p<0.01 
significantly different from Veh/Veh. ##p<0.01 significantly different from 
Veh/HP. 
 
C). The effect of caffeine and theophylline on free access sucrose intake 
is shown in table 2. One-way ANOVA for the factor treatment (Vehicle / 
Theophylline 20 mg/ Caffeine 20 mg) yielded no significant effect neither for 
5% sucrose intake (F(2,27)=0.55, n.s.) nor for 0.3% sucrose intake 
(F(2,27)=0.10, n.s.). 
 
Table 2. Effect of theophylline and caffeine (0.0 and 20 mg/kg) on free 5% 
sucrose intake and free 0.3% sucrose intake. Mean (±SEM) ml consumed 
(average in 15 min). 
 
Experiment 9: Effect of tetrabenazine, ecopipam, haloperidol, 
GR103691, theophylline and caffeine on locomotor activity. Independent 
student’s t tests were done for every drug comparing it to vehicle. Results for 
horizontal and vertical locomotion are shown in Table 4. The t-tests yielded no 
significant effect of tetrabenazine on horizontal (horizontal (t=0.02, df=13, n.s.) 
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neither vertical locomotion  (t=1.60, df=13, n.s.) Same results were found for 
ecopipam on horizontal (t=2.65, df=14, n.s.) and vertical locomotion (t=3.33, 
df=14, n.s.), and for GR103691 on horizontal  (t=1.95, df=13, n.s.) and on 
vertical locomotion (t=1.42, df=13, n.s.). Haloperidol was the only DA receptor 
antagonist that yielded significant effects on horizontal (t=4.93, df=13, p<0.05) 
and vertical locomotion (t=6.32, df=13, p<0.05) compared to vehicle. 
Furthermore, theophylline did not alter significantly horizontal (t=2.53, df=13, 
n.s.), nor vertical locomotion (t=1.61, df=13, n.s.), while caffeine increased 
significantly both measures, horizontal (t=9.22, df=12, p<0.01), and vertical 
locomotion (t=7.80, df=12, p<0.05), compared to vehicle group. 
 
Table 3. Effect of treatment (vehicle, tetrabenazine (1 mg/kg), ecopipam (0.2 
mg/kg), haloperidol (0.1 mg/kg), GR103691 (2 mg/kg), theophylline (20 mg/kg) 
and caffeine (20 mg/kg) on horizontal and vertical locomotion. Mean (±SEM) 
number of counts in the open field. *p<0.05, **p<0.01 significantly different 
from vehicle. 
 
DISCUSSION 
The present experiments evaluated the involvement of DA in the 
regulation of motivated responses and relative preference for sweet drinks. A 
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concurrent lever-pressing/intake task was adapted from previous procedures 
(Salamone et al., 1991). These paradigm allows animals to choose between lever 
pressing in an operant FR schedule for a “better” reward (in this case 5% 
sucrose) versus consuming freely a “less preferred” reward (0.3% sucrose), thus 
allowing to separately study the neurobehavioral bases of reward seeking and of 
reward taking. Sucrose has been extensively used for the study of emotional 
reactivity and for the study of the hedonic value of rewards (Peciña et al., 1997; 
Martinez-Hernandez et al., 2012). However, very few studies have used this 
reward for the study of effort-based decision-making. Additionally, separated 
experiments assessed the preference and consumption of the high and low 
sucrose concentrations in no effort choice situations. 
We have used pharmacological tools to study the impact of DA storage 
depletion, and selective DA receptor antagonists for the D1, D2 and D3 subtypes. 
Moreover, in control experiments a reduced motivational state was established 
by allowing the animals to get satiated from both type of sucrose concentrations 
or by devaluating even more the low cost-less preferred sucrose concentration. 
Thus, DA depletion by the selective VMAT-2 blocker tetrabenazine dose 
dependently decreased lever pressing for 5% sucrose while increasing the 
volume of the concurrently available 0.3% sucrose solution consumed in the 
operant choice paradigm. Animals redirected the behavior towards the less 
effortful option and drunk higher amounts of the less preferred solution. 
However, no dose of tetrabenazine modified the preference or the volume 
consumed of these sucrose concentrations in the non-operant concurrently 
available procedure, indicating that tetrabenazine leaves intact the palatability of 
sucrose. In previous studies, the neurotoxic agent 6-OHDA injected in Nacb 
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produced long lasting (days or weeks) DAergic depletions that have 
demonstrated to decrease lever pressing for palatable food but increase freely 
available chow consumption in a very similar paradigm (Cousins et al., 1994). 
Tetrabenazine has preferential effects on VMAT-2 in DA containing terminals, as 
shown by imaging studies that utilize the radiotracer 
11
C-DTBZ as a stable 
structural marker of DA neurons (Blesa et al. 2010; Okamura et al. 2010; Kilbourn 
et al. 2010; Tong et al. 2008). This drug is commonly used in humans to treat 
hyperkinectic disorders, but common side effects include fatigue and anergia 
(Astin and Gumpert 1974; Kingston 1979; Jankovic and Beach 1997; Kenney et al. 
2007). 
To identify which family or DA subtype receptor’s is implicated on the 
observed results after DA depletion in this paradigm, selective antagonists acting 
on D1, D2 and D3 receptors were also tested. Ecopipam (SCH39166, D1 
antagonist) as well as haloperidol (D2 antagonist) dose dependently decreased 
lever pressing for 5% sucrose intake, producing a shift on the animal’s choice 
towards consuming greater amounts of 0.3% sucrose solution. Previous work 
has shown that peripherally or intra-accumbens D1-family antagonists 
SCH23390, SKF83566 and ecopipam (Cousins et al. 1994; Nowend et al. 2001; 
Salamone et al. 2002; Sink et al., 2008; Worden et al., 2009; Nunes et al., 2010) 
as well as the D2 DA antagonists haloperidol, raclopride and eticlopride 
(Salamone et al. 1991, 1996, 2009; Cousins et al. 1994; Koch et al. 2000), 
decrease lever pressing and increase chow consumption on the food concurrent 
choice task.  
However, the D3 antagonist GR103691 did not produce changes in any of 
the dependent variables evaluated, neither in the operant procedure nor in the 
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free choice situation. There are not many data on the behavioral effects of this 
D3 antagonist. When injected directly into the basolateral amygdala it produced 
anxiolytic effects at doses that did not affected locomotion or rearing (Diaz et 
al., 2011). In a range of doses from 0.008 to 1.0 mg/kg IP, GR103691 did not 
affect parameters such as locomotion, rearing, grooming, sniffing or eating in 
rats (Clifford and Waddington 1998). The range of doses used in the present 
experiments (0.5-2.0 mg/kg, IP) expands the range of doses, but still no effect 
was obtained. The only other study that has assessed the role of D3 antagonist on 
effort based decision making has used a single dose of U99194, and has find no 
alteration of choice in a T maze paradigm (Bardgett et al., 2009).  
From all these data it seems clear that DA implication on effort-related 
processes is mediated by D1 and D2 receptors, but not D3 receptors. Although, 
the use of higher doses and different D3 antagonists would be necessary to 
clearly conclude that this type of receptors are not involved in the regulation of 
effort based decision-making. D1 and D2 family antagonists have consistently 
shown to produce similar effects on response allocation as measured by the 
concurrent FR5 lever pressing/chow feeding task (Salamone et al., 1991). This 
effort-related choice has been linked to DA function in Nacb (Salamone et al., 
1997, 2007, 2009a, 2010). Neurons of the Nacb not only express D1 and D2 
receptors, but they express D3 receptors as well. In fact, Nacb is one of the few 
brain areas where this type of receptor is highly expressed (Diaz et al., 1995; Le 
Moine and Bloch, 1996). D3 receptors seem to be co-localized with both type of 
receptors (Le Moine and Bloch, 1996), thus is possible that the D3 contribution 
to Nacb function regulation is dependent on D1 or D2 activation.   
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Thus, under this new operant task in which animals have a choice between 
pressing a lever under FR7 schedule to obtain 5% sucrose solution and freely 
drinking from 0.3% sucrose, they chose to press the lever under control 
condition but, DA depletion and DA antagonism on D1 and D2 receptor produces 
a reorganization of behavior, increasing low free access sucrose intake, 
essentially selecting a new “path” to obtain the sucrose solution, although at the 
same time leaving intact the palatability and preference for 5% sucrose when 
there is no effort attached to this high concentration. The use of this task as a 
measure of effort-related choice behavior has been validated in several ways. 
For instance, the above described pattern of effects was not produced by pre-
feeding to reduce sucrose motivation. After reducing motivation by allowing 
free consumption of 5% and 0.3 % sucrose solutions, satiated animals showed a 
decrease on lever pressing and 5% sucrose consumption but they did not shifted 
behavior towards the other source of sucrose. In fact, if anything, the rats reduce 
their intake of the low concentrated sucrose to almost 0 ml. Thus from both pre-
feeding experiments (operant and free) we can conclude that the animals still 
chose to drink some 5% sucrose solution although significantly less than control 
non-satiated animals, and drink negligible amounts of 0.3% sucrose solution. 
These results are in accordance with experiments using food as the reinforcer in 
the operant situation (Salamone et al., 1991). Moreover, all the pharmacological 
conditions that produce the shift in the operant situation did not alter sucrose 
intake or preference in free-drinking choice tests, which indicates that DAergic 
manipulations were not simply changing sucrose palatability. Additionally, 
lowering the concentration of the already low concentrated solution (from 0.3 to 
0.2%), thus, devaluating the free fluid sucrose concentration, animals behavior 
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resemble the pre-exposure condition; haloperidol decreased lever pressing and 
5% sucrose solution, but there was no shift towards the consumption of the 0.2% 
sucrose solution. The 0.2% sucrose is a concentration that, in most of our 
animals, seems not to be perceived as a reinforcer since 100% of animals 
significantly consumed much more 0.3% over 0.2%, but when 0.2% was offered 
concurrently to 0.1% there was not a significant difference between them.  
DA does not participate in effort-related processes in isolation. The 
interaction between DA and adenosine has also been studied based on the co-
localization between DA/adenosine receptors in medium-spiny neurons of the 
striatum (Fink et al. 1992; Ferré 1997; Ferré et al. 1997, 2008b; Hettinger et al. 
2001; Chen et al. 2001; Hillion et al. 2002; Fuxe et al. 2003). This fact has 
guided previous studies of motivation, behavioral activation and effort-related 
processes (Farrar et al., 2007; Font et al., 2008; Mingote et al., 2008; Mott et al., 
2009; Salamone et al., 2007; Worden et al., 2009). Non selective adenosine 
antagonists such as caffeine and theophylline act as minor stimulants that 
enhance motor activity in rodents and humans (Lopez-Cruz et al., 2011; Garret 
and Holtzman, 1994; Daly and Fredholm, 1998; Karcz-Kubicha et al., 2003; 
Antoniou et al., 2005, Kuribara et al., 1992) and are commonly consumed by 
humans for their “energetic effects” (Antoniou et al., 2005; Ferré, 2008; Reissig 
et al., 2009). The present study examined the ability of these two non selective 
adenosine antagonists that, acting on A1 as well as A2A receptors, can produce 
effects in both D1 and D2 containing neurons. In the present studies, caffeine and 
theophylline, did not affect preference and volume of 5% and 0.3% sucrose 
consumed in the non-operant situation, showing no impaired palatability after 
adenosine antagonism. However, they were not able to reverse the effects of D1 
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antagonism in the operant choice task, at a dose that significantly stimulated 
FR20 performance in an operant task for food (Randall et al., 2011). In previous 
studies it has been demonstrated that the effect of D1 antagonism on effort based 
decision making is not reversed either by selective A1 antagonists and is 
minimally reversed by A2A antagonists (Nunes et al., 2010). In general, the 
effects of D1 antagonist ecopipam were harder to reverse with selective 
adenosine antagonists that the effects of the D2 antagonist haloperidol (Nunes et 
al., 2010). Because in rats caffeine has demonstrated to reverse the effects on 
food choice behavior modulated by haloperidol (Salamone et al., 2009), in our 
next experiment, theophylline was used to reverse the effect of haloperidol in a 
group of rats that had a low baseline performance in lever pressing (below the 
median split from all the other groups; 241 lever presses), and did not reach 
criterion. In these animals theophylline (20 mg/kg) significantly reversed the 
effects of haloperidol in all three variables. Thus, non-selective adenosine 
antagonists have potential utility for the treatment of energy-related dysfunctions 
(such as anergia) that can affect the activational component of motivation. 
Sucrose drinking has been used to measure the putative reward functions 
of DA (Berridgem 2000; Berridge and Robinson, 1998; Nowend et al., 2001; 
Schneider et al., 1992; Smith, 1995). It has been reported that high doses of DA 
antagonists decrease sucrose consumption (Xenakis and Sclafani, 1982; 
Schneider et al., 1992; Hsiao and Smith, 1995; Hajnal et al., 2007). However, 
although after lower doses of D1 and D2 antagonists there is no effect on 
sucrose intake (Hajnal et al., 2007), the results of high doses have been used to 
state that DA antagonists blunt the ‘hedonic’ or ‘reward’ value of natural 
reinforcers such as sucrose, or suppress the appetite for them, or impair the 
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unconditioned responses to them.  
The term “hedonic” refers to an emotion (Ribot 1989). Thus, the 
“anhedonic” effects of DA antagonists focus in the unconditioned emotional 
response to sucrose as well as in the role of DA in directing behavior towards the 
acquisition and consumption of sucrose. In relation to the first point, previous 
work has concluded that DA transmission interference, produced by DA 
antagonists or reducing DA levels directly on Nacb or striatum, does not modify 
gustative reactivity to sucrose a test developed for the evaluation of 
unconditioned emotional responses in rodents and other animals including 
humans (Berridge, 2000; Berridge and Robinson, 1998). As for the second point, 
measures of the directional component or motivated behaviors or the appetite to 
consume a reward are voluntary intake and preference tests (Berridge and 
Robinson, 1998; Salamone and Correa 2002). With these measurements, it has 
been demonstrated that DA antagonists injected into Nacb in low doses that 
impaired learning or suppressed locomotion did not suppress food or water 
consumption (Baldo et al., 2002). In our results haloperidol reduced locomotion 
but it did not affect non-effort consumption and preference for the high 
concentration of sucrose. Consistently, flupentixol injected in Nacb reduced 
speed to approach 20% sucrose at the end of a corridor, but did not affect final 
sucrose intake (Ikemoto and Panksepp, 1996).  
DA antagonists can be producing many different processes that are not 
related to “hedonics”. The literature on DAergic involvement in sucrose 
drinking, like the literature on chow consumption, demonstrates that conditions 
that suppress sucrose drinking are accompanied by signs of motor dysfunction, 
specifically orofacial functions (see Fowler and Mortell, 1992; Das and Fowler, 
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1996). Several motor parameters related to licking are impaired by DA 
antagonists, including lap volume and tongue extension, lick force, lick duration, 
and lick efficiency (Fowler and Das, 1994; Fowler and Mortell, 1992; Gramling 
and Fowler, 1985; Hsiao and Chen, 1995; Schneinder et al., 1990). As for food 
high doses of DA antagonists affect rate of feeding (Blundell, 1987; Salamone et 
al., 1990, 1993). These motor effects of high doses of DA antagonists, therefore, 
place additional emphasis on studies that employ low doses of these substances. 
Low-to-moderate doses of DA antagonists are not acting as appetite 
suppressants that generally blunt primary food motivation, but instead are acting 
on other processes (e.g., behavioral activation, instrumental response output, 
response allocation, effort-related processes; Salamone et al., 1991, 1997, 2002, 
2003, 2005, 2007; Kelley et al., 2005; Baldo and Kelley, 2007; Barbano and 
Cador, 2007; Niv et al., 2007; Phillips et al., 2007; Floresco et al., 2008; Sink et 
al,. 2008; Nunes et al., 2010). Salamone (1988) suggested that moderate 
interference with accumbens or striatal DA systems affects activational aspects 
of motivated behavior, but has little direct effect on directional aspects. 
Fundamental aspects of motivation, including perception and discrimination of 
the reward magnitude, and appetite, are left intact after DA antagonists or Nacb 
DA depletions (Martin-Iverson et a., 1987; Salamone et al., 1990, 1994; Treit 
and Berridge, 1990; Cousins et al., 1996; Aparicio, 1998; Berridge and 
Robinson, 1998; Berridge, 2000). If interference with DA systems blunted 
primary food motivation, then the effects of DA antagonists or DA depletions 
should closely mimic the effects of pre-feeding to reduce food motivation. In 
fact, several studies have demonstrated that the effects of DA antagonists or DA 
depletions differ substantially from the effects of pre-feeding. In terms of food 
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intake, the effects of haloperidol or forebrain DA depletions on the patterns of 
eating (e.g. rate of feeding, time spent feeding) differ substantially from the 
effects of pre-feeding (Salamone et al., 1991). As we have observed in present 
and previous experiments with sucrose and food, in the concurrent lever 
pressing/ free drinking task, pre-exposure to the sucrose solutions suppressed 
both lever pressing and free consumption, while DA antagonists and Nacb DA 
depletions decreased lever pressing but increased free consumption (Salamone et 
al., 1991).  
 
Taking all these data together, under control conditions, rats press the lever 
to obtain the higher concentration of sucrose even if a low concentration of 
sucrose is freely available in the chamber. This preference for the high 
concentration sucrose was consistent also among the non-operant free concurrent 
access situation. However, if low doses of DA antagonists suppress lever 
pressing for natural reinforcers because they produce a general reduction in 
motivation (activational and directional components), or appetite, or the primary 
reinforcing or incentive properties of sucrose, then reductions of sucrose intake 
should be evident in the same dose range as the suppression of lever pressing. 
Yet, as it has been demonstrated in the present set of results, that is not the case. 
However, interference with DA transmission interacts powerfully with the work 
requirements of instrumental tasks, enhancing the costs associated with 
instrumental actions that have high work requirements. Rats with impaired Nacb 
DA transmission are less likely to work for a reinforcer, and in choice tasks, they 
are biased towards alternative paths to reinforcers that have lower work-related 
response costs (see Salamone et al. 2007, 2009b for review). Thus, in an FR8 
task to obtain 60 microliters of 10% sucrose solution, the number of rewards 
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earned is reduced by injection of D1 or D2 receptor antagonists into the Nacb 
core, an effect that was not observed in an FR1 task (Nicola 2010). The D1 
antagonists SCH23390 injected into VTA failed to alter a single response 
requirement (RR) of 20 or RR1 lever presses for 20 minutes access to 2% 
sucrose fluid (Czachowsi et al., 2012). Both of these RR schedules require a 
very low rate of response in 30 minutes (animals typically lever press 50 times 
or 8 time respectively) compared to the 200 lever presses in 15 minutes required 
in the present experiment. Hsiao and Chen (1995) demonstrated that the 
response requirement (i.e. height of the spout) was an important determinant of 
the effect of the D2 antagonist pimozide on 2% sucrose drinking. Thus DA 
antagonist shifted the behavior of water deprived animals from high effort 
sucrose consumption towards low effort (ease reachable water spout) less 
preferred fluid (tap water). Rats remained fully capable of assuming the standing 
posture for sustained and efficient licking of sucrose if no option was available. 
The authors define the behavior of DA antagonist treated rats as "indolent" 
(Hsiao and Chen, 1995). 
In the present studies interference with DA transmission is not lowering 
the reinforcing value of sucrose, but rather, is lowering the reinforcing value of 
the instrumental actions required to obtain sucrose. In summary, DA depleting 
agents and DA antagonism using low-to-moderate doses of DA antagonists, 
reduce the tendency to work for a reinforcer while leaving intact appetite or 
primary food or sucrose motivation.  
Moreover, within the last few years, we have determined that adenosine 
interacts with DA in the regulation of these effort-related functions. The DA 
antagonism effect has been reversed or attenuated by adenosine antagonists, 
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giving support to the notion that link DA and adenosine systems in Nacb in the 
regulation of instrumental response output and effort-related choice behavior 
(Farrar et al., 2007; Font et al., 2008; Mingote et al., 2008; Mott et al., 2009; 
Salamone et al., 2007, 2009; Worden et al., 2009). Further understanding on 
these processes can help to approach pathologies related to behavioral activation 
and effort (Salamone et al., 2007). Symptoms as anergia, psychomotor slowing 
and fatigue can be seen in depression and other disorders (Demyttenaere et al., 
2005; Salamone et al., 2007) and there is increasing evidence proposing 
adenosine antagonists as new targets for treating them (Salamone et al., 2007).  
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CHAPTER 2: 
 
DOPAMINERGIC MODULATION OF EFFORT-RELATED 
CHOICE BEHAVIOR AS ASSESSED BY A PROGRESSIVE RATIO 
CHOW FEEDING CHOICE TASK: PHARMACOLOGICAL STUDIES 
AND THE ROLE OF INDIVIDUAL DIFFERENCES. 
 
Abstract  
Mesolimbic dopamine (DA) is involved in behavioral activation and 
effort-related processes.  Rats with impaired DA transmission reallocate their 
instrumental behavior away from food-reinforced tasks with high response 
requirements, and instead select less effortful food-seeking behaviors. In the 
present study, the effects of the DA D2 antagonist haloperidol, as well as other 
treatments, were assessed using a progressive ratio (PROG)/chow feeding 
concurrent choice task. With this task, rats can lever press on a PROG schedule 
reinforced by a preferred high-carbohydrate food pellet, or alternatively 
approach and consume the less-preferred laboratory chow that was concurrently 
available. Rats pass through each ratio level by completing 15 ratios, after which 
the ratio requirement is incremented by one additional response (e.g. FR1 15 
times, FR2 15 times, etc.). Haloperidol (0.025-0.1 mg/kg) reduced number of 
lever presses and highest ratio achieved but did not significantly affect chow 
intake. In contrast, the adenosine A2A antagonist MSX-3 increased lever presses 
and highest ratio achieved, but decreased chow consumption. The cannabinoid 
CB1 inverse agonist and putative appetite suppressant AM251 decreased lever 
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presses, highest ratio achieved, and chow intake; this effect was similar to that 
produced by pre-feeding. In the final study, DA-related signal transduction 
activity (pDARPP-32(Thr34) expression) was greater in high responders (i.e., 
rats with high lever pressing output) compared to low responders.  Thus, the 
effects of DA antagonism differed greatly from those produced by reduced food 
motivation or decreases in CB1 transmission.  It appears unlikely that 
haloperidol is reducing PROG responding because of a general reduction in the 
valuation of food reinforcement.  Furthermore, nucleus accumbens core signal 
transduction activity is related to individual differences in work output. 
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INTRODUCTION 
Nucleus accumbens dopamine (DA) plays an important role in regulating 
activational aspects of motivated behaviors (i.e., vigor, persistence, exertion of 
effort), which enable organisms to overcome work-related response costs in 
order to gain access to significant stimuli (Salamone, 1992; Salamone et al., 
1991, 1997, 2003, 2007; Salamone and Correa, 2002; Van den Bos et al., 2006).  
The increased activity induced by scheduled presentation of food reinforcement 
pellets is accompanied by increases in accumbens DA release, and is reduced by 
DA antagonism and accumbens DA depletions (Salamone 1986, 1988; 
McCullough and Salamone 1992).  Rats with accumbens DA depletions are very 
sensitive to ratio requirements in operant lever pressing schedules (Sokolowski 
and Salamone, 1998; Aberman and Salamone, 1999; Correa et al., 2002; 
Mingote et al., 2005). Moreover, DA antagonism or interference with 
accumbens DA transmission alters response allocation in tasks that measure 
effort-related choice behavior (Salamone et al., 1991, 1997, 2003, 2005, 2006, 
2007).   
Several behavioral tasks have been used to investigate the role of DA in 
effort-related choice.  Some studies have used the T-maze barrier task in which 
the animal must choose to either climb a barrier to receive a high density of food 
reward or instead choose the arm of the maze with no barrier that leads to a 
lower density of food reward; in these studies, interference with DA 
transmission decreased selection of the barrier arm and increased choice of the 
low effort arm with no barrier (Salamone et al., 1994; Cousins et al., 1996; Denk 
et al. 2005; Mott et al., 2009; Pardo et al. 2012; Mai et al. 2012).  T-maze and 
lever pressing versions of effort discounting tasks also have demonstrated that 
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DA antagonism shifts choice behavior of rats towards low effort alternatives 
(Floresco et al. 2008; Bardgett et al. 2009). Another task that has been used is 
the concurrent fixed-ratio 5 (FR5)/chow feeding procedure in which rats can 
either lever press on a FR5 schedule for a preferred high-carbohydrate food, or 
approach and consume less-preferred rodent chow that is freely available in the 
chamber (Salamone et al., 1991, 2002, 2003, 2007). Under baseline or control 
conditions, rats tested with this procedure typically obtain most of their food by 
lever pressing while consuming very little of the chow.  Systemic or intra-
accumbens administration of DA antagonists, as well as accumbens DA 
depletions, have been shown to produce a shift in response allocation such that 
lever pressing is decreased but chow intake is substantially increased (Salamone 
et al., 1991, 1996, 2002; Cousins and Salamone, 1994; Cousins et al., 1994; 
Koch et al. 2000; Nowend et al. 2001; Sink et al., 2008; Farrar et al., 2010).  
This effect is not due to drug-induced changes in food preference or 
consumption (Salamone et al. 1991; Koch et al. 2000). Moreover, the effects 
induced by DA antagonism or depletion differ substantially from those seen 
following pre-feeding (Salamone et al., 1991) or treatment with appetite 
suppressant drugs such as fenfluramine (Salamone et al., 2002) or cannabinoid 
CB1 antagonists/ inverse agonists (Sink et al., 2008); these appetite-related 
manipulations failed to increase chow intake at doses that suppress lever 
pressing.   
In addition to nucleus accumbens DA, there is a body of research 
implicating adenosine in behavioral activation and effort-related processes 
(Farrar et al., 2007; Font et al., 2008; Mingote et al., 2008). Adenosine A2A 
receptors are primarily localized in striatal areas, including both neostriatum and 
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nucleus accumbens (Jarvis and Williams, 1989; Schiffmann et al., 1991; DeMet 
and Chicz-DeMet, 2002; Ferre et al., 2004). Furthermore, there is a functional 
interaction between DA D2 and adenosine A2A receptors (Fink et al., 1992; 
Ferre, 1997; Hillion et al., 2002; Fuxe et al., 2003).  Intra-accumbens injections 
of the adenosine A2A agonist CGS 21680 decreased locomotor activity (Barraco 
et al. 1993) and lever pressing on a ratio schedule (Mingote et al. 2008), and also 
produced changes in effort-related choice behavior similar to the effects of DA 
antagonism (Font et al. 2008).  In contrast, adenosine A2A antagonists have been 
shown to stimulate locomotor activity (Collins et al. 2010), and increase fixed 
interval response rate (Randall et al. 2011). Furthermore, several studies have 
shown that adenosine A2A antagonists are capable of reversing the effects of DA 
D2 antagonists on tests of effort-related choice behavior (Farrar et al., 2007; 
Worden et al., 2009; Mott et al. 2009; Salamone et al., 2009; Nunes et al. 2010; 
Farrar et al. 2010; Pardo et al. 2012).  
The present studies were undertaken to investigate a novel variant of the 
operant choice procedure that utilizes a progressive ratio (PROG) work 
requirement. Similar to the FR5/chow feeding choice task, rats tested with this 
PROG/chow feeding procedure have the choice of either responding on the lever 
reinforced by presentation of the more preferred operant pellets vs. approaching 
and consuming the less preferred rodent chow. To assess potential differences in 
behavioral effects across a variety of conditions, four separate experiments were 
conducted using the PROG/chow feeding choice task to study the effects of the 
DA D2 antagonist haloperidol, the adenosine A2A antagonist MSX-3, the 
cannabinoid CB1 antagonist/inverse agonist and putative appetite suppressant 
AM251, and the reinforcer devaluation provided by pre-feeding.  In addition to 
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behavioral pharmacology, DARPP-32-Thr34 immunohistochemistry was 
utilized to further investigate signal transduction activity in 4 specific regions of 
interest. Because the nucleus accumbens is implicated in effort-related decision 
making, both the core and shell divisions were selected for analysis. 
Furthermore, Schweimer and Hauber (2005) demonstrated the importance of DA 
signaling in the anterior cingulate cortex in effort-related decision making, 
therefore the CG1 and CG2 divisions of the cingulate cortex were analyzed for 
DA activity following a PROG/Choice behavioral session.   
It was hypothesized that haloperidol would affect PROG responding in a 
manner that was not dependent upon decreases in primary food motivation or 
appetite, and thus would decrease PROG lever pressing but leave chow intake 
intact.  In addition, it was hypothesized that MSX-3 would produce a behavioral 
effect that was generally opposite to that produced by haloperidol (i.e., increases 
in PROG lever pressing and decreases in chow intake).  Due to the putative 
appetite suppressant effects of interfering with cannabinoid CB1 receptor 
transmission (McLaughlin et al. 2003; Salamone et al. 2007; Sink et al. 2008; 
Randall et al. 2010), it was expected that AM251, as well as pre-feeding, would 
decrease both lever pressing and chow consumption.  Finally, it was 
hypothesized that DARPP-32 immunoreactivity in nucleus accumbens would be 
greater in animals with high baseline levels of lever pressing (i.e., “high 
responders”) than in rats with low levels of lever pressing.  
 
MATERIALS AND METHODS 
Animals 
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48 adult male Sprague-Dawley rats (Harlan, Indianapolis, IN, USA) were 
housed in a colony maintained at 23 °C with 12-h light/dark cycles (lights on at 
0:700 h). Rats weighed 300–350 g at the beginning of the study, and were 
initially food deprived to 85% of their free-feeding body weight for operant 
training. Rats were fed supplemental chow to maintain the food restriction 
throughout the study, with water available ad libitum in the home cages. Despite 
food restriction, rats were allowed modest weight gain throughout the 
experiment. All animal protocols were approved by the University of 
Connecticut Institutional Animal Care and Use Committee, and followed NIH 
guidelines.  
Pharmacological Agents  
Haloperidol was obtained from Sigma-Aldrich (St. Louis, MO) and was 
dissolved in 0.2% tartaric acid solution. This solution also served as the vehicle 
control for haloperidol.  MSX-3 was synthesized in the laboratory of Christa 
Müller (University of Bonn, Bonn, Germany). MSX-3 was dissolved in 0.9% 
saline solution and then pH adjusted with 1M sodium hydroxide to a final pH of 
7.4.. 0.9% saline solution served as the vehicle control for MSX-3. AM251 was 
synthesized in the laboratory of Alex Makriyannis (Northeastern University, 
Boston, MA). AM251 was dissolved in dimethylsulfoxide (DMSO), Tween 80, 
and 0.9% saline at a ratio of 1:1:8. This solution also served as the vehicle 
control for AM251. All doses were selected based on previous work (Sink et al., 
2008; Randall et al., 2011).  
Apparatus and testing procedures 
Preliminary studies were conducted to determine the optimal rate at which 
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the schedule progressed (i.e., number of reinforcements per ratio level and by 
how much the ratio requirement increased with each level). Initial studies used 
either 9 or 12 separate ratios at each ratio level; these schedules produced 
animals that received most of their food from consuming the freely available lab 
chow as opposed to responding on the lever (data not shown). It was found that 
by having to complete15 ratios at each ratio level rats generally lever pressed at 
higher levels before switching to chow.  Behavioral sessions were conducted in 
operant conditioning chambers (28x23x23 cm
3
; Med Associates). Rats were 
initially trained to lever press on a continuous reinforcement schedule (30-min 
sessions; 45-mg pellets, Bioserve, Frenchtown, NJ, USA) for 1 week. Animals 
were then were shifted to the PROG schedule (30-min sessions, 5 days/week) 
and trained for several additional weeks. For PROG sessions, the ratio started at 
FR1 and was increased by one additional response every time 15 reinforcements 
were obtained (FR1x15, FR2x15, FR3x15,…). Additionally, this schedule 
included a “time-out” feature that would deactivate the response lever, removing 
the option for reinforcement for the remainder of the session, if 2 minutes 
elapsed without a ratio being completed. Upon reaching a stable baseline of 
responding, rats were then trained on the concurrent PROG/chow-feeding 
procedure. With this task weighed amounts of laboratory chow (Laboratory Diet, 
5P00 Prolab RMH 3000, Purina Mills, St. Louis, MO, USA; typically 15–20 g) 
were concurrently available on the floor of the chamber during the PROG 
sessions. At the end of the session, rats were immediately removed from the 
chamber, and food intake was determined by weighing the remaining food 
(including spillage). Rats were trained until they attained stable levels of 
baseline lever pressing and chow intake, after which drug testing began. For 
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most baseline days rats did not receive supplemental feeding, however, over 
weekends and after drug tests, rats received supplemental chow in the home 
cage. On baseline and drug treatment days, rats normally consumed all the 
operant pellets that were delivered from lever pressing during each session.  
pDARPP32(Thr34) visualization and quantification 
Free floating coronal sections (50μm) were serially cut using a cryostat 
freezing microtome (Weymouth, MA, USA) and rinsed in 0.01M PBS (pH 7.4). 
Sections for pDARPP32-Thr34 visualization were incubated in a solution of 
0.1% triton-X, 5% normal donkey serum, and PBS for 30 min to block 
endogenous staining. pDARPP32(Thr34) sections were transferred into the 
primary antibody anti-pDARPP32(Thr34) at a concentration of 1:1000 (Santa 
Cruz Biotechnology, USA) for 48 h incubation.   Following the primary 
antibody treatment, sections were rinsed in PBS and incubated in the secondary 
antibody, anti-rabbit HRP conjugate, envision plus (DAKO, Carpinteria, CA, 
USA) for 2 h. The immunohistochemical reaction was developed using 
diaminobenzidine (DAB) as the chromagen. Processed sections were then 
mounted to un-coated slides, air dried, and cover-slipped using Cytoseal 60 
(Thermo Scientific) as a mounting medium.  The sections were examined and 
photographed using a Nikon Eclipse E600 (Melville, NY, USA) upright 
microscope equipped with an Insight Spot digital camera (Diagnostic 
Instruments, Inc). Images of the regions of interest were magnified at 20x and 
captured digitally using SPOT software. Cells that were positively labeled for 
pDARPP32(Thr 34) were quantified with ImageJ software (v. 1.42, National 
Institutes of Health sponsored image analysis program) and a macro written to 
automate particle counting with regions of interest that correspond to pixel 
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intensity. The size of the “region of interest” section counted was 1000x1000μm. 
For each animal, cell counts were at levels that correspond to 1.70mm through 
0.70mm relative to bregma (Paxinos and Watson, 1998) bilaterally from at least 
three sections, and counts were averaged across sides and sections. All cell 
counting was done by an observer who was blind to the experimental conditions.   
Experiments 
For experiments 1-3a and 4, the same group of animals was used (n=32), 
while a different group of animals was used for experiment 3b (n=16). For all 
experiments using drug manipulations (1,2,4), all animals were given a single 
vehicle injection 1 week prior to the beginning of testing to habituate them to the 
testing procedures. Experiments 1,2, and 3b used a within-group design in which 
each rat received all drug or vehicle treatments (IP) in their particular 
experiment in a randomly varied order (one treatment per week). Baseline 
training sessions (i.e., non-drug) were conducted 4 days per week. 
Experiment 1: Effects of the dopamine D2 antagonist haloperidol on 
PROG/chow feeding choice performance. To assess the effects of haloperidol, 
rats were trained on the PROG/chow procedure described above. On test days, 
animals received injections of 0.025, 0.05, 0.1 mg/kg haloperidol or vehicle, 50 
minutes prior to behavioral testing.  
Experiment 2: Effects of the adenosine A2A antagonist MSX-3 on 
PROG/chow feeding choice performance. To assess the effects of the adenosine 
A2A antagonist MSX-3 on progressive choice performance, the same group of 
animals was used. The animals were first given 1 week off from any drug 
testing, but continued normal baseline training. On test days, animals received 
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injections of 0.5, 1.0, 2.0 mg/kg MSX-3 or vehicle, 20 minutes prior to 
behavioral testing.  
Experiment 3: Effects of appetite manipulations on PROG/chow 
performance.  
3A. Effects of pre-feeding to reduce food motivation. To assess the effects 
of pre-feeding on progressive/choice performance, the same group of animals 
was again given 1 week off from testing. The night before testing, animals were 
taken off of food restriction and given ad libitum access to lab chow. On the test 
day, several hours before behavioral testing, animals were given ad libitum 
access to Bioserve pellets in the home cage.  Performance on test day was then 
compared to performance on the previous baseline day.  
3B: Effects of the cannabinoid CB1 inverse agonist and putative appetite 
suppressant AM251. To assess these effects, a new group of animals (n=16) 
were trained on the PROG/choice procedure described above. On test days, 
animals received injections of 2.0, 4.0, 8.0 mg/kg AM251 or vehicle, 30 minutes 
prior to behavioral testing, once per week, in a randomly varied order.  
Experiment 4: Effects of PROG/chow responding on pDARPP32-THR34 
expression: high vs. low responders.Following the conclusion of experiment 3, 
animals (n=32) were given 1 week to re-stabilize their baselines. During the 
following week, 90 minutes after a baseline training session, animals were 
sacrificed and perfused to obtain tissue for pDARPP32-(Thr34) 
immunohistochemical analysis as explained below. For statistical analysis, these 
animals were divided into two groups; high performers and low performers 
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determined by a median split of lever pressing performance on the day of 
perfusion. 
 Statistical analysis 
For the behavioral pharmacology experiments, number of lever presses, 
maximum ratio achieved, active lever time (in seconds) and chow intake (grams) 
were analyzed using repeated measures analysis of variance (ANOVA). Non-
orthogonal planned comparisons using the ANOVA error term (Keppel, 1991) 
were used to compare each treatment with the vehicle control. In addition, to 
provide another statistical measure of the reciprocal relationship between lever 
pressing and chow intake in each experiment, correlations were performed 
between number of lever presses and chow intake data collapsed across all 
conditions within the experiment (e.g., Salamone et al. 2002).  For experiment 4, 
pDARPP32(Thr34) cell counts were analyzed for differences in expression 
between high and low responders (after a median split of the lever pressing data) 
for each of 4 regions of interest, and t-tests were performed to determine 
significant differences.  
 
RESULTS 
Experiment 1: Effects of the DA D2 antagonist haloperidol. Haloperidol 
significantly decreased the number of lever presses (F(3,93) = 4.598, p < 0.01, 
see figure 1A). Planned comparisons revealed that there was a significant 
difference between 0.1 mg/kg haloperidol and vehicle conditions (p < 0.05). 
Coinciding with the decreases in raw numbers of presses, haloperidol also 
significantly decreased maximum ratio achieved (F(3,93) = 8.661, p < 0.01, 
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figure 1B), and the amount of time the lever remained active (F(3,93) = 6.723, p 
< 0.01, figure 1C); for both measures, planned comparisons showed a significant 
difference between vehicle and 0.1 mg/kg haloperidol (p < 0.05).  Haloperidol 
produced no significant effects on chow consumption in the dose range tested 
(figure 1D). However, there was a tendency for animals that had high control 
rates of responding, and correspondingly low vehicle levels of chow intake, to 
show increases in chow intake with haloperidol; this was marked by the 
significant correlation between vehicle number of lever presses and the change 
in chow consumption from vehicle to the highest dose of haloperidol (r = 0.69, 
df = 30, p < 0.05).  Collapsed across all conditions, there was a significant 
negative correlation between number of lever presses and chow consumption (r 
= -0.765, df = 126, p < 0.05), which demonstrated the overall inverse 
relationship between lever pressing and chow intake.  
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Fig 1 (A-D). Effects of Haloperidol on the concurrent PROG/chow-feeding 
procedure. (A): Mean (+SEM) number of lever presses in 30 minutes. (B): Mean 
(+SEM) maximum ratio achieved during test sessions (C): Mean (+SEM) time 
in seconds that the lever remained active. (D): Mean (+SEM) amount of chow 
intake. *p<0.05, different from vehicle (VEH).   
 
Experiment 2: Effects of the adenosine A2A antagonist MSX-3. MSX-3 
affected all four of the observed behavioral measures. MSX-3 significantly 
increased number of lever presses (F(3,93) = 4.120, p < 0.01, figure 2A), and 
planned comparisons showed that both 1.0 and 2.0 mg/kg doses of MSX-3 
increased number of lever presses compared to vehicle (p < 0.05). There also 
was a significant increase in maximum ratio achieved (F(3,93) = 8.206, p < 0.01, 
see figure 2B), with the 1.0 and 2.0 mg/kg doses of MSX-3 differing 
significantly from vehicle (p < 0.05). Furthermore, MSX-3 increased active lever 
time (F(3,93) = 3.784, p < 0.05, figure 2C). Planned comparisons showed that 
only the 2.0 mg/kg MSX-3 significantly affected active lever time (p < 0.05). 
Conversely, MSX-3 significantly decreased chow intake (F(3,93) = 8.017, p < 
0.01, see figure 2D). Planned comparisons revealed that chow intake was 
decreased at a dose of 2.0 mg/kg MSX-3 compared to vehicle (p < 0.05).  As 
with experiment 1, there was a significant negative correlation between lever 
pressing and chow intake when the data were collapsed across all conditions (r = 
-0.781, df = 126, p < 0.05). 
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Fig 2. (A-D). Effects of MSX-3 on the concurrent PROG/chow-feeding 
procedure. (A): Mean (+SEM) number of lever presses in 30 minutes. (B): Mean 
(+SEM) maximum ratio achieved during test sessions. (C): Mean (+SEM) time 
in seconds that the lever remained active. (D): Mean (+SEM) amount of chow 
intake. *p<0.05, different from vehicle (VEH).   
 
Experiment 3: Effects of appetite-related manipulations on PROG/chow 
performance: effects of pre-feeding and the putative appetite suppressant 
AM251. Experiment 3a studied the effects of pre-feeding on PROG/chow intake 
choice performance. Compared to the previous baseline day, pre-feeding the 
animals prior to the session produced marked decreases in number of lever 
presses (t = 2.96, df = 31, p < 0.05), and maximum ratio achieved (t = 3.94, df = 
31, p < 0.05), but no significant effect on active lever time (figures 3A-C).  Pre-
feeding significantly decreased chow intake (t = 13.69, df = 31, p < 0.01) 
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compared to previous day baseline performance (figure 3D). There was no 
significant overall correlation between number of lever presses and chow 
consumption (r = 0.12, df = 62, n.s.).  
 
Fig 3. (A-D). Effects of AM251 on the concurrent PROG/chow-feeding 
procedure. (A): Mean (+SEM) number of lever presses in 30 minutes. (B): Mean 
(+SEM) maximum ratio achieved during test sessions. (C): Mean (+SEM) time 
in seconds that the lever remained active. (D): Mean (+SEM) amount of chow 
intake. *p<0.05, different from Baseline. 
 
Experiment 3b studied the effects of the cannabinoid CB1 inverse agonist 
AM251 on PROG/chow performance. AM251 decreased the number of lever 
presses (F(3,45) = 3.891, p < 0.05, figure 4A), and the maximum ratio achieved 
(F(3,45) = 5.811, p < 0.05, see figure 4B). Planned comparisons showed that 
with both measures, only the highest dose of 8.0 mg/kg AM251 significantly 
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differed from vehicle (p < 0.05). AM251 did not produce any significant 
changes in active lever time (figure 4C), but it did produce a significant decrease 
in chow intake (F(3,45) = 45.634, p < 0.01, figure 4D), with all doses being 
significantly different from vehicle (p < 0.05). There was no significant overall 
correlation between number of lever presses and chow consumption (r = -0.05, 
df = 62, n.s.).  
 
Fig 4. (A-D). Effects of Pre-Feeding on the concurrent PROG/chow-feeding 
procedure. (A): Mean (+SEM) number of lever presses in 30 minutes. (B): Mean 
(+SEM) maximum ratio achieved during test sessions. (C): Mean (+SEM) time 
in seconds that the lever remained active. (D): Mean (+SEM) amount of chow 
intake. *p<0.05, different from vehicle (VEH).   
 
Experiment 4: pDARPP-32(Thr34) Immunohistochemistry in high and 
low responders. Performance on the progressive ratio/chow feeding choice task 
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was highly variable; some rats lever pressed fewer than 100 times and had high 
levels of chow intake, while others lever pressed more than 1000 times and 
consumed only small amounts of chow.  This variability was seen across all the 
experiments described above, and in some cases was related to the drug effects 
seen. For example, the effects of haloperidol were more marked in rats with 
higher control levels of lever pressing.  When a median split was done, and high 
and low lever pressing was used as a factor in a 2 x 4 factorial ANOVA, there 
was an overall effect of dose (F(3,90) = 5.071, p < 0.05) and importantly, a dose 
by group interaction (F(3,90) = 4.189, p < 0.05). Although the repeated 
measures ANOVA demonstrated that both low and high responders showed 
significant decreases in number of lever presses (low responders: F(3,45) = 
2.790, p < 0.05; high responders: F(3,45) = 4.638, p < 0.05), analysis of effect 
sizes showed that the suppressive effect of haloperidol on number of lever 
presses was greater in high responders (eta
2
 = 0.236) than low responders (eta
2
 = 
0.157).  Similar analyses revealed differences between high and low responders 
in the AM251 experiment, with only the high responders showing a significant 
drug effect on number of lever presses.  Because of this large variability, the 
final experiment investigated potential neurochemical differences between high 
and low responders, using pDARPP-32(Thr34) as a marker of signal 
transduction activity.  To analyze the pDARPP-32(Thr34) expression data, a 
median split based upon behavioral performance during the final test day was 
performed, yielding two groups: high responders (n = 16, mean = 812.44, SEM 
= 201.68, range = 205–2852) and low responders (n = 16, mean = 116.31, SEM 
= 12.81, range = 54–190). Four regions of interest were selected for analysis: 
cingulate cortex CG1/CG2 and nucleus accumbens core/shell (Figures 5-6). 
 127 
There was no difference in pDARPP-32(Thr34) expression between high and 
low responders in CG1 (t = -0.066, df = 28, n.s.) or CG2 (t = 0.172, df = 25, 
n.s.). When examining the nucleus accumbens, the shell showed no significant 
differences in pDARPP-32(Thr34) expression between high and low responders 
(t = 1.415, df = 30, n.s.).  In contrast, nucleus accumbens core showed a 
significant difference in expression between high and low responders (t = 2.703, 
df = 29, p < 0.05, Figures 5-6).  
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Fig 5 (A-D). pDARPP-32(Thr34) immunocytochemistry – (A and B): Atlas 
plates (modified from Paxinos and Watson, 1998) with regions of interest 
denoted by squares. (C): High magnification photomicrograph of pDARPP-
32(Thr34) immunoreactive cells at 40x magnification. (D): Mean (+SEM) 
number of pDARPP-32(Thr34) positive cells counted in each region of interest 
in high performers and low performers. There were significantly more pDARPP-
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32(Thr34) positive cells counted in the nucleus accumbens core of high 
performers compared to low performers. (* p < 0.05) 
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Fig 6 (A-H). Pictures showing expression of pDARPP-32-Thr34 
immunoreactivity in CG1 (A-B) CG2 (C-D), Nacb core (E-F) and shell (G-H) in 
a representative animal of the high responders group (right side images) and of 
the low responders group (left side images) tested in the concurrent 
PROG/chow-feeding procedure. Scale bar: 50 microm.  
 
DISCUSSION 
The present studies investigated the effects of several manipulations on a 
concurrent progressive ratio/chow feeding task. Experiment 1 demonstrated that 
the DA D2 antagonist haloperidol decreased number or lever presses, maximum 
ratio achieved, and active lever time (i.e., the time the PROG schedule was 
active). These findings are consistent with previous studies showing the ability 
of DA antagonists or accumbens DA depletions to reduce food-reinforced lever 
pressing in animals responding on the concurrent FR5/choice task (Salamone et 
al., 1991, 2002; Sink et al., 2008), as well as conventional operant schedules, 
including various versions of the progressive ratio schedule (Aberman et al., 
1998; Hamill et al. 1999).   Despite producing clear reductions in multiple 
measures of operant responding, haloperidol did not decrease chow intake, 
which indicates that primary food motivation was intact in haloperidol-treated 
rats.  Moreover, previous studies have shown that 0.1 mg/kg haloperidol does 
not change preference for high carbohydrate food pellets relative to chow, or 
reduce total intake of either food type (Salamone et al. 1990, 1991). In fact, there 
was a slight tendency for some rats to show increased chow intake after 
haloperidol treatment, which was marked by the significant correlation between 
vehicle lever pressing and the change in chow intake between vehicle and the 
highest dose of haloperidol.  In other words, animals that were high lever press 
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responders under the vehicle condition, and therefore had correspondingly low 
levels of chow intake, showed greater increases in chow consumption on 
haloperidol than low responders did.  In fact, the four rats with the highest level 
of lever pressing showed very substantial increases in chow intake after 
haloperidol injection (i.e., increases of 4-7 grams compared to baseline). 
Nevertheless, unlike the previous experiments using the FR5/chow choice 
procedure (e.g. Salamone et al. 1991, 2002; Sink et al. 2008), haloperidol did not 
produce an overall significant increase in chow intake.  One possible explanation 
for this pattern is the different levels of chow intake with the two procedures.  
With the FR5/chow choice procedure, baseline or control levels of lever pressing 
are relatively high, while chow intake is relatively low (i.e., 1-2 grams), making 
it possible to observe an increase in chow intake with administration of a DA 
antagonist. In contrast, baseline or control levels of chow intake are much higher 
with the PROG/chow choice procedure (i.e., 7-8 grams), and are near ceiling 
levels of chow intake for a 30 minute period without water being available.  For 
example, Randall et al. (2010) demonstrated that food-restricted rats in a free 
feeding study consume approximately 8 grams of chow in a 30-minute period.  
Thus, with the PROG/chow choice procedure, it is difficult to observe drug-
induced increases in chow intake in animals that are already eating chow at 
maximal or near maximal levels.  
Experiment 2 showed that the adenosine A2A antagonist MSX-3 
produced effects that were opposite to those of haloperidol; MSX-3 increased 
number of lever presses and maximum ratio achieved, and also increased the 
amount of time that animals kept the lever active during the session. This is 
consistent with previous work showing that adenosine A2A antagonists have 
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stimulant-like properties. For example, the adenosine A2A antagonists MSX-3 
and istradefylline were both shown to increase lever pressing on a fixed interval 
4-minute schedule, which generates a relatively low baseline rate of responding 
(Randall et al., 2011).  Nevertheless, the present results are the first to 
demonstrate that an adenosine A2A antagonist can increase lever presses and 
break point on a progressive ratio schedule.  In addition, the PROG/chow 
feeding choice procedure allowed for parallel assessment of food intake, and 
MSX-3 was observed to decrease chow consumption at the highest dose.  
Interestingly, although MSX-3 and haloperidol produced opposite effects on 
measures of PROG lever pressing and chow intake, in both experiments, the 
reciprocal relation between lever pressing and chow intake was preserved, as 
indicated by the high negative correlations between lever pressing and chow 
intake across all treatments (-0.76 and -0.78).  This inverse correlation between 
lever pressing and chow intake has been reported in previous experiments 
studying the effects of DA antagonists or depletions on FR5/chow feeding 
choice performance (Cousins et al. 1993; Salamone et al. 2002; Sink et al. 2008). 
Experiment 3 was conducted to determine the effect of appetite-related 
manipulations on PROG/chow feeding choice performance, in order to provide a 
contrast with the effects of haloperidol.  Two different appetite manipulations 
were employed: pre-feeding, and administration of a cannabinoid CB1 receptor 
antagonist/inverse agonist.  Pre-feeding animals prior to their test session, which 
was used to reduce food motivation and thereby devalue the food reinforcement 
(Salamone et al. 1990; Aberman and Salamone 1999), produced marked 
decreases in number of lever presses and highest ratio achieved. But, unlike the 
effects of haloperidol, pre-feeding also substantially reduced chow consumption.  
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In experiment 3b, the CB1 receptor antagonist/inverse agonist AM251 produced 
similar effects to those resulting from pre-feeding. CB1 antagonists/inverse 
agonists are putative appetite suppressant drugs that have been shown to 
decrease food intake in animals (Chen et al., 2004; Colombo et al., 1998; 
Shearman et al., 2003; McLaughlin et al., 2003, 2005, 2006; Sink et al., 2008, 
Randall et al., 2010) and humans (Pi-Sunyer et al., 2006; Despres et al., 2005; 
Van Gaal et al., 2005). On the PROG/chow feeding choice task, AM251 
decreased number of lever presses, maximum ratio achieved, and chow 
consumption.   Thus, the pattern of effects on lever pressing and chow intake 
produced by pre-feeding and AM251 differed markedly from those produced by 
haloperidol.  Moreover, while there was a high inverse correlation between lever 
pressing and chow intake in the haloperidol experiment, there were no 
significant correlations between these measures in the pre-feeding and AM251 
experiments.  This analysis shows that the inverse relation between lever 
pressing and chow intake, which is evident under baseline conditions and also in 
the haloperidol experiment, is not shown when primary food motivation is 
reduced by pre-feeding or drugs, because under appetite-related manipulations 
rats show decreases in both food reinforced lever pressing and chow 
consumption (Salamone et al. 2002; Sink et al. 2008).  Taken together, these 
results demonstrate that it is exceedingly unlikely that haloperidol is decreasing 
PROG lever pressing because of a reduction in primary food motivation or 
reinforcement. Clearly, in the absence of parallel measures of food intake, 
progressive ratio break points should not be used as markers of food “reward”, 
or hedonic reactivity to food.  
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An important aspect of the PROG/choice procedure is that performance 
is characterized by substantial individual variability.  While some rats lever 
pressed relatively little (i.e., < 100 times) and had high levels of chow intake, 
others lever pressed much more (i.e., up to > 2800 responses) and ate relatively 
little chow.  Analysis of the first experiment showed that the effects of 
haloperidol on lever pressing were greater in rats with higher control levels of 
lever pressing.  Experiment 4 employed pDARPP-32-(Thr34) 
immunohistochemistry to determine if there were neurochemical differences 
between high responders and low responders.  The entire group of animals was 
divided in two by a median split based upon numbers of lever presses, and 
DARPP-32 expression was determined in four regions of interest.  High 
responders did not differ from low responders in terms of DARPP-32 expression 
in CG1 or CG2 regions of anterior cingulate cortex, or in nucleus accumbens 
shell. However, high responders did show greater DARPP-32 expression in 
nucleus accumbens core than low responders.   DARPP-32 immunoreactivity 
was used to provide a signal transduction marker of neural activity, and evidence 
indicates that DA acting through the D1 receptor and the G proteins (Gs/Golf) 
activates adenylate cyclase activity, thereby stimulating PKA-mediated 
phosphorylation of DARPP-32 at the Thr34 site (Nishi et al. 2000; Kuroiwa et 
al. 2008; Bateup et al. 2008; Yger and Girault 2011).  DARPP-32 expression has 
been used to study of drug action (Bateup et al. 2008; Yger and Girault 2011), 
and a few studies have focused on changes in DARPP-32 immunoreactivity 
associated with behavioral manipulations.  Danielli et al. (2010) demonstrated 
that DARPP-32 showed increased expression in nucleus accumbens shell during 
the first exposure to a novel food.  Recently, Segovia et al. (2012) reported that 
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pDARPP-32(Thr34) expression in nucleus accumbens shell and core was 
increased in animals undergoing FR5 operant training.  Although several 
neurochemical factors can influence pDARPP-32(Thr34) production, it is 
reasonable to suggest that the higher level of pDARPP-32(Thr34) expression in 
high responders relative to low responders could reflect greater DA transmission 
in the animals working harder on the lever pressing component of the task 
(Segovia et al. 2011, 2012).   If so, this could indicate that individual differences 
in work output are related to increased DA transmission in ventral striatum, as 
recently shown in a human imaging study (Treadway et al. 2012). 
In summary, the DA antagonist haloperidol reduced the number of lever 
presses and highest ratio achieved but did not significantly affect chow intake. In 
contrast, the adenosine A2A antagonist and minor stimulant MSX-3 increased 
lever presses and highest ratio achieved, but decreased chow consumption.  Pre-
feeding and administration of the cannabinoid CB1 antagonist/inverse agonist 
AM251 decreased lever presses, highest ratio achieved, and chow intake. Thus, 
the effects of DA antagonism differed greatly from those produced by reduced 
food motivation or decreases in CB1 transmission.  It appears unlikely that 
haloperidol is reducing PROG responding because of a general reduction in the 
valuation of food reinforcement.   Furthermore, DA-related signal transduction 
activity (pDARPP-32(Thr34) expression) was greater in high responders (i.e., 
rats with high lever pressing output) compared to low responders, indicating that 
nucleus accumbens core signal transduction activity is related to individual 
differences in work output. Future studies should compare the effects of DA D1 
and D2 antagonists, and should determine if adenosine A2A antagonism is 
capable of reversing the effects of DA antagonism.  Studies comparing 
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cannabinoid CB1 inverse agonists with neutral antagonists (e.g. Sink et al. 2008; 
Randall et al. 2010) would be useful for further exploration of the role of CB1 
receptor signaling in performance on this procedure.  Finally, additional 
neurochemical correlates should be investigated for their possible relation to 
lever pressing output on this task, including microdialysis studies of DA release 
(Segovia et al. 2011), and other markers of signal transduction activity (e.g. c-
Fos, pDARPP-32(Thr75)) in different striatal cell types (e.g. encephalin or 
substance P positive neurons; Segovia et al. 2012).  
 
REFERENCES 
Aberman JE, Salamone JD (1999) Nucleus accumbens dopamine depletions 
make rats more sensitive to high ratio requirements but do not impair primary food 
reinforcement. Neuroscience 92: 545-552 
Aberman JE, Ward SJ, Salamone JD (1998) Effects of dopamine antagonists 
and accumbens dopamine depletions on time-constrained progressive-ratio 
performance. Pharmacol Biochem Behav 61:341-348 
Bardgett ME, Depenbrock M, Downs N, Points M, Green L (2009) Dopamine 
modulates effort-based decision making in rats. Behav Neurosci 123:242-251 
Barraco RA, Martens KA, Parizon M, Normile HJ (1993) Adenosine A2a 
receptors in the nucleus accumbens mediate locomotor depression. Brain Res Bull 
31:397-404 
Bateup HS, Svenningsson P, Kuroiwa M, Gong S, Nishi A, Heintz N, 
Greengard P (2008) Cell type-specific regulation of DAPP-32 phosphorylation by 
psychostimulant and antipsychotic drugs. Nat Neurosci 11: 932-939  
Chen RZ, Huang RR, Shen CP, MacNeil DJ, Fong TM (2004) Synergistic 
effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food 
intake in mice. Brain Res 999: 227-230 
Collins LE, Galtieri DJ, Collins P, Jones SK, Port RG, Paul NE, Hockemeyer J, 
Müller CE, Salamone JD (2010) Interactions between adenosine and dopamine receptor 
antagonists with different selectivity profiles: Effects on locomotor activity. Behav 
Brain Res 211:148-155 
Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL (1998) Appetite 
suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 
63:113-117 
 137 
Correa M, Carlson BB, Wisniecki A, Salamone JD (2002) Nucleus accumbens 
dopamine and work requirements on interval schedules. Behav Brain Res 137:179-187 
Cousins MS, Wei W, Salamone JD (1994) Pharmacological characterization of 
performance on a concurrent lever pressing/feeding choice procedure: effects of 
dopamine antagonist, cholinomimetic, sedative and stimulant drugs.  
Psychopharmacology 116:529-537  
Cousins MS, Atherton A, Turner L, Salamone JD (1996) Nucleus accumbens 
dopamine depletions alter relative response allocation in a T-maze cost/benefit task. 
Behavioral Brain Research 74:189-197 
Cousins MS, Salamone JD (1994) Nucleus accumbens dopamine depletions in 
rats affect relative response allocation in a novel cost/benefit procedure. Pharmacol 
Biochem Behav 49:85-91 
Cousins MS, Sokolowski JD, Salamone JD (1993) Different effects of nucleus 
accumbens and ventrolateral striatal dopamine depletions on instrumental response 
selection in the rat. Pharmacol Biochem Behav 46:943-951 
Danielli B, Scheggi S, Grappi S, Marchese G, De Montis MG, Tagliamonte A, 
Gambarana C (2010). Modifications in DARPP-32 phosphorylation patterns after 
repeated palatable food consumption undergo rapid habituation in the nucleus 
accumbens shell of non-food-deprived rats. J Neurochem 112: 531-541  
DeMet EM, Chicz-DeMet A (2002) Localization of adenosine A2A-receptors in 
rat brain with [3H]ZM-241385. Naunyn Schmiedebergs Arch Pharmacol 366:478-481 
Denk F, Walton ME, Jennings KA, Sharp T, Rushworth MF, Bannerman DM 
(2005) Differential involvement of serotonin and dopamine systems in cost–benefit 
decisions about delay or effort. Psychopharmacology 179:587-596 
Després JP, Golay A, Sjöström L, Rimonabant in Obesity-Lipids Study Group 
(2005) Effects of rimonabant on metabolic risk factors in overweight patients with 
dyslipidemia. N Engl J Med 353: 2121-2134 
Farrar AM, Segovia KN, Randall PA, Nunes EJ, Collins LE, Stopper CM, Port 
RG, Hockemeyer J, Müller CE, Correa M, Salamone JD (2010) Nucleus accumbens and 
effort-related functions: behavioral and neural markers of the interactions between 
adenosine A2A and dopamine D2 receptors. Neuroscience 166:1056-1067 
Farrar AM, Pereira M, Velasco F, Hockemeyer J, Muller CE, Salamone JD 
(2007) Adenosine A(2A) receptor antagonism reverses the effects of dopamine receptor 
antagonism on instrumental output and effort-related choice in the rat: implications for 
studies of psychomotor slowing. Psychopharmacology 191:579-586 
Ferré S, Ciruela F, Canals M, Marcellino D, Burgueno J, Casado V, Hillion J, 
Torvinen M, Fanelli F, Benedetti PP, Goldberg SR, Bouvier M, Fuxe K, Agnati LF, 
Lluis C, Franco R, Woods A (2004) Adenosine A2A-dopamine D2 receptor-receptor 
heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat. Disord. 
10:265-271 
Ferré S (1997) Adenosine-dopamine interactions in the ventral striatum. 
Implications for the treatment of schizophrenia. Psychopharmacology 133:107-120 
Fink JS, Weaver DR, Rivkees SA, Peterfreund RA, Pollack AE, Adler EM, 
Reppert SM (1992) Molecular cloning of the rat A2 adenosine receptor: selective co-
 138 
expression with D2 dopamine receptors in rat striatum. Brain Res Mol Brain Res 
14:186-195 
Floresco SB, Tse MT, Ghods-Sharifi S (2008) Dopaminergic ad glutamatergic 
regulation of effort- and delay-based decision making. Neuropsychopharmacology 
33:1966-1979 
Font L, Mingote S, Farrar AM, Pereira M, Worden L, Stopper C, Port RG, 
Salamone JD (2008) Intra-accumbens injections of the adenosine A(2A) agonist CGS 
21680 affect effort-related choice behavior in rats. Psychopharmacology 199:515-526 
Fuxe K, Agnati LF, Jacobsen K, Hillion J, Canals M, Torvinen M, Tinner-
Staines B, Staines W, Rosin D, Terasmaa A, Popoli P, Leo G, Vergoni V, Lluis C, 
Ciruela F, Franco R, Ferré S (2003) Receptor heteromerization in adenosine A2A 
receptor signaling: relevance for striatal function and Parkinson's disease. Neurology 
61:S19-23 
Hamill S, Trevitt JT, Nowend KL, Carlson BB, Salamone JD (1999) Nucleus 
accumbens dopamine depletions and time-constrained progressive ratio performance: 
effects of different ratio requirements. Pharmacol Biochem Behav 64: 21-27 
Hillion J, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A, Hansson A, 
Watson S, Olah ME, Mallol J, Canela EI, Zoli M, Agnati LF, Ibanez CF, Lluis C, 
Franco R, Ferre S, Fuxe K (2002) Coaggregation, cointernalization, and 
codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 
277:18091-1809 
Jarvis MF, Williams M (1989) Direct autoradiographic localization of 
adenosine A2 receptors in the rat braing using the A2-selective agonist. [3H]CGS 
21680. Eur J Pharmacol 168: 243-246  
Keppel G (1991) Design and Analysis: a researchers handbook. Prentice-Hall, 
Englewood Cliffs, NJ. 
Koch M, Schmid A, Schnitzler HU (2000) Role of nucleus accumbens 
dopamine D1 and D2 receptors in instrumental and Pavlovian paradigms of conditioned 
reward. Psychopharmacology 152:67-73 
Kuroiwa M, Mateup HS, Higashi H, Tanaka M, Nishi A (2008) Regulation of 
DARPP-32 phosphorylation by three distinc dopamine D1-like receptor signaling 
pathways in the neostriatum. J Neurochem 107: 1014-1026  
Mai B, Sommer S, Hauber W (2012) Motivational states influence effort-based 
decision making in rats: the role of dopamine in the nucleus accumbens. Cogn Affect 
Behav Neurosci 12: 74-84 
McCullough LD, Salamone JD (1992) Involvement of nucleus accumbens 
dopamine in the motor activity induced by periodic food presentation: a microdialysis 
and behavioral study. Brain Res 592:29-36 
McLaughlin PJ, Winston K, Swezey L, Wisniecki A, Aberman J, Tardif DJ, 
Betz AJ, Ishiwari K, Makriyannis A, Salamone JD (2003) The cannabinoid CB1 
antagonists SR 141716A and AM 251 supress food intake and food-reinforced behavior 
in a variety of tasks in rats. Behav Pharmacol 14: 583-588 
McLaughlin PJ, Lu D, Winston KM, Thakur G, Swezey LA, Makriyannis A, 
Salamone JD (2005) Behavioral effects of the novel cannabinoid full agonist AM 411. 
Pharmacol Biochem Behav 81: 78-88 
 139 
McLaughlin PJ, Qian L, Wood JT, Wisniecki A, Winston KM, Swezey LA, 
Ishiwari K, Betz AJ, Pandarinathan L, Xu W, Makriyannis A, Salamone JD (2006) 
Suppression on food intake and food-reinforced behavior produced by the novel CB1 
receptor antagonist/inverse agonist AM 1387. Pharmacol Biochem Behav 83: 396-402 
Mingote S, Font L, Farrar AM, Vontell R, Worden LT, Stopper CM, Port RG, 
Sink KS, Bunce JG, Chrobak JJ, Salamone JD (2008) Nucleus accumbens adenosine 
A2A receptors regulate exertion of effort by acting on the ventral striatopallidal 
pathway. J Neurosci 28:9037-9046 
Mingote S, Weber SM, Ishiwari K, Correa M, Salamone JD (2005) Ratio and 
time requirements on operant schedules: effort-related effects of nucleus accumbens 
dopamine depletions. Eur J Neurosci 21:1749-1757 
Mott AM, Nunes EJ, Collins LE, Port RG, Sink KS, Hockemeyer J, Müller CE, 
Salamone JD (2009) The adenosine A2A antagonist MSX-3 reverses the effects of the 
dopamine antagonist haloperidol on effort-related decision making in a T-maze 
cost/benefit procedure. Psychopharmacology 204:103-112 
Nishi A, Bibb JA, Snyder GL, Higashi H, Nairn AC, Greengard P (2000) 
Amplification of dopaminergic signaling by a positive feedback loop. Proc Natl Acad 
Sci USA 97: 12840-12845 
Nowend KL, Arizzi M, Carlson BB, Salamone JD (2001) D1 or D2 antagonism 
in nucleus accumbens core or dorsomedial shell suppresses lever pressing for food but 
leads to compensatory increases in chow consumption. Pharmacol Biochem Behav 
69:373-382 
 Nunes EJ, Randall PA, Santerre JL, Given AB, Sager TN, Correa M, Salamone 
JD (2010) Differential effects of selective adenosine antagonists on the effort-related 
impairments induced by dopamine D1 and D2 antagonism. Neuroscience 170:268-280 
Pardo M, Lopez-Cruz L, Valverde O, Ledent C, Baqi Y, Müller CE, Salamone 
JD, Correa M (2012) Adenosine A2A receptor antagonism and genetic deletion 
attenuate the effects of dopamine D2 antagonism on effort-based decisión making in 
mice. Neuropharmacology 62: 2068-2077 
Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J (2006) Effect of rimonabant, 
a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in 
overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 
295: 761–775 
Randall PA, Vemuri VK, Segovia KN, Torres EF, Hosmer S, Nunes EJ, 
Santerre JL, Makriyannis A, Salamone JD (2010) The novel cannabinoid CB1 
antagonist AM6545 suppresses food intake and food-reinforced behavior. Pharmacol 
Biochem Behav 97:179-184 
Randall PA, Nunes EJ, Janniere SL, Stoper CM, Farrar AM, Sager TN, Baqi Y, 
Hockemeyer J, Müller CE, Salamone JD (2011) Stimulant effects of adenosine 
antagonists on operant behavior: differential actions of selective A2A and A1 
antagonists. Psychopharmacology 216: 173-86 
Salamone JD (1986) Different effects of haloperidol and extinction on 
instrumental behaviours. Psychopharmacology 88:18-23 
 140 
Salamone JD (1988) Dopaminergic involvement in activational aspects of 
motivation: effects of haloperidol on schedule induced activity, feeding and foraging in 
rats. Psychobiology 16:196-206 
Salamone JD (1994) The involvement of nucleus accumbens dopamine in 
appetitive and aversive motivation. Behav Brain Res 61:117-133 
Salamone JD (1996) The behavioral neurochemistry of motivation: 
methodological and conceptual issues in studies of the dynamic activity of nucleus 
accumbens dopamine. J Neurosci Methods 64:137-149 
  Salamone JD, Correa M (2002) Motivational views of reinforcement: 
implications for understanding the behavioral functions of nucleus accumbens 
dopamine. Behav Brain Res 137:3-25 
Salamone JD, Zigmond MJ, Stricker EM (1990) Characterization of the 
impaired feeding behavior in rats given haloperidol or dopamine-depleting brain 
lesions. Neuroscience 39: 17-24 
Salamone JD, Steinpreis RE, McCullough LD, Smith P, Grebel D, Mahan K 
(1991) Haloperidol and nucleus accumbens dopamine depletion suppress lever pressing 
for food but increase free food consumption in a novel food choice procedure. 
Psychopharmacology 104:515-521 
Salamone JD (1992) Complex motor and sensorimotor functions of striatal and 
accumbens dopamine: involvement in instrumental behavior processes. 
Psychopharmacology 107:160-174 
Salamone JD, Cousins MS, Bucher S (1994) Anhedonia or anergia? Effects of 
haloperidol and nucleus accumbens dopamine depletion on instrumental response 
selection in a T-maze cost/benefit procedure. Behav Brain Res 65:221-229  
Salamone JD, Cousins MS, Maio C, Champion M, Turski T, Kovach J (1996) 
Different behavioral effects of haloperidol, clozapine and thioridazine in a concurrent 
lever pressing and feeding procedure. Psychopharmacology 125:105-112 
Salamone JD, Cousins MS, Snyder BJ (1997) Behavioral functions of nucleus 
accumbens dopamine: empirical and conceptual problems with the anhedonia 
hypothesis. Neurosci Biobehav Rev 21:341-359 
Salamone JD, Arizzi M, Sandoval MD, Cervone KM, Aberman JE (2002) 
Dopamine antagonsts alter response allocation but do not suppress appetite for food in 
rats: Contrast between the effects of SKF 83566, raclopride and fenfluramine on a 
concurrent choice task. Psychopharmacology 160:371-380 
Salamone JD, Correa M, Mingote S, Weber SM (2003) Nucleus accumbens 
dopamine and the regulation of effort in food-seeking behavior: implications for studies 
of natural motivation, psychiatry, and drug abuse. J Pharmacol Exp Ther 305:1-8 
Salamone JD, Correa M, Mingote SM, Weber SM (2005) Beyond the reward 
hypothesis: alternative functions of nucleus accumbens dopamine. Curr Opin Pharmacol 
5:34-41 
Salamone JD, Correa M, Mingote SM, Weber SM, Farrar AM (2006) Nucleus 
accumbens dopamine and the forebrain circuitry involved in behavioral activation and 
effort-related decision making: implications of understanding anergia and psychomotor 
slowing and depression. Curr Psychiat Rev 2:267-280 
 141 
Salamone JD, Correa M, Farrar A, Mingote SM (2007) Effort-related functions 
of nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology 
191:461-482 
Salamone JD, Correa M, Farrar AM, Nunes EJ, Pardo M (2009a) Dopamine, 
behavioral economics, and effort. Front Behav Neurosci 3:13 
Salamone JD, Farrar AM, Font L, Patel V, Schlar DE, Nunes EJ, Collins LE, 
Sager TN (2009b) Differential actions of adenosine A1 and A2A antagonists on the 
effort-related effects of dopamine D2 antagonism. Behav Brain Res 201:216-222 
Schiffmann SN, Jacobs O, Vanderhaeghen JJ (1991) Striatal restricted 
adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P 
neurons: an in situ hybridization histochemistry study. J Neurochem 57:1062-1067 
Schweimer J, Saft S, Hauber W (2005) Involvement of catecholamine 
neurotransmission in the rat anterior cingulate in effort-related decision making. Behav 
Neurosci 119:1687-1692 
Segovia KN, Correa M, Salamone JD (2011) Slow phasic changes in nucleus 
accumbens dopamine release during fixed ratio acquisition: a microdialysis study. 
Neuroscience 196: 178-188 
Segovia KN, Correa M, Lennington JB, Conover JC, Salamone JD (2012) 
Changes in nucleus accumbens and neostriatal c-Fos and DARPP-32 immunoreactivity 
during different stages of food-reinforced instrumental training. Eur J Neurosci 
35:1354-1367.  
Sink KS, Vemuri VK, Olszewska T, Makriyannis A, Salamone JD (2008) 
Cannabinoid CB1 antagonists and dopamine antagonists produce different effects on a 
task involving response allocation and effort-related choice in food-seeking behavior 
Psychopharmacology 196:565-574 
Sokolowski JD, Salamone JD (1998) The role of nucleus accumbens dopamine 
in lever pressing and response allocation: Effects of 6-OHDA injected into core and 
dorsomedial shell. Pharmacology Biochemistry and Behavior 59:557-566 
Treadway MT, Buckholtz JW, Cowan RL, Woodward ND, Li R, Ansari MS, 
Baldwin RM, Schwartzman AN, Kessler RM, Zald DH (2012) Dopaminergic 
mechanisms of individual differences in human effort-based decision-making. J 
Neurosci 32: 6170-6176 
Van den Bos R, Van der Harst J, Jonkman S, Schilders M, Spruijt B (2006) Rats 
assess costs and benefits according to an internal standard. Behav Brain Res 171:350-
354 
Van Gaal LF, RIssanen AM, Scheen AJ, Ziegler O, Rössner S, RIO-Europe 
Study Group (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on 
weight reduction and cardiovascular risk factors in overweight patients: 1-year 
experience from the RIO-Europe study. Lancet 365: 1389-1397 
  Worden LT, Shahriari M, Farrar AM, Sink KS, Hockemeyer J, Müller 
C, Salamone JD (2009) The adenosine A2A antagonist MSX-3 reverses the effort-related 
effects of dopamine blockade: differential interaction with D1 and D2 family 
antagonists. Psychopharmacology 203:489-499 
Yger M, Girault JA (2011) DARPP-32, jack of all trades…master of which? 
Front Behav Neurosci 5: 56 
 142 
 
 
 143 
CHAPTER 3: 
 
EFFECT OF SUBTYPE –SELECTIVE ADENOSINE RECEPTOR 
ANTAGONISTS ON BASAL OR HALOPERIDOL-REGULATED 
STRIATAL FUNCTION: STUDIES OF C-FOS EXPRESSION AND 
MOTOR ACTIVITIES IN OUTBRED AND A2AR KO MICE. 
 
Abstract 
Dopamine (DA) regulates behavioral activation, and typical 
antipsychotic drugs produce psychomotor slowing. In contrast, minor stimulants 
that act on adenosine can facilitate behavioral activation at low doses. We 
studied the locomotor stimulating properties of adenosine antagonists with 
different selectivity profiles for adenosine receptors, and their impact on the 
impaired locomotion produced by the DA D2 receptor antagonist haloperidol, as 
well as c-Fos expression in 5 striatal subregions. Additionally we assessed the 
impact of haloperidol on locomotion in adenosine A2A receptor knockout 
(A2ARKO) mice. Male CD1 and A2ARKO mice were evaluated for horizontal 
and vertical locomotion in an open field. Theophylline (5.0-15.0 mg/kg) and the 
A2A antagonist MSX-3 (2.0 mg/kg) increased horizontal locomotion. The A1 
antagonist CPT did not. Haloperidol (0.05-0.1 mg/kg) produced a dose 
dependent decrease in both measures of locomotion. Co-administration of 
theophylline (10.0-15.0 mg/kg), MSX-3 (1.0-3.0 mg/kg) and CPT (9.0 mg/kg) 
reversed haloperidol effects. A2ARKO mice were resistant to the effects of 
haloperidol. Although adenosine antagonists did not increase c-Fos expression 
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on their own, theophylline and MSX-3, but not CPT, attenuated haloperidol 
induction of c-Fos expression. Our results indicate that D2 and A2A receptors 
interact to regulate exploratory behaviors, and c-Fos immunoreactivity in all 
striatal subregions.  
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INTRODUCTION 
In rodents, locomotor activity is an innate exploratory behavior (Kelley, 
1993) regulated by a complex cascade of neurochemical interactions involving 
the basal ganglia and related brain areas. Locomotion in rodents can be used as a 
measure of motor function, but also as a marker of behavioral activation in 
response to environmental events such as novelty (Hooks and Kalivas, 1995) or 
scheduled presentation of food pellets to food-deprived animals (Salamone, 
1988). Dopamine (DA) is a key neurotransmitter in the regulation of behavioral 
activation, and it is well known that dopaminergic mechanisms play an 
important role in regulating locomotor activity (Fishman et al., 1983). In 
particular, nucleus accumbens (Nacb) DA has been clearly implicated in the 
regulation of spontaneous, novelty-induced, food-induced, and drug-induced 
locomotion (Kelley and Iversen, 1976; Koob et al., 1978; Ahlenius et al., 1987; 
McCullough and Salamone, 1992; Correa et al., 2002, 2004).  Administration of 
DA antagonists decreases a variety of activities, including horizontal and vertical 
locomotion (Janssen et al., 1966; Salamone, 1987). Locomotion in the open field 
has been shown to be effectively suppressed by both D1 and D2 antagonists 
(Janssen et al., 1966; Beninger, 1983; Fishman et al., 1983; Molloy et al., 1986). 
Decreases in locomotion induced by DA D2 antagonists could be related to the 
psychomotor slowing that is induced in humans treated with these drugs (Heinz 
et al., 1998). In contrast, psychostimulant drugs by potentiating DA function, 
either directly or indirectly, can facilitate behavioral activation (Antoniou et al., 
1998; Karcz-Kubicha et al., 2003; Quarta et al., 2004), although at high doses 
they can induce stereotypies that translate into reduced interaction with the 
environment (Antoniou et al., 1998).  
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Within the last few years, evidence has begun to emerge indicating that 
brain adenosine plays an important role in regulating the behavioral functions of 
the basal ganglia (Ferré et al., 1997; Hauber, 1998; Svenningsson et al., 1999). 
Striatal areas that are rich in DA, including neostriatum and Nacb, also have a 
high concentration of adenosine receptors (Jarvis and Williams, 1989; 
Schiffmann et al., 1991; DeMet and Chicz-DeMet, 2002; Ferré et al., 2004). 
Several subtypes of adenosine receptors are expressed in the brain, of which the 
A1 and A2A adenosine receptor subtypes are most prevalent in the basal ganglia. 
Moreover, A2A receptors are expressed at very high levels in the striatum and 
Nacb (Ferré et al., 1993; Svenningsson et al., 1997; Tanganelli et al., 2004; 
Pinna et al., 2005), while A1 receptors are expressed throughout the brain 
(Fastbom et al., 1986, 1987a,b; Svenningsson et al., 1997). There is considerable 
interest in the behavioral actions of drugs that modulate adenosine receptor 
function. Nonselective adenosine receptor antagonists such as caffeine act as 
minor stimulants and are commonly consumed by humans to produce activation, 
providing “energy” and alertness (Antoniou et al., 2005; Ferré, 2008; Ferré et al., 
2008b; Reissig et al., 2009). Consistent with its profile as a minor stimulant, 
caffeine has been shown repeatedly to enhance locomotor activity in rodents 
(Garrett and Holtzman, 1994; Daly and Fredholm, 1998; Karcz-Kubicha et al., 
2003; Antoniou et al., 2005). Moreover, pharmacological modulation of 
adenosine A2A receptors has a profound influence on motor control. Thus, while 
A2A receptor stimulation exerts a suppressive effect on motor function (Barraco 
et al., 1993, 1994), adenosine A2A antagonists can increase locomotion (Popoli et 
al., 1998; Antoniou et al., 2005; Collins et al., 2010). The locomotor stimulant 
effects of A1 antagonists appear to be more variable and may depend upon the 
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selectivity of the particular drug used (Marston et al., 1998; Popoli et al., 1998; 
Karcz-Kubicha et al., 2003; Collins et al., 2010). Previous evidence indicates 
that adenosine A2A receptors in Nacb may be important for mediating the 
locomotor effects of A2A antagonists. Thus, when injected directly into the Nacb 
adenosine A2A agonists have been shown to suppress locomotion (Barraco et al., 
1993, 1994; Hauber and Munkle 1997) and A2A antagonists produce a dose-
related increase in locomotor activity (Nagel et al., 2003). 
In neostriatum and Nacb, DA D2 receptors are reported to interact with 
high affinity with the adenosine subtype A2A receptors on the enkephalin-
positive striatopalllidal neurons (Schiffmann et al., 1991; Fink et al., 1992; 
Ferré, 1997; Rosin et al., 1998; Svenningsson et al., 1999; Hettinger et al., 2001; 
Chen et al., 2001; Hillion et al., 2002; Fuxe et al., 2003; Ferré et al., 2008a). 
Thus, adenosine A2A antagonists are being intensively studied for their potential 
antiparkinsonian effects (Malec, 1997; Hauber et al., 2001; Moo-Puc et al., 
2003; Correa et al., 2004; Antoniou et al., 2005; Ishiwari et al., 2007; Salamone 
et al., 2008a,b; Varty et al., 2008) and also for the treatment of anergic 
symptoms such as psychomotor slowing and fatigue that are seen in patients 
with depression and other disorders (Farrar et al., 2007, 2010; Salamone et al., 
2007, 2009, 2010; Nunes et al., 2010).  
Because of the interest in the neurochemical interactions involved in 
psychomotor slowing and motor control, as well as the interest in identifying 
novel treatments for effort-related symptoms of depression, and non-
dopaminergic treatments for parkinsonism, it is important to characterize the 
effects of adenosine antagonists in both human clinical trials and animal models. 
Most of the preclinical studies of DA/adenosine interactions have been 
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conducted in rats. However, studies of these pharmacological interactions in 
mice are important for establishing generalizations across multiple species 
(McKerchar and Fowler, 2005). Moreover, genetic knockout models circumvent 
the intrinsic limitations of pharmacological agents with partial specificity, and 
these tools are widely available in mice. In the present work we studied the 
locomotor stimulating properties of adenosine antagonists with different 
selectivity profiles for adenosine receptors, and their impact on the locomotor 
suppression induced by the DA D2 receptor antagonist haloperidol. Thus, we 
characterized the locomotor effects of low doses of the non-selective adenosine 
antagonist theophylline, the A1 antagonist CPT, and the selective A2A antagonist 
MSX-3, either alone or in combination with haloperidol. We also determined if 
adenosine A2AR KO mice are resistant to the locomotor effects of haloperidol. 
Finally the impact of all these pharmacological manipulations on striatal and 
Nacb areas was studied using c-Fos expression as a marker of neural activity. 
 
MATERIALS AND METHODS 
Animals 
A total of 226 CD1 adult male mice (n=7-10 per group) purchased from 
Harlan-Interfauna Ibérica S.A. (Barcelona, Spain) were 6 weeks old (25-30 g) at 
the beginning of the study. Male mice lacking the A2A adenosine receptor type 
and wild-type (WT) littermates weighed 25–30 g at the beginning of the study 
(Universite Libre de Bruxelles, Brussels, Belgium), and were generated as 
previously reported (Ledent et al., 1997; Soria et al., 2006) from a CD1 
background. Mice were housed in groups of three or four per cage, with standard 
laboratory rodent chow and tap water available ad libitum. Subjects were 
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maintained at 22 + 2 ºC with 12-h light/dark cycles (lights on at 13:00 hours). 
All animals were under a protocol approved by the Institutional Animal Care 
and Use Committee of Universitat Jaume I, and all experimental procedures 
complied with European Community Council directive (86/609/ECC). 
Pharmacological agents 
All drugs were administered intraperitoneally (IP). Theophylline 
(TOCRIS Bioscience) was dissolved in 0.9% w/v saline (pH=7.4). MSX-3 ((E)-
phosphoric acid mono-[3-[8-[2-(3- methoxphenyl)vinyl]-7-methyl-2,6-dioxo-1-
prop-2-ynyl-1,2,6,7-tetrahydropurin-3-yl]propyl] ester disodium salt) was 
synthesized at the laboratory of Dr. Christa Müller at the Pharmazeutisches 
Institut, Universität Bonn, in Bonn, Germany (Hockemeyer et al., 2004). MSX-3 
(free acid) was dissolved in 0.9% w/v saline (pH=7.4). CPT (8-
cyclopentyltheophylline) (Sigma Química C.O), was dissolved in 0.9% w/v 
saline (pH=7.4). Haloperidol (Sigma Química C.O), a relatively selective DA D2 
family receptor antagonist, selected because it is a widely prescribed 
antipsychotic drug, was dissolved in a 0.3% tartaric acid solution in water 
(pH=4.0), which also was used as the vehicle control. Doses of all four drugs 
were taken from previous mouse and rat studies from our laboratories (Ishiwari 
et al., 2007; Pardo et al., 2012).  
Apparatus and testing procedures 
Open-field Locomotion. Mice were handled and weighed twice a week 
during 10 weeks after arriving to the laboratory. However, the animals were not 
pre-exposed to the behavioral paradigm. Testing was performed in an open-field, 
which consisted of a Plexiglas cylinder with translucent walls (30 cm in 
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diameter and 30 cm high) and an opaque floor divided into four equal quadrants 
by two intersecting lines. On the test day, treatments were administered acutely 
IP; haloperidol 50 minutes, and CPT, MSX-3 or theophylline, 20 minutes before 
the open field test started. After these time intervals, animals were placed in the 
center of the cylinder and immediately observed for 15 minutes. The behavioral 
test room was illuminated with a soft light, and external noise was attenuated. 
Locomotor activity was registered manually. For horizontal locomotion an 
activity count was registered each time the animal crossed from a quadrant to 
another with all four legs. A count of vertical locomotion was registered each 
time the animal raised its forepaws in the air higher than its back, or rested them 
on the wall.  
c-Fos visualization and quantification. Free floating coronal sections (40 
um) were serially cut using a microtome cryostat (Weymouth, MA, USA), rinsed 
in 0.01 M PBS (pH 7.4) and incubated in 0.3% hydrogen peroxide (H2O2) for 30 
min to block endogenous staining. Sections were then rinsed in PBS (3 × for 5 
min) and transferred into the primary antibody, anti-c-Fos (Calbiochem, 
Germany) for a 24 h incubation. Following the primary antibody treatment, the 
sections were rinsed in PBS and incubated in the secondary antibody, anti-rabbit 
HRP conjugate, envision plus (DAKO, Denmark) for 2 h. The 
immunohistochemical reaction was developed using diaminobenzidine (DAB) as 
the chromagen. Processed sections were then mounted to gelatin-coated slides, 
air dried, and cover-slipped using Cytoseal 60 (Thermo Scientific) as a mounting 
medium. The sections were examined and photographed using a Nikon Eclipse 
E600 (Melville, NY, USA) upright microscope equipped with an Insight Spot 
digital camera (Diagnostic Instruments, Inc). Images of the regions of interest 
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(Nacb core, Nacb shell, DLS) were magnified at 20X and captured digitally using 
SPOT software. Cells that were positively labeled for c-Fos were quantified with 
ImageJ software (v. 1.42, National Institutes of Health sponsored image analysis 
program) in three sections per animal, and the average value was used for 
statistical analysis. 
Experiments 
A total of seven experiments were performed in this study. All 
experiments used a between-groups design.  
Experiment 1: Effect of haloperidol on locomotor activity in the open-
field. Mice (N=30) received one injection of haloperidol (0.0, 0.025, 0.05 or 0.1 
mg/kg) 50 min before being tested in the open field for 15 min. Horizontal (Fig. 
1A) and vertical (Fig. 1B) locomotion were simultaneously recorded. 
Experiment 2. A. Effect of theophylline on locomotor activity in the open 
field. Mice (N=32) received one dose of theophylline (0.0, 5.0, 10.0 or 15.0 
mg/kg) 20 minutes before the open field test started. Horizontal (Fig. 2A) and 
vertical (Fig. 3A) locomotion were simultaneously recorded. 
Experiment 2. B. Effect of theophylline on haloperidol reduction of 
locomotion in the open field. Mice (N=32) received one injection of haloperidol 
(0.1 mg/kg) 30 minutes before receiving one injection of theophylline (0.0, 5.0, 
10.0 or 15.0 mg/kg). Twenty minutes after the second injection animals were 
introduced in the open field and testing started. Horizontal (Fig. 2B) and vertical 
(Fig. 3B) locomotion were simultaneously recorded. 
Experiment 3. A. Effect of CPT on locomotor activity in the open field. 
Mice (N=34) were tested during 15 minutes in the open field after an IP 
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injection of CPT (0.0, 3.0, 6.0 or 9.0 mg/kg) 20 minutes before testing. 
Horizontal (Fig. 4A) and vertical (Fig. 5A) locomotion were simultaneously 
recorded. 
Experiment 3. B. Effect of CPT on haloperidol reduction of locomotion 
in the open field. Mice (N=34) received one haloperidol injection (0.1 mg/kg) 
plus a CPT (0.0, 3.0, 6.0 or 9.0 mg/kg) injection at the same time intervals as in 
experiment 2.B. Horizontal (Fig. 4B) and vertical (Fig. 5B) locomotion were 
simultaneously recorded. 
Experiment 4. A. Effect of MSX-3 on locomotor activity in the open field. 
Mice (N=32) received an injection of MSX-3 (0.0, 1.0, 2.0 or 3.0 mg/kg) 20 
minutes before being tested during 15 minutes in the open field. Horizontal (Fig. 
6A) and vertical (Fig. 7A) locomotion were simultaneously recorded. 
Experiment 4. B. Effect of MSX-3 on haloperidol reduction of locomotion 
in the open field. Mice (N=32) were treated with haloperidol (0.1 mg/kg) and 
MSX-3 (0.0, 1.0, 2.0 or 3.0 mg/kg) and tested as described in experiment 2.B. 
Horizontal (Fig. 6B) and vertical (Fig. 7B) locomotion were simultaneously 
recorded. 
Experiment 5: Effect of haloperidol on A2AR KO mice in the open-field. 
Mice (WT N=19 and KO N=20) received one injection of haloperidol (0.0 or 0.1 
mg/kg) 50 min before being tested in the open field for 15 min. Horizontal (Fig. 
8A) and vertical (Fig. 8B) locomotion were simultaneously recorded. 
Experiment 6: Effect of Theophylline, CPT or MSX-3 on c-Fos 
immunoreactivity in different areas of the Nacb and striatum. After completion 
of the open field session, mice (N=25) were anesthesized and perfused, and 
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brain sections were stained for c-Fos immunoreactivity as described above. 
Thus, mice received treatments of either vehicle, 15.0 mg/kg theophylline, 9.0 
mg/kg CPT, or 3.0 mg/kg MSX-3, 140 minutes before anesthesia.  
Experiment 7: Effect of theophylline, CPT or MSX-3 on c-Fos 
immunoreactivity after haloperidol administration in different areas of the Nacb 
and striatum. After completion of the open field session, mice (N=36) were 
anesthesized and perfused, and brain sections were stained for c-Fos 
immunoreactivity as described above. All mice were treated with tartaric acid 
vehicle or haloperidol (0.1 mg/kg) 140 min before anesthesia, and then 30 min 
after the first injection they received treatments of either saline vehicle, 15.0 
mg/kg theophylline, 9.0 mg/kg CPT, or 3.0 mg/kg MSX-3.   
Statistical analyses 
Number of horizontal and vertical locomotion counts were analyzed 
separately in all the experiments. With the exception of experiment 5, all the 
other experiments were analyzed using a one way between-groups simple 
ANOVA followed by non-orthogonal planned comparisons using the overall 
error term, comparing vehicle to the other doses in experiments with no 
haloperidol and the haloperidol plus vehicle treatment with each of the other 
treatment conditions (including the vehicle alone group) in the reversal studies 
(Keppel, 1991). Since the behavior of animals receiving a single injection of 
vehicle or two separate injections of vehicle were not statistically different, and 
in order to reduce the total number of animals, only one vehicle group 
(represented in the graphs as a discontinuous line) was used for experiments A 
and B. In experiment 5 a two-way ANOVA and Tukey post hoc test were used. 
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STATISTICA 7 software was used for statistical analysis of the data. All data 
were expressed as mean ±SEM, and significance was set at p<0.05. 
 
RESULTS 
Experiment 1: Effect of haloperidol on locomotor activity in the open-
field. One way ANOVA for the haloperidol dose factor (0.0, 0.025, 0.05 or 0.1 
mg/kg) showed a significant effect of dose on horizontal locomotion 
(F(3,36)=12.42, p<0.01; Fig. 1A). Planned comparisons yielded significant 
differences between vehicle and the two highest doses of haloperidol (p<0.01). 
The ANOVA for the vertical locomotion data (Fig. 1B) showed a significant 
effect of the factor haloperidol dose (F(3,36)=10.28, p<0.01). Planned 
comparisons revealed significant differences between vehicle and the lowest 
(p<0.05) and highest (p<0.01) doses of haloperidol. Because the 0.1 mg/kg dose 
of haloperidol consistently reduced horizontal and vertical locomotion, for the 
following experiments we used this dose to study the potential reversal effects of 
adenosine antagonists on haloperidol-induced suppression of locomotion. 
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Fig. 1 A and B. Effect of haloperidol (0.0, 0.025, 0.05 or 0.1 mg/kg) on A) 
horizontal locomotion and B) vertical locomotion. Mean (±SEM) number of 
counts in the open field. *p<0.05 **p<0.01 significantly different from vehicle. 
 
Experiment 2A. Effect of theophylline on locomotor activity in the open 
field. One-way ANOVA for the theophylline dose factor (0, 5, 10 or 15 mg/kg) 
yielded a significant effect on horizontal locomotion (Fig. 2A; F(3,28)=4.2, 
p<0.05). Planned comparisons showed that all doses were different from control 
condition, 5.0, 15.0 mg/kg (p<0.05) and 10.0 mg/kg (p<0.01). However, the one-
way ANOVA for the theophylline dose factor showed no significant effect on 
vertical locomotion (Fig. 3A). 
Experiment 2B. Effect of theophylline on haloperidol reduction of 
locomotion in the open field. The one-way ANOVA for the drug treatment factor 
with 5 levels (Veh-Veh, HP-Veh, HP-5, HP-10 or HP-15) showed a significant 
effect of the treatment on horizontal locomotion (F(4,35)=25.25, p<0.01). 
Planned comparisons demonstrated that haloperidol reduced horizontal 
locomotion compared to vehicle (p<0.01), and that theophylline at all doses 
significantly increased open-field locomotor activity relative to haloperidol (Fig. 
2B; p<0.01). The ANOVA for the drug treatment factor on the vertical 
locomotion activity showed also a significant effect (F(4,35)=6.26, p<0.01). 
Planned comparisons revealed significant differences between animals treated 
with haloperidol compared to animals treated with vehicle (p<0.01). Moreover, 
the two highest doses of theophylline, 10.0 and 15.0 mg/kg (p<0.05), reversed 
the suppression on locomotion produced by haloperidol. These results can be 
seen in Fig. 3B. 
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Fig. 2 A and B. Effects of different doses of theophylline alone (A), or in 
combination with haloperidol (0.1 mg/kg) (B) on mice horizontal locomotion. 
The discontinuous horizontal line represents the mean value for the vehicle 
group. Mean (±SEM) number of counts in the open field. *p<0.05, **p<0.01 
significantly different from vehicle. ##p<0.01 significantly different from 
HP/Veh. 
 157 
 
Fig. 3 A and B. Effects of different doses of theophylline alone (A), or in 
combination with haloperidol (0.1 mg/kg) (B) on mice vertical locomotion. The 
discontinuous horizontal line represents the mean value for the vehicle group. 
Mean (±SEM) number of counts in the open field. **p<0.01 significantly 
different from vehicle. #p<0.05 significantly different from HP/Veh. 
 
Experiment 3A. Effect of CPT on locomotor activity in the open field. 
The one-way ANOVA for the factor CPT dose (0.0, 3.0, 6.0 or 9.0 mg/kg) did 
not yield statistical significance, for either horizontal locomotion (Fig. 4A), or 
vertical locomotion (Fig. 5A).   
Experiment 3B. Effect of CPT on haloperidol reduction of locomotion in 
the open field.  The ANOVA for the factor drug treatment (Veh-Veh, HP-Veh, 
HP-3, HP-6 or HP-9) yielded a significant effect on horizontal locomotion 
(F(4,37)=7.52, p<0.01; Fig. 4B). Planned comparisons indicated that haloperidol 
suppressed locomotion compared to vehicle (p<0.01). The group that received 
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haloperidol plus 9.0 mg/kg of CPT and the group haloperidol plus vehicle were 
significantly different (p<0.05). The one-way ANOVA for the vertical 
locomotion data showed a significant effect of the treatment (F(4,37)=11.48, 
p<0.01; Fig. 5B). Planned comparisons indicated that haloperidol suppressed 
rearing compared to vehicle (p<0.01). However, none of the doses of CPT 
reversed the effects of haloperidol on vertical locomotion.  
 
Fig. 4 A and B. Effects of different doses of CPT alone (A), or in combination 
with haloperidol (0.1 mg/kg) (B) on mice horizontal locomotion. The 
discontinuous horizontal line represents the mean value for the vehicle group. 
Mean (±SEM) number of counts in the open field. **p<0.01 significantly 
different from vehicle. #p<0.05 significantly different from HP/Veh. 
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Fig. 5 A and B. Effects of different doses of CPT alone (A), or in combination 
with haloperidol (0.1 mg/kg) (B) on mice vertical locomotion. The 
discontinuous horizontal line represents the mean value for the vehicle group. 
Mean (±SEM) number of counts in the open field. **p<0.01 significantly 
different from vehicle. 
 
Experiment 4A. Effect of MSX-3 on locomotor activity in the open field. 
The one-way ANOVA for the factor MSX-3 dose (00, 1.0, 2.0 or 3.0 mg/kg) 
showed a significant effect of dose on horizontal locomotion (F(3,28)=3.77, 
p<0.05). Planned comparisons revealed significant differences (p<0.05) between 
animals treated with vehicle and the group treated with 2.0 mg/kg (Fig. 6A). 
Analysis of the vertical locomotion data showed a statistically significant effect 
of MSX-3 (F(3,28)=5.9, p<0.01), and the planned comparisons showed that the 
MSX-3 dose 2.0 mg/kg was again significantly different (p<0.01) from the 
control group (Fig. 7A). 
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Experiment 4B. Effect of MSX-3 on haloperidol reduction of locomotion 
in the open field. An ANOVA for the factor drug treatment (Veh-Veh, HP-Veh, 
HP-1, HP-2 or HP-3) yielded a significant effect of MSX-3 doses on horizontal 
locomotion (F(4,35)=11.14, p<0.01). Planned comparisons showed that all 
MSX-3 doses were different from the haloperidol plus vehicle group (p<0.01; 
Fig. 6B). The one way ANOVA also yielded a significant effect of treatment on 
vertical locomotion (F(4,35)= 4.3; p<0.01); again all MSX-3 doses were 
different from haloperidol plus vehicle (1.0 mg/kg, p<0.05 and 2.0, 3.0 mg /kg, 
p<0.01; Fig. 7B). 
 
Fig. 6 A and B. Effects of different doses of MSX-3 alone (A), or in 
combination with haloperidol (0.1 mg/kg) (B) on mice horizontal locomotion. 
The discontinuous horizontal line represents the mean value for the vehicle 
group. Mean (±SEM) number of counts in the open field. *p<0.05, **p<0.01 
significantly different from vehicle. ##p<0.01 significantly different from 
HP/Veh. 
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Fig. 7 A and B. Effects of different doses of MSX-3 alone (A), or in 
combination with haloperidol (0.1 mg/kg) (B) on mice vertical locomotion. The 
discontinuous horizontal line represents the mean value for the vehicle group. 
Mean (±SEM) number of counts in the open field. **p<0.01 significantly 
different from vehicle. #p<0.05, ##p<0.01 significantly different from HP/Veh. 
 
Experiment 5: Effect of haloperidol on locomotor activity in the open-
field in A2AR KO mice. Two-way ANOVA of the horizontal locomotion data 
(strain factor (WT vs. KO) and haloperidol treatment factor (0.0 or 0.1 mg/kg)) 
showed no significant effect of the strain factor, but a statistically significant 
effect of the haloperidol dose (F(1,35)= 13.73, p<0.01), and a significant strain 
x haloperidol treatment interaction (F(1,35)=8.03, p<0.01). The post hoc tests 
revealed that under vehicle conditions motor activity was significantly different 
between WT and KO mice (p<0.05), and that haloperidol 0.1 mg/kg 
significantly reduced horizontal locomotion only in WT animals (p<0.01) but 
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not in KO mice (Fig. 8A). The two-way ANOVA for the vertical locomotion 
data (Fig. 8B) resulted in a significant overall strain difference (F(1,35)=6.42, 
p<0.05), a significant effect of haloperidol treatment (F(1,35)=11.30, p<0.01), 
and also a significant interaction (F(1,35)=13.01, p<0.01). The post hoc tests 
yielded significant differences between WT and KO mice after receiving vehicle 
injections (p<0.01), and haloperidol 0.1 mg/kg significantly reduced vertical 
locomotion only in WT animals (p<0.01) but not in KO mice. These results 
indicate that A2AR KO mice were resistant to the suppressing effects of this dose 
of haloperidol on both forms of locomotion.  
 
Fig. 8 A and B. Effect of haloperidol (0 or 0.1 mg/kg) in WT and A2AR KO mice 
on (A) horizontal and (B) vertical locomotion. Mean (±SEM) counts in the open 
field. **p<0.01 significantly different from vehicle in the corresponding 
substrain group. 
 
Experiment 6: Effect of Theophylline, CPT or MSX-3 on c-Fos 
immunoreactivity in different areas of the Nacb and striatum. The c-Fos counts 
in different brain areas (see Fig. 9) were analyzed by two-way (treatment x brain 
area) factorial ANOVA. There was not an effect of the drug treatment factor, but 
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a significant difference between brain areas were found (F(4,103)=14.99, 
p<0.01), and no significant treatment x brain area interaction. Even though there 
was not an interaction, we analyzed every brain area separately, and again found 
that the corresponding one-way ANOVA for the drug treatment factor (Vehicle, 
theophylline 15.0 mg/kg, CPT 9.0 mg/kg and MSX-3 3.0 mg/kg) on c-Fos 
positive cells in the different brain areas was not significant for any of them. 
Thus, none of the adenosine antagonist at these doses had an effect on c-Fos 
expression by themselves.  
 
Fig. 9. Left: Effect of different treatments; vehicle, theophylline 15 mg/kg, CPT 
9 mg/kg, and MSX-3 3 mg/kg on c-Fos expression in the Nacb Core, Nacb 
Shell, ventrolateral striatum (VLS), dorsolateral striatum (DLS) and dorsomedial 
striatum (DMS). Mean (±SEM) number of c-Fos positive cells per mm
2
. Right: 
Diagram of coronal sections with bregma coordinates from Franklin and Paxinos 
2007, showing location of the brain areas for c-Fos counting. 
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Experiment 7: Effect of theophylline, CPT or MSX-3 on c-Fos 
immunoreactivity after haloperidol administration in different areas of the Nacb 
and striatum. The c-Fos counts in different brain areas (see Fig. 10) were 
analyzed by a two-way (treatment x brain area) factorial ANOVA. There was a 
significant overall treatment effect (F(4,153)=28.06; p<0.01), but no significant 
difference between brain areas, and no significant treatment x brain area 
interaction. Planned comparisons on the data collapsed across brain areas 
indicated that haloperidol produced a significant overall induction of c-Fos 
expression compared to vehicle-vehicle (p<0.01), which was attenuated by co-
administration of MSX-3 and theophylline (p<0.01). 
 
Fig. 10. Left upper part: Effect of theophylline 15 mg/kg, CPT 9 mg/kg, and 
MSX-3 3 mg/kg on c-Fos immunoreactivity after haloperidol (0.1 mg/kg) 
administration in the Nacb Core and Shell, VLS, DLS, and DMS. Mean (±SEM) 
number of c-Fos positive cells per mm
2
. **p<0.01 significantly different from 
Veh/Veh; ##p<0.01 significantly different from HP/Veh. Right and left lower 
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part: Diagram of coronal section with bregma coordinates from Franklin and 
Paxinos 2007, showing location of two brain areas for c-Fos counting. 
Photomicrographs of c-Fos staining in DLS and Nacb Core from representative 
animals in each treatment group. Low power images (20x). Scale bar=250 um.  
 
DISCUSSION 
The present experiments were conducted to characterize and compare the 
impact of adenosine antagonists with different selectivity profiles on several 
aspects of exploratory behavior in mice. Moreover, we studied the interaction 
between DA D2 and adenosine A2A receptors in the regulation of horizontal and 
vertical locomotion in WT as well as genetically modified mice. To do so we 
used the same range of doses that, in one of our previous studies in mice, was 
able to reverse haloperidol-induced impairments in effort-related choice 
behavior in a T-maze paradigm (Pardo et al., 2012).  
Acute administration of haloperidol suppresses locomotion in rats 
(Ishiwari et al., 2004) and mice (Satrr and Starr 1986; Fujiwara, 1992). The 
present results show that haloperidol produced a decrease in horizontal 
locomotion at the two highest doses employed 0.05 and 0.1 mg/kg dose, an 
effect that was also observed for vertical locomotion at the highest dose. The 
low dose of haloperidol (0.025 mg/kg) did not suppress locomotion, and in fact, 
it actually increased rearing. Thus, for the remaining experiments we used the 
highest dose (0.1 mg/kg) to study the impact of the adenosine antagonists on 
haloperidol-induced suppression of horizontal and vertical locomotion.  
In experiment 2 we studied the impact of the non-selective adenosine 
antagonist theophylline on spontaneous locomotion, and in a second study we 
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evaluated its potential to reverse haloperidol-induced locomotor suppression. 
When administered alone, theophylline enhanced horizontal locomotion at all 
doses tested (5.0-15.0 mg/kg), but did not significantly induce rearing. 
Theophylline and caffeine are methylxanthines that act as minor stimulants that 
potentiate locomotion over a broad range of doses (Malec and Poleszak, 2006; 
Zhang et al., 2011). We selected doses in the lower range to induce exploration 
but to minimize the possible appearance of stereotypes that can reduce 
exploratory behavior at higher doses. Thus, with these low doses, haloperidol-
induced behavioral impairments were restored by co-administration of 
theophylline at all doses in the case of horizontal locomotion, and at the two 
highest doses for the rearing. These data are in accordance with previous studies 
showing an attenuation of haloperidol-induced motor deficits after theophylline 
treatment in rats (Bishnoi et al., 2007). In the present results, behavior was 
restored to control levels with the two highest doses of theophylline.   
 In experiment 3, the adenosine A1 antagonist CPT was used because this 
drug has been shown to stimulate locomotion in rats (Karcz-Kubicha et al., 
2003). In the present study CPT administered alone did not produce any 
significant effect on horizontal or vertical locomotion at the doses tested (3.0-9.0 
mg/kg). Our doses in mice are very similar to doses used in rats (1.0-10.0 mg/kg; 
Karcz-Kubicha et al., 2003) in which CPT did increase locomotion. This 
discrepancy may be due to the fact that two different type of species (mice vs. 
rats) and procedures (non-habituated vs. habituated animals) were used. Previous 
studies in mice have also found that CPT does not have any stimulant properties 
by itself (1.2-6.0 mg/kg; Dall'Igna et al., 2001; Malec and Poleszak, 2006). 
Moreover, low doses (1.0 mg/kg) of CPT in mice suppressed locomotion (Florio 
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et al., 1997; Dall'Igna et al., 2001). However, in the present work CPT reversed 
haloperidol-induced suppression of horizontal locomotion at the highest dose 
(9.0 mg/kg), although no effect was found on vertical locomotion. In rats, CPT 
(12.0 mg/kg) also appears to produce a mild reversal of the effects of D2 
antagonists on motor function. Thus, CPT produced a partial reversal of 
eticlopride-induced suppression of locomotion (Collins et al., 2010), as well as 
haloperidol-induced catalepsy (Trevitt et al., 2009). Thus, CPT in mice seems 
not to have clear stimulatory actions, but can minimally reverse neuroleptic 
actions on motor performance. CPT shows lower A1 vs. A2A binding selectivity 
than other A1 antagonists (Maemoto et al., 1997). Thus, it is possible that the 
minimal reversal of D2 antagonist effects observed in the present study and also 
in previous results (Trevitt et al., 2009; Collins et al., 2010) was due to some 
activity of CPT on A2A receptors interacting with D2 receptors. 
In experiment 4 the results show an induction of both vertical and 
horizontal locomotion after administration of the intermediate (2.0 mg/kg) dose 
of the selective A2A antagonist MSX-3. Previous results in mice also show a 
diversity of results on A2A effects on spontaneous locomotion. MSX-3 (5.0 
mg/kg) SCH58261 (2.0-6.0 mg/kg), and SCH442416 (3.0 mg/kg) were shown to 
induce locomotion (Hsu et al., 2009; Marcellino et al., 2010; Lerner et al., 2010). 
However, DMPX (1.0-6.0 mg/kg) and KW 6002 (0.3 mg/kg) were not able to 
increase motor activity (Dall'Igna et al., 2001; Kachroo et al., 2005). In the 
present results, MSX-3 restored the normal pattern of horizontal as well as 
vertical locomotion in haloperidol-treated mice at all doses used (1.0, 2.0 and 3.0 
mg/kg). Our results are in accordance with genetic and pharmacological models 
of parkinsonian bradykinesia. Thus, in mice with a genetically induced 
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progressive depletion of DA, MSX-3 (5.0 mg/kg) reversed impaired locomotion 
(Marcellino et al., 2010). In rats, systemic injections of MSX-3 (0.5-10.0 mg/kg) 
were able to reverse the locomotor suppression produced by haloperidol (0.5 
mg/kg; Ishiwari et al., 2007), and eticlopride (Collins et al., 2010), an effect that 
was also achieved after local MSX-3 administration into the Nacb core (Ishiwari 
et al., 2007).  
In summary, although methylxanthines seem to clearly have stimulant 
properties both in habituated and non-habituated mice across a broad range of 
doses (El Yacoubi et al., 2000; Pastor et al., 2005; present studies), the picture 
for selective A1 and A2A antagonists seems less clear. In the literature A2A 
antagonists appear to be more likely to exhibit motor activating effects than A1 
antagonists, and our results comparing selective and non-selective adenosine 
antagonists indicate that A2A receptor antagonism seems more relevant for the 
stimulant properties of methylxanthines. This conclusion has been suggested in 
previous studies based on the lack of stimulation by caffeine in A2AR KO mice 
but not in A1R KO (El Yacoubi et al., 2000; Yang et al., 2009; Lazarus et al., 
2011), and in studies of operant behavior in rats (Randall et al., 2011). 
Moreover, a large number of studies demonstrate that A2A antagonism can 
reverse the effects of D2 antagonism on behavioral tests in mice as well as rats. 
Thus, as predicted, the antagonism of adenosine A2A receptors was more 
effective than A1 antagonism in restoring the behavior impaired by DA D2 
antagonism. It is likely that this pattern of results in drug interaction studies is 
due to the co-localization of A2A receptors with D2 receptors (Mott et al., 2009; 
Salamone et al., 2009; Nunes et al., 2010). Adenosine A2A receptors are located 
on striatal GABAergic enkephalin-positive neurons that also express DA D2 
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receptors (Fink et al., 1992; Ferré et al., 1997; Svenningsson et al., 1999; Chen 
et al., 2001). DA D2 and adenosine A2A receptors converge onto the same signal 
transduction mechanisms and show the capacity to form heteromers (Fink et al., 
1992; Ferré et al., 1997, 2004, 2008a; Svenningsson et al., 1999; Fuxe et al., 
2003). A2A receptors, through their coupling to Golf proteins, can stimulate 
adenylyl-cyclase activity and activate the cAMP-PKA signaling pathway, with 
phosphorylation of several PKA substrates, such as DARPP-32 and CREB and 
the consequent increase in the expression of different genes, such as c-fos or 
preproenkephalin in the GABAergic enkephalinergic neuron (Ferré et al., 
2008a). The tonic activation of D2 receptors blocks the ability of A2A receptors 
to signal through the cAMP-PKA signaling pathway. Administration of D2 
receptor antagonists produces a significant increase in the PKA-dependent 
phosphorylation of DARPP-32 and an increase in the expression of c-fos and 
preproenkephalin genes, which depends on the ability of D2 receptor blockade to 
liberate A2A receptor signaling activated by endogenous adenosine. Thus, the 
neural effects of DA D2 receptor antagonists can be counteracted by co-
administration of A2A receptor antagonists (Ferré et al., 2008a). 
Taking all these results into consideration, in experiment 5, we decided to 
investigate spontaneous locomotion and the impact of D2 antagonism on WT and 
adenosine A2AR KO mice. Our results showed that adenosine A2AR KO mice 
had reduced levels of spontaneous activity, which is consistent with previous 
studies (Ledent et al., 1997; Chen et al., 2001). However, after receiving 0.1 
mg/kg of haloperidol, A2AR KO mice did not show suppression of either 
horizontal or vertical locomotion, thus showing resistance to the effects of a dose 
of haloperidol that significantly suppressed both types of locomotion in WT 
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mice. A2AR KO mice have been demonstrated to be more resistant than WT 
animals to the cataleptic effect of DA antagonists like haloperidol or SCH 23390 
(Chen et al., 2001; El Yacoubi et al., 2001). Moreover, in a previous study these 
KO mice have been shown to be more resistant to haloperidol-induced 
impairments in effort-related decision making (Pardo et al., 2012). There are a 
few possible mechanisms that could underlie the lack of effect of haloperidol on 
A2AR KO mice. First, it is possible that genetic deletion of striatal A2A receptors 
could alter striatal D2 receptor function. There is evidence of antagonistic 
intramembrane A2A– D2 interactions, by which stimulation of adenosine A2A 
receptors decreases the ability of DA to displace a D2 antagonist from binding to 
D2 receptors (Ferré et al., 1999). Thus, A2AR KO could be enhancing the ability 
of endogenous DA to compete with haloperidol for binding to DA receptors. In 
addition, because adenosine A2A and DA D2 receptors converge onto the same 
adenylyl cyclase-related signal transduction cascade (Ferré et al., 1997, 2008a), 
deletion of A2A receptors could be altering the signal transduction effects of D2 
receptor blockade. 
Finally, c-Fos expression was quantified in experiments 6-7. Although 
previous studies have reported that very high doses of adenosine antagonists 
could affect c-Fos expression (Nakajima et al., 1989; Le et al., 1992; Johansson 
et al., 1992, 1994; Svenningsson et al., 1995; Dassesse et al., 1999), the results 
of experiment 6 showed that none of the adenosine antagonists studied had any 
effects on c-Fos expression when administered alone at the doses used in the 
behavioral experiments.  In experiment 7, c-Fos expression was evaluated in 
mice that had been exposed to the open field, and also had received injections of 
a D2 antagonist. Because D2 and adenosine A2A receptor stimulation has opposite 
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effects on stimulation of cAMP-related pathways, it was hypothesized that 
adenosine A2A antagonism would blunt the ability of the D2 antagonist to affect 
transcription of immediate early genes and induce formation of Fos-related 
proteins. Earlier reports have shown increased c-Fos expression in striatal areas, 
including Nacb as well as neostriatum, after systemic administration of D2 
family antagonists mainly in rats (Betz et al., 2009; Farrar et al., 2010; Hussain 
et al., 2002; Pinna et al., 1999; Svenningsson et al., 1999). Also, it has been 
previously observed that the increases in c-Fos expression induced by D2 
antagonists in striatal areas can be attenuated by co-administration of A2A 
receptor antagonists or by theophylline (Boegman and Vincent, 1996; Pinna et 
al., 1999; Ward and Dorsa, 1999; Hussain et al., 2002; Betz et al., 2009; Farrar 
et al., 2010; Pardo et al., 2012). The present results demonstrated that a 
relatively low dose of haloperidol (0.1 mg/kg), which decreased open field 
locomotion, also produced a parallel increase in c-Fos expression across all the 
striatal structures studied. Moreover, at doses that did not have an effect on their 
own, theophylline and MSX-3 both reversed the haloperidol-induced increase in 
c-Fos expression. This pattern of results is very similar to the results reported in 
a recent paper from our laboratory using the same range of doses for all drugs 
(Pardo et al., 2012). In that paper, haloperidol injections reduced high effort 
instrumental behaviors, and led to the selection of responses that were less 
demanding in terms of effort. This effect on behavior was reversed by 
theophylline and MSX-3, and these results were paralleled by c-Fos expression 
in the same animals that were performing the task (Pardo et al., 2012). In the 
present studies, c-Fos expression was determined in mice that also were tested in 
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the open field, thus providing a behaviorally relevant cellular marker of the 
interaction between DA D2 and adenosine A2A receptors.  
In humans, antipsychotic drugs that act as D2 antagonists induce many 
side effects, including parkinsonism (Marsden et al., 1975) and psychomotor 
slowing (Heinz et al., 1998). The present studies suggest that adenosine A2A 
antagonists such as MSX-3 could be a useful therapeutic tool for the treatment of 
neuroleptic-induced parkinsonism and psychomotor slowing, since they do not 
have strong stimulant effects, but they nevertheless attenuate the behavioral 
impairments produced by antipsychotic drugs. Furthermore, our 
pharmacological results are supported by the finding that genetic deletion of the 
A2A receptor makes animals resistant to the effects of haloperidol. In contrast, 
adenosine A1 antagonism produced a minor reversal in the reduced exploration 
produced by DA D2 antagonism. Interestingly, although the doses of 
theophylline employed showed that it has a clear psychostimulant profile, it also 
is capable of reducing haloperidol-induced impairments in several aspects of 
exploratory behavior and willingness to exert effort in goal directed behaviors 
(Pardo et al., 2012).   
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CHAPTER 4:  
 
ADENOSINE A2A RECEPTOR ANTAGONISM AND GENETIC 
DELETION ATTENUATE THE EFFECTS OF DOPAMINE D2 
ANTAGONISM ON EFFORT-BASED DECISION MAKING IN MICE: 
STUDIES USING A T-MAZE WITH BARRIER 
 
Abstract 
Brain dopamine (DA) and adenosine interact in the regulation of 
behavioral activation and effort related processes. In the present studies, a T-
maze task was developed in mice for the assessment of effort-related decision 
making. With this task, the two arms of the maze have different reinforcement 
densities, and a vertical barrier is positioned in the arm with the higher density 
(HD), presenting the animal with an effort-related challenge. Under control 
conditions mice prefer the HD arm, and climb the barrier to obtain the larger 
amount of food. The DA D2 receptor antagonist haloperidol decreased selection 
of the HD arm and increased selection of the arm with the low density of 
reinforcement. However, the HD arm was still the preferred choice in 
haloperidol-treated mice trained with barriers in both arms. Pre-feeding the mice 
to reduce food motivation dramatically increased omissions, an effect that was 
distinct from the actions of haloperidol. Co-administration of theophylline, a 
nonselective adenosine receptor antagonist, partially reversed the effects of 
haloperidol. This effect seems to be mediated by the A2A receptor but not the A1 
receptor, since the A2A antagonist MSX-3, but not the A1 antagonist CPT, dose 
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dependently reversed the effects of haloperidol on effort-related choice and on c-
Fos expression in the dorsal striatum and nucleus accumbens. In addition, 
adenosine A2A receptor knockout mice were resistant to the effects of 
haloperidol on effort-related choice in the maze. These results indicate that DA 
D2 and adenosine A2A receptors interact to regulate effort-related decision 
making and effort expenditure in mice. 
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INTRODUCTION 
Vigor, persistence, and high work output are fundamental features of 
motivated behavior (Salamone, 2010). These activational aspects of motivation 
are highly adaptive because they enable organisms to overcome obstacles or 
work related response costs that separate them from significant stimuli 
(Salamone, 2010; Salamone et al., 1994, 2003, 2007; Salamone and Correa, 
2002; van den Bos et al., 2006). An important feature of adaptive behavior in 
the face of work-related challenges is effort-related decision making. Organisms 
frequently must make cost/benefit analyses in which they weigh the value of 
available rewards vs. the costs involved in procuring them (Day et al., 2011; 
Phillips et al., 2007; Salamone and Correa, 2002; Walton et al., 2006). 
Several lines of evidence have identified dopamine (DA), particularly in 
nucleus accumbens (Nacb), as a critical component of the brain circuitry 
regulating behavioral activation and effort-related processes (Barbano and 
Cador, 2006; Cagniard et al., 2006; Floresco et al., 2008; Phillips et al., 2007; 
Salamone, 2010; Salamone et al., 1991, 2003, 2005, 2007, 2009). Interference 
with DA transmission by administering DA antagonists or DA depleting agents 
typically biases rats towards low effort alternatives for obtaining access to food 
(Salamone et al., 2007, 2009). Considerable evidence indicates that brain 
adenosine receptor mechanisms interact with DA systems in the regulation of 
effort-related choice behavior (Salamone and Correa, 2009). In addition to Nacb 
DA, other transmitters (GABA, glutamate, adenosine) and brain areas 
(prefrontal/anterior cingulate cortex, basolateral amygdala, ventral pallidum) 
also are involved (Farrar et al., 2008; Floresco et al., 2008; Ghods-Sharifi et al., 
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2009; Hauber and Sommer, 2009; Salamone et al., 2007, 2009; Walton et al., 
2002, 2003). Nacb and caudate/putamen have a high concentration of adenosine 
A2A receptors (DeMet and Chicz-DeMet, 2002; Ferré et al., 2004; Jarvis and 
Williams, 1989). DA D2 and adenosine A2A receptors are co-localized on 
enkephalin-containing medium spiny neurons, and these receptors interact by 
forming heteromers, and by convergence on to the same signal transduction 
pathways (Ferré, 2008; Ferré et al., 1997, 2008; Fink et al., 1992; Fuxe et al., 
2003). Recent evidence indicates that DA D2 and adenosine A2A receptors 
interact to regulate effort-related functions (Font et al., 2008; Mingote et al., 
2008; Salamone and Correa, 2009). Microinjections of the adenosine A2A agonist 
CGS 21680 into the Nacb produced effects on instrumental behavior and effort-
related choice that resembled those produced by Nacb DA antagonism or 
depletion (Font et al., 2008; Mingote et al., 2008). Furthermore, adenosine A2A 
antagonists such as MSX-3 and istradefylline (KW6002) were able to reverse the 
effects of the DA D2 antagonists haloperidol and eticlopride on effort-related 
choice behavior, under conditions that employed a concurrent FR5/feeding 
choice procedure (Farrar et al., 2007, 2010; Nunes et al., 2010; Salamone et al., 
2009; Worden et al., 2009), and a T-maze barrier choice task (Mott et al., 2009).   
One shortcoming of this work is that virtually all of it has been conducted 
in rats; only a few studies of effort-related choice have been performed in mice 
(Beeler et al., 2010; Cagniard et al., 2006), and there have been no mouse studies 
focused upon the DA/adenosine interactions involved in this aspect of 
motivation. It is critical to study mice as well as rats to establish generalizations 
across multiple species (McKerchar and Fowler, 2005). Moreover, genetic 
knockout models circumvent the intrinsic limitations of pharmacological agents 
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with partial specificity, and these tools are widely available in mice. Thus, 
studies of motivated behavior involving mice with DA transport knockdown 
(Beeler et al., 2010; Cagniard et al., 2006) or DA deficiency (Robinson et al., 
2005, 2006, 2007) have contributed substantially to our understanding of the 
behavioral functions of brain DA. Moreover, genetic deletion of the adenosine 
A2A receptor in mice has been shown to alter the locomotor response to 
adenosine antagonists (El Yacoubi et al., 2000; Halldner et al., 2004; Yu et al., 
2008; Lazarus et al., 2011), and to affect amphetamine sensitization (Chen et al., 
2003) and self-administration of cocaine and MDMA (Ruiz-Medina et al., 2011; 
Soria et al., 2006), as well as aspects of cognition and motor function (Wei and 
Chen, 2011; Xiao et al., 2011).  
The present studies were undertaken to develop and validate a mouse test 
of effort-related choice behavior (experiments 1-3) using a variant of the T-maze 
barrier task developed originally for rats (Cousins et al., 1996; Mott et al., 2009; 
Salamone et al., 1994), to assess the ability of adenosine antagonists with 
different selectivity profiles (theophylline, MSX-3, and CPT) to attenuate the 
effects of the DA D2 antagonist haloperidol (experiments 4-6) or to exert actions 
when administered alone (experiment 7), and to determine if adenosine A2A 
receptor knockout (A2AR KO) mice are resistant to the effects of haloperidol on 
T-maze performance (experiment 8). Finally, evaluations of the impact of these 
pharmacological manipulations on the expression of c-Fos in Nacb core and 
shell, as well as the dorsolateral neostriatum (DLS), were conducted (experiment 
9) in order to provide a cellular marker of the interaction between DA D2 and 
adenosine A2A receptor antagonists in mice performing in the T maze.  
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MATERIALS AND METHODS 
Animals 
CD1 male mice (N= 73) weighed 24-28 g at the beginning of the study 
(Harlan-Interfauna Ibérica S.A., Barcelona, Spain). Male mice lacking the A2A 
adenosine receptor type and wild-type (WT) littermates (N=7 and 9 respectively) 
weighed 25–30 g at the beginning of the study (Universite Libre de Bruxelles, 
Brussels, Belgium), and were generated as previously reported (Ledent et al., 
1997; Soria et al., 2006) from a CD1 background. All mice were housed in 
groups of 3 or 4 animals per cage with tap water available ad libitum, and were 
food-restricted to reach 85% free-feeding body weight throughout the study. The 
colony was kept at a temperature of 22 + 2 ºC with lights on from 0800 to 2000 
hours. All animals were under a protocol approved by the Institutional Animal 
Care and Use Committee of Universitat Jaume I, and all experimental procedures 
complied with European Community Council directive (86/609/ECC). All efforts 
were made to minimize animal suffering, and to reduce the number of animals 
used. 
Pharmacological agents  
All drugs were administered intraperitoneally (IP). Haloperidol (Sigma 
Química C.O), a relatively selective DA D2 family receptor antagonist, was 
dissolved in a 0.3% tartaric acid solution (pH=4.0), which also was used as the 
vehicle control. Haloperidol was selected because this widely prescribed 
antipsychotic drug has been used in previous T-maze experiments in rats 
(Salamone et al., 1994; Denk et al., 2005; Mott et al., 2009), and therefore could 
provide a useful cross-species validation. Theophylline (TOCRIS Bioscience), 
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CPT (8-cyclopentyltheophylline) (Sigma Química C.O), and MSX-3 ((E)-
phosphoric acid mono-[3-[8-[2-(3-methoxphenyl)vinyl]-7-methyl-2,6-dioxo-1-
prop-2-ynyl-1,2,6,7-tetrahydropurin- 3-yl] propyl] ester disodium salt; 
synthesized at the laboratory of Dr. Christa E. Müller at the Pharmazeutisches 
Institut, Universität Bonn, in Bonn, Germany), were dissolved in 0.9% w/v saline 
(pH 7.4). MSX-3 is a prodrug that is cleaved in vivo to the pharmacologically 
active compound MSX-2 (Hockemeyer et al., 2004). 
Apparatus and testing procedures 
The T-maze apparatus consisted of a central corridor with two opposed 
arms (see Fig. 1). Each arm provided a different density of food: 2 pellets (15 mg 
each) were in the high density (HD) arm and 1 pellet was in the low density (LD) 
arm. For most experiments, the HD arm contained 14 cm vertical barrier that 
provided the effort-related challenge. Pellets (Bioserve, Frenchtown, NJ, USA) 
were located in dishes placed near the far walls of the maze arms. Half the mice 
had the HD arm with the barrier consistently located on the left side, while half 
the mice had the HD arm and barrier on the right side. 
Training phases: During the first training phase no barrier was present. 
The first 2 days of the initial training, mice had free access to both arms of the T-
maze upon exiting the start arm, and were allowed to consume all pellets in both 
HD and LD arms of the maze before being returned to the start arm. Upon 
completion of this initial training, mice were then trained to select between the 
HD or the LD arm, with no barrier in place. For this and all subsequent training 
and testing procedures, the animals were only allowed to choose one arm of the 
maze; after the initial arm choice, the other arm was blocked. The criterion 
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before a new learning phase started was set so that animals had to choose the HD 
arm at least 85% of the time for 2 consecutive days. In the second training phase 
a small barrier (5.5 cm high) was introduced in the HD arm. In the third phase a 
medium barrier (12 cm high) replaced the short one. Finally, in the fourth 
training phase and for the rest of the experiment, the high barrier (14 cm high) 
was used. The average training sessions for the CD1 animals in the 4 phases 
across experiments was 36 total sessions: Phase 1: 12 sessions; Phase 2: 6 
sessions; Phase 3: 7 sessions; and Phase 4: 11 sessions.  For the KO and WT 
animals was 34 total sessions: Phase 1: 10 sessions; Phase 2: 5 sessions; Phase 3: 
5 sessions; and Phase 4: 14 sessions. A total of five animals that did not 
consistently reach the 85% criterion before the drug testing phase started were 
removed from experiments 1, 5 and 6.  
High Barrier Training and Test Sessions: Each trial started when the gate 
in the start arm was opened. Latency measurements marked the time from the 
opening of the start arm until the initiation of food consumption in the selected 
arm. In each trial every mouse had the option of going to any of the two choice 
arms to consume the pellets. When the mice entered into one arm the other arm 
was blocked. Immediately after the animals finished consuming the food, they 
climbed back across the barrier and returned by themselves to the start arm where 
they were briefly held for the inter-trial interval (2-3 seconds), during which the 
food pellets that had been consumed were replaced. This procedure was repeated 
for 30 trials during each daily training session. Sessions started two hours after 
the colony lights where on. Animals had one training session per day, 5 days a 
week. Baseline training under these conditions continued for several weeks, until 
stable performance was achieved. During the drug testing phase there was one 
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drug treatment day and 4 baseline days before the next drug day.  
Additional Behavioral Validation Procedures: In experiment 2, when the 
mice completed the fourth phase with one barrier in the HD arm, one additional 
training week was conducted with a high barrier in the HD arm and an additional 
high barrier in the LD arm, after which drug testing was conducted. In 
experiment 3, mice were trained as in experiment 1, but on the day of the pre-
feeding test, animals had ad libitum access to food for 24 hrs in their home cages 
the day before the test session. During the test session the number of HD or LD 
selections, or omissions (no arm selection for 40 seconds), were recorded.  
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Fig.1. Top view of the mouse T-maze apparatus used in the present study. All the 
surfaces and the doorway were constructed out of Plexiglas, and the top of all 
arms were open. The barrier (depicted in the high density arm, to the left) was 
constructed of wire mesh. The HD arm contained 2 food pellets, and the LD arm 
contained 1 food pellet.  
 
c-Fos visualization and quantification 
Free floating coronal sections (50 m) were serially cut using a 
microtome cryostat (Weymouth, MA, USA), rinsed in 0.01 M PBS (pH 7.4) and 
incubated in 0.3% hydrogen peroxide (H2O2) for 30 min to block endogenous 
staining. Sections were then rinsed in PBS (3 × for 5 min) and transferred into 
the primary antibody, anti-c-Fos (Calbiochem, Germany) for a 48 h incubation. 
Following the primary antibody treatment, the sections were rinsed in PBS and 
incubated in the secondary antibody, anti-rabbit HRP conjugate, envision plus 
(DAKO, Denmark) for 2 h. The immunohistochemical reaction was developed 
using diaminobenzidine (DAB) as the chromagen. Processed sections were then 
mounted to gelatin-coated slides, air dried, and cover-slipped using Cytoseal 60 
(Thermo Scientific) as a mounting medium. The sections were examined and 
photographed using a Nikon Eclipse E600 (Melville, NY, USA) upright 
microscope equipped with an Insight Spot digital camera (Diagnostic 
Instruments, Inc). Images of the regions of interest (Nacb core, Nacb shell, DLS) 
were magnified at 20X and captured digitally using SPOT software. Cells that 
were positively labeled for c-Fos were quantified with ImageJ software (v. 1.42, 
National Institutes of Health sponsored image analysis program) in three sections 
per animal, and the average value was used for statistical analysis. 
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Experiments 
Experiments used a within-groups design, in which each mouse received 
all treatments in a random order over consecutive weeks, once a week (no 
treatment sequence was repeated across different animals in any of the 
experiments). During the test session the number of HD or LD selections and the 
latency to reach the food was recorded by an observer who was unaware of the 
experimental condition. All T-maze experiments were conducted with a single 
barrier (in the HD arm) except for experiment 2. 
Experiment 1: Effect of different doses of haloperidol on performance in 
the T-maze. Mice (N=7) received injections of tartaric acid vehicle, 0.025, 0.05 
or 0.1 mg/kg haloperidol 50 min before the test. 
Experiment 2:  Effect of 0.1 mg/kg of haloperidol on performance in the 
T-maze with two barriers. Mice (N=12) received injections of either tartaric acid 
or haloperidol 0.1 mg/kg 50 min before the test. 
Experiment 3: Effect of pre-feeding on performance in the T-maze. Mice 
(N=12) were tested under three experimental conditions: pre-feeding, tartaric 
acid or haloperidol (0.1 mg/kg). 
Experiment 4: Effect of theophylline on T-maze performance after 
haloperidol administration. Mice (N=12) received injections of tartaric acid 
vehicle or haloperidol (0.1 mg/kg), which were administered 50 min before test. 
Saline vehicle or theophylline (5.0, 10.0 and 15.0 mg/kg) was administered 20 
min before testing.  
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Experiment 5: Effect of CPT on T-maze performance after haloperidol 
administration. Mice (N=10) received the following treatments: tartaric acid 
vehicle or haloperidol (0.1 mg/kg), which were administered 50 min before test. 
Saline vehicle or CPT (3.0, 6.0 and 9.0 mg/kg) was administered 20 min before 
testing.  
Experiment 6: Effect of MSX-3 on T-maze performance after haloperidol 
administration. Mice (N=8) were injected with tartaric acid vehicle or 
haloperidol (0.1 mg/kg) 50 min before testing began. Saline vehicle or MSX-3 
(1.0, 2.0 and 3.0 mg/kg) was administered 20 min before testing.  
Experiment 7: Effect of theophylline, CPT and MSX-3 alone on T-maze 
performance. Mice (N=12) received injections of either saline vehicle, 
theophylline (15.0 mg/kg), CPT (9.0 mg/kg), or MSX-3 (3.0 mg/kg), 20 min 
before testing.  
Experiment 8: Effect of haloperidol on T-maze performance in A2AR KO 
and WT mice. Adenosine A2AR KO mice and WT control animals (N=7 and 9, 
respectively) received the following treatments: tartaric acid vehicle, 0.05 or 0.1 
mg/kg haloperidol, 50 min before the test.  
Experiment 9: Effect of theophylline, CPT or MSX-3 on c-Fos 
immunoreactivity after haloperidol administration. After completion of the T-
maze session in experiments 4, 5 and 6, mice (n=30) were anesthesized and 
perfused, and brain sections were stained for c-Fos immunoreactivity as 
described above. All mice were treated with tartaric acid vehicle or haloperidol 
(0.1 mg/kg) 140 min before anesthesia, and then 30 min after the first injection 
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they received treatments of either saline vehicle, 15.0 mg/kg theophylline, 9.0 
mg/kg CPT, or 3.0 mg/kg MSX-3, 30 min later.  
Statistical analysis 
The total numbers of HD arm selections and the latencies to reach the 
food across treatments were analyzed using repeated measures ANOVA, 
followed by Tukey HSD post hoc test. Data for experiment 8 were analyzed 
using a two way-factorial ANOVA. STATISTICA 7 software was used for 
statistical analysis of the data. All data were expressed as mean ±SEM, and 
significance was set at p<0.05.  
 
RESULTS 
Experiment 1: Effect of different doses of haloperidol on performance in 
the T-maze. Repeated measures ANOVA indicated a significant effect of 
haloperidol treatment (F(3,18)=7.90; p<0.01) on HD choice (Fig. 2 left panel). 
Post hoc analyses with the Tukey test revealed significant differences between 
0.0 mg/kg and the two highest doses of haloperidol, 0.05 mg/kg and 0.1 mg/kg 
(p<0.05 and 0.01 respectively). These results indicate a dose-related effect of 
haloperidol on HD choice behavior, with the lowest dose not producing a 
significant effect and the two highest doses significantly reducing the selection of 
the HD arm that had the barrier. With the latency measure repeated measures 
ANOVA revealed a significant effect of haloperidol treatment (F(3,18)=3.24; 
p<0.05). Mean + SEM latencies (seconds) were as follows: Veh=2.9 + 0.3 / HP 
(0.025mg/kg)= 2.6 + 0.2 / HP (0.05mg/kg)=3.2 + 0.4 / HP (0.1mg/kg)=3.5 + 0.4. 
However, the Tukey test did not reveal significant differences between vehicle 
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treatment and any dose of haloperidol; the only significant difference was 
between the 0.025 mg/kg dose and the 0.1 mg/kg dose (p<0.05). 
Experiment 2: Effect of 0.1 mg/kg of haloperidol on performance in the 
T-maze with two barriers. Repeated measures ANOVA showed that when both 
arms had a vertical barrier, there was no significant effect of haloperidol 
treatment on either the HD arm choice (Fig. 2 right panel) or the latency measure 
(Veh=2.5 + 0.3 seconds; HP (0.1mg/kg)=4.4 + 1.4 seconds). 
 
Fig. 2. Effect of haloperidol on HD arm choice in the T-maze with one barrier in 
the HD arm (left panel), and in the T-maze with barriers in both the HD and the 
LD arm (right panel). Mean (±SEM) number of HD arm choices. *p<0.05, 
**p<0.01 significantly different from vehicle in the corresponding experiment.   
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Experiment 3: Effect of pre-feeding on performance in the T-maze. 
Figure 3 depicts the results of the pre-feeding experiment. A separate ANOVA 
was performed for each of the three behavioral measures obtained. There was a 
significant treatment effect on HD arm crossings (F(2,22)=35.46; p<0.01). The 
Tukey test indicated that all three groups differed from each other (p<0.01). In 
addition, there was a significant effect on LD arm crossings (F(2,22)=4.45; 
p<0.05); the haloperidol-treated group differed from vehicle (p<0.05). Finally, 
there also was a significant effect on omissions (F(2,22)=9.19; p<0.01). On this 
measure, the pre-fed condition significantly differed from both the haloperidol 
condition and the vehicle condition (p<0.01). 
 
Fig. 3. Effect of different conditions (vehicle control, haloperidol treatment and 
pre-fed) on HD arm selection, LD arm selection, and omissions. Mean (±SEM) 
number of choices in the T-maze with barrier in the HD arm. *p<0.05, **p<0.01 
significantly different from the vehicle control group in the same arm selection; 
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##p<0.01 significantly different from haloperidol in the same arm selection. 
 
Experiment 4: Effect of theophylline on T-maze performance after 
haloperidol administration. In the theophylline reversal studies (Fig. 4 left 
panel), repeated measures ANOVA revealed that there was an overall effect of 
drug treatment (F(4,44)=19.05; p<0.01) on HD arm selection. The Tukey test 
revealed significant differences between control condition (Veh/Veh) and the 
haloperidol condition (HP/Veh) (p<0.01). Also, co-administration of 
theophylline with haloperidol significantly increased HD arm selection at the two 
highest doses (HP/10T and HP/15T; p<0.01 and p<0.05 respectively) compared 
to the HP/Veh condition, indicating an attenuation of the effect of haloperidol at 
these doses of theophylline. Repeated measures ANOVA yielded no significant 
effect on the latency measure (Mean + SEM latencies in seconds: 
Veh/Veh=2.7+0.2; HP/Veh=4.0+0.3; HP/Theophylline (5.0 mg/kg)=3.8+0.6; 
HP/Theophylline (10.0 mg/kg)=3.2 + 0.4; HP/Theophylline (15.0 mg/kg)=3.6 + 
0.4). 
Experiment 5: Effect of CPT on T-maze performance after haloperidol 
administration. Repeated measures ANOVA across treatments showed that there 
was a significant overall effect of drug treatment on HD arm selection 
(F(4,36)=33.38; p<0.01; Fig. 4 middle panel). The Tukey test revealed a 
significant difference between the control condition (Veh/Veh) and haloperidol 
plus vehicle (p<0.01). However, there were no significant differences between 
the HP/Veh condition and any of the HP/CPT conditions, indicating that CPT did 
not alter the effect of haloperidol. Repeated measures ANOVA showed that there 
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was a significant overall treatment effect on latency to reach the HD arm 
(F(4,36)=2.83; p<0.05). When analyzed with the Tukey test animals treated with 
the highest dose of CPT (9.0 mg/kg) plus haloperidol showed significant 
increases in latency compared to Veh/Veh condition (p<0.05), indicating that 
CPT plus haloperidol were making the animal slower in reaching the food, thus 
possibly contributing to a reduced choice of the HD arm; mean + SEM latencies 
(seconds) were as follows: Veh/Veh=3.4 + 0.6; HP/Veh=6.8 + 2.3; HP/CPT(3.0 
mg/kg)=7.8 + 2.4; HP/CPT(6.0 mg/kg)=12.0 + 3.5; HP/CPT(9.0 mg/kg)= 12.1 + 
3.4*. 
Experiment 6: Effect of MSX-3 on T-maze performance after haloperidol 
administration. MSX-3 produced a robust and significant reversal of the effects 
of haloperidol on HD arm selection (Fig. 4 right panel). Repeated measures 
ANOVA across conditions indicated a significant overall treatment effect 
(F(4,28)=16.44; p<0.01). Tukey test showed that the HP/Veh condition was 
significantly different from the Veh/Veh control condition (p<0.01). In addition, 
co-administration of MSX-3 with haloperidol significantly increased HD arm 
selection at all three doses (HP/M1 p<0.05, HP/M2 and HP/M3 p<0.01 
respectively) compared to the HP/Veh condition, indicating an attenuation of the 
effect of haloperidol at all doses of MSX-3. Repeated measures ANOVA of the 
latency data showed no significant differences between conditions; Mean + SEM 
latencies (seconds) were: Veh/Veh= 2.4 + 0.1; HP/Veh= 3.9 + 0.8; HP/MSX-3 
(1.0 mg/kg)= 2.9 + 0.3; HP/MSX-3 (2.0 mg/kg)= 2.7 + 0.3; HP/MSX-3 (3.0 
mg/kg)= 2.9 + 0.4. 
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Fig. 4. Effects of theophylline (left panel), CPT (middle panel), and MSX-3 
(right panel) in mice co-administered haloperidol on HD arm choice. Mean 
(±SEM) number of HD arm choices in the T-maze with barrier in the HD arm. 
##p<0.01 significantly different from Veh/Veh in the corresponding experiment; 
*p<0.05, **p<0.01 significantly different from HP/Veh in the corresponding 
experiment.  
 
Experiment 7: Effect of theophylline, CPT and MSX-3 alone on T-maze 
performance. The highest doses of theophylline, CPT and MSX-3 used in 
experiments 4, 5 and 6, were tested in the absence of haloperidol (Table 1). 
Repeated measures ANOVA across drug treatments 
(Vehicle/Theophylline/CPT/MSX-3) showed a significant effect on HD arm 
selections (F(3,33)=6.84; p<0.01). Tukey test analyses showed that theophylline 
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(p<0.05) and MSX-3 (p<0.01) significantly reduced selection of the HD arm 
compared to vehicle, effects that were in the opposite direction from those shown 
when these drugs were co-administered with haloperidol in experiments 4 and 6.  
Repeated measures ANOVA for the latency measure was not significant; Mean + 
SEM latencies (seconds) were: Veh= 3.0 + 0.6 / Theophylline (15.0 mg/kg)= 2.4 
+ 0.3 / CPT (9.0 mg/kg)= 3.2 + 0.5 / MSX-3 (3.0 mg/kg)= 2.3 + 0.2. 
 
 
 
 
 
Table 1. Effect of different treatments on HD arm choice in the T-maze. 
Mean (±SEM) number of HD arm choices. *p<0.05, **p<0.01 significantly 
different from Vehicle.  
 
Experiment 8: Effect of haloperidol on T-maze performance in A2A R KO 
and WT mice. In figure 5, the impact of haloperidol on the two substrains of mice 
(A2AR KO and WT) is depicted. Factorial ANOVA with a repeated measures 
factor (drug treatment; 0.0/0.05/0.1 mg/kg haloperidol) and a between-groups 
factor (group; A2AR KO /WT) showed no effect of group on HD arm selection, 
but did yield a statistically significant effect of haloperidol treatment 
(F(2,28)=29.82; p<0.01). Importantly, the haloperidol treatment x group 
Treatment 
HD arm choice (in 
30 trials) 
Vehicle 24.2 + 0.7 
Theophylline (15 
mg/kg) 
21.1 + 0.9* 
CPT (9 mg/kg) 23.1 + 1.0 
MSX-3 (3 mg/kg) 20.2 + 1.2** 
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interaction was also significant (F(2,28)=11.04; p<0.01), demonstrating that the 
effect of drug treatment differed between WT and KO mice. The Tukey post hoc 
test showed significant differences between both doses of haloperidol compared 
to vehicle in WT animals (p<0.01). However, among the KO mice, no dose was 
significantly different from vehicle. Thus, haloperidol decreased the HD arm 
selection in WT mice, but not in KO mice, indicating that A2AR KO mice were 
resistant to the disruptive effect of haloperidol. ANOVA with the latency 
measure yielded a significant effect of the drug treatment factor (F(2,28)=3.80; 
p<0.05), indicating that haloperidol in general increased the latency in both 
groups of animals. Mean + SEM latencies (seconds) were as follows: 
WT/Veh=1.8 + 0.1; A2AR KO /Veh=2.5 + 0.2; WT/HP (0.05 mg/kg)= 2.0 + 0.1; 
A2AR KO /HP (0.05 mg/kg)=2.6 + 0.3; WT/HP (0.1 mg/kg)=3.6 + 1.1; A2AR KO 
/HP (0.1 mg/kg)=3.6 + 1.1. However, there was no significant effect of mouse 
type, nor was there an interaction between the two main factors.  
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Fig. 5. Effect of haloperidol (0.0, 0.05 and 0.1 mg/kg) in WT and A2AR KO mice 
on HD arm choice. Mean (±SEM) number of HD arm choices in the T-maze with 
barrier in the HD arm. **p<0.01 significantly different from vehicle in the 
corresponding substrain group. 
 
Experiment 9: Effect of theophylline, CPT or MSX-3 on c-Fos 
immunoreactivity after haloperidol administration. The c-Fos counts in different 
brain areas (see Fig. 6) were analyzed by a two-way (treatment x brain area) 
factorial ANOVA. There was a significant overall treatment effect 
(F(4,76)=8.34; p<0.01), but no significant difference between brain areas, and no 
significant treatment x brain area interaction. Tukey tests on the data collapsed 
across brain areas indicated that haloperidol produced a significant overall 
induction of c-Fos expression compared to vehicle (p<0.01), which was 
attenuated by co-administration of MSX-3 (p<0.05).  
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Fig. 6.  Left upper part: Effect of different treatments on c-Fos expression in the 
nucleus accumbens (Nacb) Shell, Core and dorsolateral neostriatum (DLS). 
Mean (±SEM) number of c-Fos positive cells per mm
2
 (vehicle plus vehicle 
(Veh/Veh), Haloperidol 0.1mg/kg plus Vehicle (HP/Veh), Haloperidol 0.1 mg/kg 
plus Theophylline 15 mg/kg (HP/T), Haloperidol 0.1 mg/kg plus CPT 9 mg/kg 
(HP/CPT), or Haloperidol 0.1 mg/kg plus MSX-3 3 mg/kg (HP/MSX-3). 
##p<0.01 significantly different from Veh/Veh; *p<0.05, significantly different 
from HP/Veh. Left lower part: Photomicrographs of c-Fos staining in DLS from 
representative animals in each treatment group. Low power images (20x). Scale 
bar=250 m. Right part: Diagram of coronal sections with bregma coordinates 
from Franklin and Paxinos 2007, showing location of the brain areas for c-Fos 
counting. 
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DISCUSSION 
The present studies were undertaken to characterize the interaction 
between DA D2 and adenosine A2A receptors in the regulation of effort-based 
decision making in WT as well as genetically modified mice. This research 
employed a variant of the T-maze barrier choice paradigm originally developed 
for rats (Cousins et al., 1996; Salamone et al., 1994), and a number of validation 
tests and control experiments also were performed. In addition, c-Fos 
immunoreactivity studies were conducted, focusing upon striatal areas (Nacb and 
neostriatum) that contain a high concentration of adenosine A2A receptors, and 
which have a high degree of D2/A2A co-localization. Taking all the results in to 
consideration, it is clear that the T-maze barrier choice procedure is a useful task 
for the exploration of effort-based decision making in mice. 
In experiment 1, the results demonstrated that low doses of haloperidol 
redirected the behavior of CD1 mice towards the less effortful response option, 
substantially decreasing HD arm selection. Moreover, because vehicle and 
haloperidol-treated mice in experiment 1 always chose either the HD or LD arm, 
there was a concomitant increase in selection of the LD arm (i.e., the arm without 
the barrier, see Fig. 4) in haloperidol-treated mice. The shift from selection of the 
HD arm to the LD arm with no barrier occurred in a dose-dependent manner, 
with the greatest effects being seen at 0.1 mg/kg. The dose response curve 
observed in the present results points to a more potent effect of haloperidol in 
CD1 mice compared to Sprague-Dawley rats, since in mice the dose at which 
there was a significant effect on choice was 0.05 mg/kg, while in Sprague-
Dawley rats the minimum dose was 0.1 mg/kg (Mott et al., 2009; Salamone et 
al., 1994) and in Lister Hooded rats it was 0.2 mg/kg (Denk et al., 2005; Walton 
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et al., 2005). Based upon the present results and previous findings, it is clear that 
despite the effects of haloperidol on maze arm selection, rodents were still able to 
engage in food-motivated behaviors by selecting an alternative route of food that 
does not require climbing a barrier (Mott et al., 2009; Salamone et al., 1994). 
This observation supports the idea that fundamental features of food motivation 
remain intact after DA antagonism at the doses used (Salamone and Correa, 
2002; Salamone et al., 2007; see experiment 3 discussion below).  
The results of experiment 2, in which the T-maze had a 14 cm barrier in 
both arms, demonstrated that when mice had no choice other than climbing a 
barrier to get some food, there was no effect of haloperidol (0.1 mg/kg) on arm 
selection. Thus, DA antagonism did not appear to reduce barrier crossings and 
cause animals to shift to the LD arm in experiment 1 simply because this 
treatment set an absolute ceiling on the number of barrier crossings the mice 
could perform. Furthermore, these data indicate that haloperidol-induced 
reductions in selection of the HD arm with the barrier in the other experiments 
were not due to changes in memory or discrimination between the arms, and also 
suggest that haloperidol was not affecting discrimination or preference of the 
density of reward (Martin-Iverson et al., 1987; Salamone et al., 1994). Consistent 
with these observations, 0.1 mg/kg IP haloperidol did not affect arm choice 
between HD and LD when there was no barrier present (Salamone et al., 1994). 
In Hooded rats, when a barrier was also placed in the LD arm, haloperidol (0.2 
mg/kg, IP) treated animals continued to show a strong preference for the HD arm 
(Denk et al., 2005), and in Sprague Dawley rats, DA depletions in the anterior 
cingulate cortex (Schweimer et al., 2005) produced a shift to the LD arm in the 
one barrier T-maze, but had no effect on the animal’s choice in the two barrier T-
 205 
maze, thus showing the same pattern as that shown in CD1 mice in the present 
study. Nacb DA depletions produced a shift from the HD to the LD arm when the 
LD arm had no barrier (Cousins et al., 1996; Salamone et al., 1994), but, as was 
the case with haloperidol administration, DA depletions did not affect choice 
when neither the HD nor the LD arm had a barrier (Salamone et al., 1994). 
Moreover, accumbens DA depletions had no significant effect on barrier 
climbing when rats had to choose between an arm with a barrier that had 4 food 
pellets vs. another arm that had no barrier but also no food (Cousins et al., 1996). 
Taken together with the present results, these studies indicate that low doses of 
DA antagonists, as well as Nacb DA depletions, establish a condition in which 
barrier crossings are reduced, so long as the rodents have an alternative path for 
obtaining food at low response costs.   
In experiment 3, the effects of haloperidol were compared with those 
produced by pre-feeding to reduce food motivation. In this experiment, an 
additional behavioral measure was recorded (i.e., omissions: failure to make a 
choice after leaving the start box). The results of experiment 3 showed that there 
were virtually no trials in which vehicle or haloperidol-treated animals failed to 
choose one of the two arms of the maze. Nevertheless, pre-fed animals sowed a 
dramatic increase in omissions, and a relative indifference between the three 
options (HD selection, LD selection, omission). Thus, haloperidol did not display 
a pattern of effects that was consistent with a drug-induced reduction in appetite 
for food. These pre-feeding results are in accordance with previous studies in rats 
showing that the effects of DA antagonists or Nacb DA depletions on food-
related tasks do not closely resemble those produced by pre-feeding or appetite 
suppressant drugs (Aberman and Salamone, 1999; Blundell and Thurlby, 1987; 
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Clifton et al., 1991; Salamone et al., 1991; Sink et al., 2008). Another choice 
paradigm developed for rats (Salamone et al., 1991), the concurrent chow/ fixed-
ratio 5 (FR5) schedule operant task, has been used to assess the impact of 
pharmacological manipulations on effort-based choice. Low to moderate doses of 
many different DA antagonists injected IP or directly into Nacb (Cousins et al., 
1994; Cousins and Salamone, 1994; Koch et al., 2000; Nowend et al., 2001; 
Salamone et al., 1991, 1996; Sokolowski and Salamone, 1998), produced a 
decrease in FR5 lever pressing for food but an increased intake of the 
concurrently available chow. In contrast to these data, it was seen that pre-
feeding, as well as some appetite suppressants (e.g. fenfluramine, CB1 
antagonists and inverse agonists) suppressed both lever pressing and chow intake 
(Salamone et al., 1991, 2002; Sink et al., 2008). Thus, the present results, 
together with previous studies, indicate that rats and mice treated with low doses 
of DA antagonists still allocate considerable time for food acquisition and 
consumption, and do not exhibit signs of satiation or reduced appetite.  
The present results indicated that haloperidol did not significantly affect 
the overall run latency in CD1 mice. Some of these results with latency measures 
appear to be somewhat different from those reported in previous papers that used 
rats. In Sprague Dawley rats (Cousins et al., 1996; Salamone et al., 1994), 0.1 
mg/kg IP of haloperidol and Nacb DA depletion significantly increased response 
latencies in both the barrier and no-barrier conditions. However, despite this 
increased latency, every animal completed the 30 trials per session. In Hooded 
rats, a relatively higher dose (0.2 mg/kg) of haloperidol caused a slight increase 
in time taken to climb the barrier, but the effect was much more robust for the 
latencies to go from the starting arm to the barrier than from the top of the barrier 
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to the food, indicating that the overall effect on latency was not specifically due 
to a difficulty to climb the barrier. However, this dose of haloperidol made some 
animals to stop completing the 10 trials per session (Denk et al., 2005). But 
despite these minor differences, the overall pattern of results from experiments 1-
3 provide a validation of the effort-based choice T-maze paradigm as a useful 
way to study motivated behaviors in mice, as well as rats.  
Of course, Nacb DA must participate in effort-related processes in 
concert with other brain structures and neurotransmitters, and for that reason the 
present studies investigated the ability of adenosine antagonists to reverse the 
effects of a D2 antagonist on the T-maze effort based choice paradigm. The 
second group of experiments (experiments 4-6) studied the interaction between 
adenosine receptor antagonists with different profiles of selectivity and the DA 
D2 family antagonist haloperidol. In particular, the interaction between DA D2 
and adenosine A1 and A2A receptors was investigated. The results showed that 
theophylline, a nonselective adenosine antagonist, could partially reverse the 
effects of haloperidol (0.1 mg/kg) on performance of the T-maze barrier choice 
paradigm. Theophylline produced a moderate improvement in the selection of the 
HD arm in haloperidol-treated animals at the two highest doses (10.0 and 15.0 
mg/kg), although theophylline did not appear to completely restore control levels 
of HD arm selection. The effects of theophylline on the T-maze choice 
impairment induced by haloperidol were similar to the effects of caffeine in the 
concurrent chow/FR5 schedule operant task (Salamone et al., 2009). In that 
study, caffeine reversed the effects of haloperidol in rats, but its effect size was 
smaller than the effect of an A2A antagonist (KW6002), and bigger than that 
produced by an A1 antagonist (DPCPX; Salamone et al., 2009). Thus, experiment 
 208 
5 and 6 were conducted to study the relative involvement of A2A and A1 receptors 
on the T-maze effort-related choice. The selective A1 antagonist CPT, in the dose 
range tested, did not reverse the effects of haloperidol. Adenosine A1 receptor 
antagonism failed to re-establish baseline levels of HD arm selection; animals co-
administered CPT and haloperidol continued selecting the LD arm for 
approximately half of the trials, showing the same pattern of behavior as mice 
treated with haloperidol plus vehicle. This was the only case among all the 
pharmacological manipulations used in the present work in which the latency to 
reach the food was increased substantially (four-fold) after co-administration of 
an adenosine antagonist with haloperidol (the highest dose of CPT (9.0 mg/kg) 
plus haloperidol significantly differed from haloperidol alone). This result 
indicates some degree of motor impairment due to the combination of both 
haloperidol and CPT, which is consistent with a previous report indicating that 
the A1 antagonist DPCPX worsened performance in haloperidol-treated rats 
(Mott et al., 2009). In experiment 6, co-administration of the adenosine A2A 
antagonist MSX-3 with haloperidol restored the normal pattern of behavior and 
substantially reversed the effects of haloperidol. These results were obtained at 
the two highest doses of MSX-3 used (2.0 and 3.0 mg/kg), which reached HD 
choice levels comparable to the Veh/Veh control group. The lowest dose of 
MSX-3 (1.0 mg/kg) partially reversed the haloperidol effects. Although MSX-3 
alone did not alter HD arm choices in rats (Mott et al., 2009), the present studies 
with mice showed that theophylline and MSX-3 administered alone could reduce 
HD selection. It is possible that these effects were due to the psychomotor 
stimulant properties of adenosine antagonists (Ferré 2008; Randall et al., 2011), 
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which could have led to a more random pattern of arm selection or more 
impulsive choice.   
Previous studies with rats, using both the T-maze procedure and operant 
choice task, showed a similar interaction between D2 family antagonists and A2A 
antagonists (Farrar et al., 2007; Mott et al., 2009; Worden et al., 2009). All these 
data together demonstrate that A2A antagonism can reverse D2 antagonism on 
tasks involving effort-related processes in mice as well as rats. Thus, as 
predicted, the antagonism of adenosine A2A receptors was more effective than A1 
antagonism in restoring the behavior impaired by DA D2 antagonism. The 
moderate effects of the two nonselective antagonists, caffeine (Salamone et al., 
2009) and theophylline (present results), can be explained by reports indicating 
that, at least in the case of caffeine, there is some degree of preference for 
adenosine A1 receptors over A2A receptors (Ferré, 2008). It is likely that this 
pattern of results in drug interaction studies is due to the co-localization of A2A 
receptors with D2 receptors (Mott et al., 2009; Nunes et al., 2010; Salamone et 
al., 2009). Adenosine A2A receptors are located on striatal GABAergic 
enkephalin-positive neurons that also express DA D2 receptors (Fink et al., 1992; 
Ferré et al., 1997; Svenningsson et al., 1999; Chen et al., 2001). DA D2 and 
adenosine A2A receptors converge onto the same signal transduction mechanisms 
and show the capacity to form heteromers (Fink et al., 1992; Ferré et al., 1997, 
2004, 2008; Svenningsson 1999; Fuxe et al., 2003). A2A receptors, through their 
coupling to Golf proteins, can stimulate adenylyl-cyclase activity and activate the 
cAMP-PKA signaling pathway, with phosphorylation of several PKA substrates, 
such as DARPP-32 and CREB and the consequent increase in the expression of 
different genes, such as c-fos or preproenkephalin in the GABAergic 
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enkephalinergic neuron (Ferré et al., 2008). The tonic activation of D2 receptors 
blocks the ability of A2A receptors to signal through the cAMP-PKA pathway. 
Administration of D2 receptor antagonists produces a significant increase in the 
PKA-dependent phosphorylation of DARPP-32 and an increase in the expression 
of c-fos and preproenkephalin genes, which depends on the ability of D2 receptor 
blockade to liberate A2A receptor signaling activated by endogenous adenosine. 
Thus, the neural effects of the D2 receptor antagonists can be counteracted by co-
administration of A2A receptor antagonist (Ferré et al., 2008). 
Taking all these results in to consideration, we decided to explore the 
impact of D2 antagonism on WT and adenosine A2AR KO mice in experiment 8. 
Our results showed that adenosine A2AR KO mice were more resistant than WT 
mice to the effects of haloperidol on HD arm selection in the T-maze. 
Haloperidol failed to produce any change in HD arm selection in the A2AR KO 
mice, while it significantly reduced choice of the HD arm in the WT mice at both 
doses. No difference was seen in the latency. Thus, genetic elimination of 
adenosine A2A receptors blocked the shift to a less effortful option in response to 
haloperidol. A2AR KO mice have been demonstrated to be more resistant than 
WT animals to the cataleptic effect of DA antagonists like haloperidol or SCH 
23390 (Chen et al., 2001; El Yacoubi et al., 2001). In our study, A2AR KO 
animals showed no significant learning deficit in the T-maze compared to the 
WT mice (see supplemental material), and previous studies with A2AR KO 
animals have showed no impairment in memory (Wang et al., 2006) in these 
animals. However, A2AR KO mice have been reported to have reduced 
spontaneous locomotion (Chen et al., 2001; Ledent et al., 1997), a factor that 
could be related to the non-significant tendency to reach higher latencies in the 
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present experiments. There are a few possible mechanisms that could underlie the 
lack of effect of haloperidol on A2AR KO mice. First, it is possible that genetic 
deletion of striatal A2A receptors could alter striatal D2 receptor function. There is 
evidence of antagonistic intramembrane A2A– D2 interactions, by which 
stimulation of adenosine A2A receptors decreases the ability of DA to displace a 
D2 antagonist from binding to D2 receptors (Ferré et al., 1999). Thus, A2AR KO 
could be enhancing the ability of endogenous DA to compete with haloperidol 
for binding to DA receptors. In addition, because adenosine A2A and DA D2 
receptors converge onto the same adenylyl cyclase-related signal transduction 
cascade (Ferré et al., 1997, 2008), deletion of A2A receptors could be altering the 
signal transduction effects of D2 receptor blockade. 
Finally, c-Fos expression was quantified as a cellular marker of D2-A2A 
interactions in Nacb and striatum in mice trained on the T-maze task. Because D2 
and adenosine A2A receptor stimulation has opposite effects on stimulation of 
cAMP-related pathways, it was thought that adenosine A2A antagonism should 
blunt the ability of the D2 antagonist to affect transcription of immediate early 
genes and induce formation of Fos-related proteins. Earlier reports have shown 
increased c-Fos expression in striatal areas, including Nacb, after systemic 
administration of D2 family antagonists (Betz et al., 2009; Farrar et al., 2010; 
Hussain et al., 2002; Pinna et al., 1999; Svenningsson et al., 1999b). Also, it has 
been previously observed that the increases in c-Fos expression induced by D2 
antagonists in striatal areas, including Nacb, can be attenuated by co-
administration of A2A receptor antagonists and by the nonselective adenosine 
antagonist, theophylline (Betz et al., 2009; Boegman and Vincent, 1996; Farrar et 
al., 2010; Pinna et al., 1999, Ward and Dorsa, 1999). So far, all the studies have 
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been done in other behavioral settings (catalepsy) or in studies that mainly 
involved untrained rats. In our results, the pharmacological manipulations were 
done in mice highly trained in the T maze procedure. Potentially, the 
neuroadaptations that underlie the establishment of a well learned or habitual 
behavior could have produced a different outcome on c-Fos expression. 
Nevertheless, the present results demonstrated that the low dose of haloperidol 
0.1 mg/kg produced a decrease in high effort selection that was parallel to the 
increase in c-Fos expression across the striatal structures studied. Moreover, 
MSX-3, an A2A receptor antagonists, that in rats has been demonstrated to reduce 
eticlopride-induced c-Fos expression in Nacb (Farrar et al., 2010), was effective 
in reversing the effect of haloperidol on c-Fos expression and arm selection in the 
T-maze choice procedure in mice. Theophylline, which is a non-selective 
adenosine receptor antagonist, also tended to show the same pattern of effects, 
but the results did not reach statistical significance. Thus, the present results with 
c-Fos provide a behaviorally relevant cellular marker of the interaction between 
DA D2 and adenosine A2A receptors in mice trained on the T-maze task. 
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CHAPTER 5:  
 
DOPAMINE D2 RECEPTOR ANTAGONISM MODULATES THE 
PREFERENCE FOR PRIMARY REINFORCERS BASED ON THEIR 
EFFORT REQUIREMENTS: STUDIES USING RUNNING WHEELS 
AND SUCROSE CONSUMPTION IN MICE. 
 
Abstract 
Organisms frequently make effort-related decisions based upon 
assessments of motivational value and response costs. Dopamine (DA), 
particularly in nucleus accumbens (Nacb), regulates effort-related processes. In 
the present experiments, the DA D2 receptor antagonist haloperidol was used to 
study the DAergic involvement in the activational and directional components of 
motivated behaviors when multiple reinforcers are available. A T-maze task was 
developed for the assessment of preference for two different types of rewards: 
physical activity (i.e., running in a wheel) in one arm and 5% sucrose access in 
the other. In Swiss male mice tested for locomotion in a running wheel (RW) 
enclosed in a cage, haloperidol (0.1 and 0.2 mg/kg) decreased spontaneous 
locomotion. In the T-maze, under normal conditions, sucrose consumption was 
less preferred than the RW. However, haloperidol produced a shift in arm 
preference, reducing time spent on the RW, but increasing selection of sucrose. 
Haloperidol fragmented the pattern of RW behavior so that the animals spent 
less total time running but increased the number of running episodes initiated. 
However, time consuming sucrose and frequency of drinking bouts for sucrose 
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were increased. Thus, D2 antagonism reduced the choice of a primary reinforcer 
that involved vigorous activity, but increased consumption of a reinforcer that 
could be freely obtained and required little effort. Pre-exposing animals to both 
reinforcers did not produce this shift towards more sucrose consumption. In 
summary, the present results implicate DA D2 receptors in the regulation of 
behavioral activation and effort-based choice. This research allows for a better 
understanding of psychiatric symptoms such as psychomotor slowing, fatigue or 
anergia that can be observed in pathologies like depression. Moreover, it 
demonstrates that DA systems regulate preference for engaging in physical 
activities relative to other reinforcing conditions. 
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INTRODUCTION 
Nucleus accumbens (Nacb) dopamine (DA) is an important component 
of the neural circuitry that regulates behavioral activation and the ability of 
organisms to overcome work-related response costs in motivated behaviors 
(Salamone et al. 2003, 2005, 2007, 2009b; Robbins and Everitt 2007). The 
effects of Nacb DA depletions or DA receptor antagonism on food-reinforced 
behavior interact powerfully with the response requirements of an instrumental 
task. Research with concurrent choice tasks involving distinct reinforcers that 
can be obtained by activities that have different work requirements has shown 
that rodents with accumbens DA depletions or DA receptor antagonists 
reallocate their instrumental behavior away from food-reinforced tasks that have 
high response requirements (e.g., ratio requirements, vigorous activities such as 
climbing), and instead select a less-effortful type of food-seeking behavior 
(Salamone et al. 2007; Pardo et al., 2012).  
In addition to being an instrumental requirement for obtaining access to 
motivational stimuli, considerable research indicates that physical activities can 
have intrinsic motivational or reinforcing properties. In research with rodents, 
one of the most commonly studied voluntary physical activities is wheel 
running. Sherwin (1998) concluded that wheel running in rodents is “self-
reinforcing” rather than being a redirected or substitute activity. Running 
appears to be motivationally regulated like other appetitive behaviors (Mueller et 
al., 1997). Thus, wheel running can be used as the motivational stimulus for the 
establishment of a conditioned place preference (Lett et al. 2000), and as an 
explicit reinforcer in operant conditioning procedures (Collier et al. 1990; 
Iversen 1993; Catania, 1966; Epling and Pierce, 1992; Premack, 1972).  
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Of course, the choice to engage in voluntary physical activity is always 
undertaken in relation to the possible selection of other alternatives, such as 
sedentary behaviors, drugs or food consumption. However, if a running wheel 
(RW) is present in a complex environment that offers other alternatives such as 
drugs of abuse, rats will spend a considerable amount of time engaged in 
running activity (McMillan et al., 1995; Kanarek et al., 1995; Cosgrove et al., 
2002). Some studies have demonstrated that when given a choice between food 
and RW, rats often choose running over food (Epling and Pierce, 1992; 
Routtenberg, 1968; Symons 1973), and food consumption decreases on days that 
rats have access to RW (Mueller et al., 1997). However, little is known about the 
neural mechanisms involved in the selection of physical activity relative to other 
gustatory reinforcers such as sucrose.  
In the present study a rodent behavioral model for investigating the 
decision making processes that allow for the selection of voluntary physical 
activity relative to other activities was developed. Thus, we employed a multi-
arm maze task that allowed mice to choose between an arm that uses the 
opportunity to engage in wheel running as the reinforcer vs. selecting other maze 
arms that lead to a bottle containing 5% sucrose or an empty arm. With this 
paradigm we assessed the impact of DA antagonism and compared it with 
conditions that reduce motivation such as free access to RW and 5% sucrose 
previous to the test session on the activational and the directional component of 
motivated behavior. 
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MATERIALS AND METHODS 
Animals 
Swiss male mice (N=22) weighed 24-28 g at the beginning of the study 
(Janvier, France).  Mice were housed in groups of three per cage; with standard 
laboratory rodent chow and tap water available ad libitum (see specific 
conditions for each experiment). Subjects were maintained at 22 + 2 ºC with 12-
h light/dark cycles. All animals were under a protocol approved by the 
Institutional Animal Care and Use Committee of Universitat Jaume I, and all 
experimental procedures complied with European Community Council directive 
(86/609/ECC). 
Pharmacological agents 
Haloperidol (Sigma Quimica C.O), a DA D2 receptor antagonist, was 
dissolved in a 0.3% tartaric acid solution (pH=4.0), which also was used as the 
vehicle control. Haloperidol was administered intraperitoneally (IP), 50 minutes 
before testing started. Sucrose (Sigma Quimica C.O) was dissolved in tap water 
(5% w/v) and used for oral self-administration.  
Apparatus and testing procedures 
Testing sessions started two hours after the colony lights were on. The 
behavioral test room was illuminated with a soft light, and external noise was 
attenuated. 
RW locomotion. The automated RW consisted of a cage (32 x 15 x 13 
cm) with a wheel (11 cm in diameter) inserted on top. Locomotor activity was 
registered by an electrical counter connected to the wheel. A completed turn of 
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the wheel was registered as 4 counts. Animals placed in the cage had free access 
to the wheel. The session lasted 30 minutes.  
T-Maze paradigm. The maze apparatus consisted of a central corridor 
with two opposed arms (25 L x 11 W x 30 H cm). Each arm provided a different 
type of reinforcer: A RW in one arm (this RW was not connected to a digital 
counter), 5% sucrose solution on the opposite arm and nothing in the central 
corridor. Half of the mice had the RW consistently located on the left arm, while 
half the mice had the RW on the right arm. Training phase 1: in pilot studies we 
observed a strong preference for the RW such that most animals did not even 
approach the sucrose arm once. Thus, for the experiment, during this first phase, 
the RW arm was blocked to force animals to explore the sucrose arm. In 
addition, for the first 4 days, mice had restricted water access in the home cage 
(3.5 ml/day/mice). After a total of 10 days of exposure only to sucrose, access to 
the RW arm was concurrently allowed. Training phase 2: Animals were trained 
once a day for 15 minutes, during 5 days before the drug tests began. Water in 
the home cage was restricted to 5 ml/day/mice. Test session: animals were 
introduced in the T maze and, during 15 minutes, accumulated time spent in the 
wheel (duration), time consuming sucrose, and number of interactions with the 
sucrose or the RW (bouts) were recorded.  
Experiments 
Experiment 1: Effect of haloperidol on locomotor behavior in the RW. 
Mice (N=12) were trained 5 days a week during 60 minutes for 3 weeks. A 
within-groups design was used. During the drug testing phase there was one 
drug treatment day and 4 baseline days before the next drug day. On the test day, 
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animals received one injection of haloperidol (0.0, 0.025, 0.05, 0.1 and 0.2 
mg/kg) 50 min before being tested in the RW for 30 min.  
Experiment 2: Effect of haloperidol on the preference for RW versus 
sucrose in the T-Maze. During the drug testing phase there was one drug 
treatment day per week and 4 baseline days before the next drug day. Thus, a 
within-groups design was used. On the test day, mice (N=10) received the 
following haloperidol doses: 0.0, 0.05, 0.1 and 0.2 mg/kg, 50 minutes before 
testing.  
Experiment 3: Effect of pre-exposure to RW and sucrose reinforcers on 
the preference in the T-Maze. Once experiment 2 was completed, mice were 
trained one additional week and then had 24 hours of free 5% sucrose in their 
home cages as well as having 2 periods of 60 minutes free access to a RW in a 
new cage where sucrose was also concurrently available. After these pre-
exposure sessions, animals were moved to their home cages 15 minutes before 
the test session started. In addition to the previous dependent variables, inactive 
time (time not engaged interacting with any of the reinforcers) was recorded 
during 15 minutes. 
Statistical analyses 
Experiments were analyzed using a one-way repeated measures ANOVA, 
followed by non-orthogonal planned comparisons using the overall error term, 
which compared vehicle to all the other doses (Keppel, 1991). Because the 
sucrose data were highly variable, data were square route transformed prior to 
performing the ANOVA. STATISTICA 7 software was used. All data were 
expressed as mean ± SEM, and significance was set at p<0.05.  
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RESULTS 
Experiment 1: Effect of haloperidol on locomotor behavior in the RW. 
Repeated measures ANOVA yielded a significant effect of the haloperidol 
treatment (0.0, 0.025, 0.05, 0.1 and 0.2 mg/kg) (F (4,44)=6.71, p<0.01) on 
number of turns in the RW (Fig. 1). Planned comparisons revealed a dose 
dependent effect of the haloperidol on RW locomotion, since only the two 
highest doses 0.1 mg/kg (p<0.05) and 0.2 mg/kg (p<0.01) were significantly 
different from the 0.0 mg/kg dose.  
 
Fig. 1. Effect of haloperidol (0.0, 0.025, 0.05 or 0.1 mg/kg) on locomotion in the 
RW. Mean (±SEM) number of counts during 30 minutes. *p<0.05 **p<0.01 
significantly different from vehicle. 
 
 227 
Experiment 2: Effect of haloperidol on the preference for RW versus 
sucrose in the T-Maze. Independent ANOVAs were performed to analyze the 
time and frequency (i.e., number of bouts initiated) data for both the RW and the 
sucrose intake measures. Repeated measures ANOVA for the main factor 
haloperidol dose (0.0, 0.05, 0.1 and 0.2 mg/kg) indicated a significant effect (F 
(3,27)=6.32, p<0.01) on time spent in the RW (Fig. 2A). Planned comparisons 
revealed significant differences between 0.0 mg/kg and all doses of haloperidol, 
0.05 mg/kg (p<0.05), 0.1 and 0.2 mg/kg (p<0.01). The ANOVA for the running 
bouts in the RW indicated also a significant effect of the haloperidol treatment 
(F (3, 27)=5.18, p<0.01; Fig. 2B). Significant differences between 0.0 mg/kg 
and 0.05 mg/kg (p<0.01), and also with 0.1 mg/kg (p<0.05) were found. The 
ANOVA for the time spent consuming sucrose yielded a significant effect of 
haloperidol treatment (F (3, 27)=3.47, p<0.05. Fig. 2C). Significant differences 
between 0.0 mg/kg and 0.05 mg/kg and 0.2 (p<0.05), and also with 0.1 mg/kg 
(p<0.01) were found, with these doses of haloperidol substantially increasing 
sucrose drinking. Finally, the repeated measures ANOVA indicated a significant 
effect of haloperidol treatment (F (3,27)=3.94, p<0.05) on sucrose drinking 
bouts (Fig. 2D). Planned comparisons revealed significant differences between 
0.0 mg/kg and 0.05 mg/kg and 0.2 (p<0.05), and also with 0.1 mg/kg (p<0.01) 
were found. 
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Fig. 2. Effect of haloperidol (0.0, 0.05, 0.1 and 0.2 mg/kg) on the T-Maze with 
different reinforcers. Mean (±SEM) on A) time spent in the RW (seconds in 15 
min), B) times behavior in the RW was initiated (counts in 15 min), C) time 
spent consuming sucrose (seconds in 15 min) and D) times of sucrose 
consumption episodes (counts in 15 min). *p<0.05 **p<0.01 significantly 
different from vehicle. 
 
Experiment 3: Effect of pre-exposure to RW and sucrose reinforcers on 
the preference in the T-Maze. Figure 3 depicts the results of comparing control 
animals with the 0.1 mg/kg haloperidol dose and the pre-exposed group on time 
spent running in the RW, consuming sucrose, or not interacting with any of these 
reinforcers. A separate ANOVA was performed for each of the three measures. 
There was a significant treatment effect on time spent on the RW (F 
(2,18)=4.93, p<0.05). Planned comparisons indicated that haloperidol and pre-
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exposure conditions differed from the control condition (p<0.01 and p<0.05 
respectively). In addition, there was a significant effect on number of sucrose 
drinking bouts (F (2,18)=10.12, p<0.01). In this case only the haloperidol 
condition differed from the other two groups (control condition, p<0.01, and 
from the pre-exposed group, p<0.05). Lastly, there also was a significant effect 
on inactive time (F (2, 18)=4.68, p<0.05). On this measure, both haloperidol and 
pre-exposure condition differed from control condition (p<0.05 and p<0.01 
respectively).  
 
Fig. 3. Effect of different treatments (vehicle control, haloperidol 0.1 mg/kg and 
pre-exposure) on time spent in the RW (left axis), time consuming sucrose and 
inactivity (right axis) in the T-maze. Mean (±SEM) seconds in 15 minutes. 
*p<0.05 **p<0.01 significantly different from the vehicle control group in the 
same selected activity; #p<0.05 significantly different from haloperidol in the 
same selected activity.  
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DISCUSSION 
The present study evaluated the impact of DA antagonism on the 
preference for two different types of reinforcers; a highly palatable reinforcer 
and an activity-based reinforcer. Normal mice have a high preference for 
engaging in physical activities (Epling and Pierce, 1992; Routtenberg, 1968; 
Symons 1973). Running on a wheel has been used as a reinforcer per se in 
rodents. Rats would press a lever (on a progressive ratio, a FR10 or a variable 
interval schedule) in order to gain access to a RW (Pierce et al., 1986; Collier et 
al. 1990; Belke and Dunbar, 1998). Even though sucrose is also a very 
reinforcing substance in animals (Pfaffmann, 1978; Bachmanov et al., 1997; 
Berridge, 2000; Steiner et al., 2001; Levine et al., 2003; Yamamoto, 2003), and 
is often preferred to other palatable reinforcers (saccharine, or food) and to drugs 
of abuse (McMillan et al., 1995; Kanarek et al., 1995; Cosgrove et al., 2002), we 
have observed that a very high percentage of mice exposed concurrently to RW 
and sucrose for the first time chose to spend most of their time interacting and 
running on the wheel and very few of them try the sucrose. This is a normal 
pattern of behavior since typically rodents display neophobia for new tastants 
(Amico et al., 2005; Mason et al., 1978; Minasyan et al., 2007; Stewart and 
Reidinger, 1984). Thus, in the initial training phase we deprived the mice of 
water and exposed them only to the sucrose solution in order to make sure that 
later on, baseline preferences were based on animals exposed to both reinforcers. 
Even then, non-water deprived control animals spent 84% of the time on the RW 
and only 1.2% of the time sniffing or drinking from the bottle spout dispensing 
5% sucrose.  
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As shown in the first experiment, haloperidol dose dependently reduces 
locomotion on a computerized RW attached to a cage. The doses that were 
effective in reducing locomotion were 0.1 and 0.2 mg/kg. Thus, for the 
preference test we included these doses but also a lower dose that did not 
suppress locomotion. The effect of haloperidol on several measures of 
preference for RW or sucrose indicate that in the T maze, mice receiving 
haloperidol (at all doses tested) showed significantly reduced time spent on the 
RW, even at the dose of 0.05 mg/kg that did not affect locomotion in the caged 
RW.  The significant effect of 0.05 mg/kg haloperidol in this case is probably 
due to the fact that, while in the caged RW the animal has no other significant 
source of sensory stimulation, in the T maze the perceived value of running on a 
wheel is weighed against another type of stimulus; the sucrose. Thus, after 
receiving a DA antagonist, and when given a choice, mice shift their preference 
by reducing time spent on the RW but significantly increasing time spent 
interacting with the less preferred sucrose reinforcer.  
In addition, haloperidol fragmented the pattern of running in the wheel. 
Although the total interaction time with the RW was significantly less, 
haloperidol treated animals stop and started this behavior more times than 
vehicle at the two lowest doses. This fragmented pattern of behavior was similar 
to that previously reported for haloperidol- treated rats in a semi-naturalistic 
foraging environment (Salamone, 1988).  In the present studies, the high dose 
did not produce this increase in running bouts; mice treated with 0.2 mg/kg 
initiate episodes of running in the wheel with the same frequency as control 
animals, although the total duration of these episodes was shorter. As for the 
sucrose, animals engaged in drinking more frequently than control animals at all 
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doses tested. In summary, this shift in relative preference produced by a D2 
antagonist, from a reinforcer that involves physical activity to a reinforcer that 
requires little energy expenditure, supports the role of DA in behavioral 
activation but not in the consumption of palatable reinforcers such as sucrose. 
Similar results were reported previously when rodents were given a choice 
between food and RW (Epling and Pierce, 1992; Routtenberg, 1968; Symons 
1973). It also has been previously demonstrated that local blockade of D1 and D2 
receptors the in Nacb of food deprived rats suppressed spontaneous motor 
activity and shifted the structure of feeding towards longer bout durations, but 
did not alter the total amount of food consumed (Baldo et al., 2002). Non-
selective DA antagonists injected into Nacb reduced speed to approach a sucrose 
solution at the end of a corridor, but drug treatment did not affect final sucrose 
intake (Ikemoto and Panksepp, 1996). The effects obtained in the present work 
were obtained in the context of a choice situation. Haloperidol reduced 
locomotion counts and total duration of RW activity, and at the same time it did 
increase preference for sucrose by increasing time spent drinking and sniffing, 
and initiating drinking bouts. On the operant FR5/chow feeding choice 
procedure, low-to-moderate doses of D1 and D2 antagonists all produced a 
decreased lever pressing for food but substantially increased intake of the 
concurrently available chow (Salamone et al., 2010).  
This pattern of effects was not produced by pre-exposing the animals to 
both reinforcers. After reducing motivation by allowing free sucrose 
consumption and free access to a RW before testing, mice reduced time spent in 
the RW, and, like haloperidol, also increased time not interacting with any of the 
reinforcers. However, differently from haloperidol, mice did not shift towards an 
 233 
increase in sucrose consumption. Thus, the pattern of effects produced by 
haloperidol does not mimic the effect of sucrose satiation. DA antagonists or 
Nacb DA depletions do not produce effects that closely resemble those produced 
by pre-feeding or appetite suppressant drugs in concurrent operant lever 
pressing/chow feeding choice tasks (Salamone et al, 1991; Blundell and 
Thurlby, 1987; Clifton et al, 1991; Aberman and Salamone, 1999; Sink et al, 
2008; Randall et al., submitted) or in a T maze with a different effort-choice 
based task (Pardo et al., 2012). Together with other results, these findings 
demonstrate that interference with DA transmission does not simply reduce 
appetite (Salamone and Correa 2009). 
A different T-maze procedure for rats and mice that is closely related to 
the present study was developed previously in order to assess the effects of 
accumbens DA depletions on effort-related choice behavior (Salamone et al., 
1994; Pardo et al., 2012). With this procedure, the two choice arms of the maze 
can have different food reinforcement densities, and a barrier can be placed in 
the arm with the higher density of food to vary task difficulty. When no barrier 
was present in the arm with the high reinforcement density, rodents mostly chose 
that arm, and neither haloperidol nor Nacb DA depletion altered their response 
choice (Salamone et al., 1994). When the arm with the barrier contained pellets, 
but the other arm was empty, rodents with Nacb DA depletions were slower than 
control rats, but still managed to choose the high density arm, climb the barrier, 
and consume the pellets (Cousins et al., 1996). Yet Nacb DA depletions and DA 
antagonists dramatically altered choice behavior when the high density arm had 
the barrier in place, and the arm without the barrier contained an alternative food 
source. In this case, animals with compromised DA function showed decreased 
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choice for the high density arm, and increased choice for the low density arm 
(Cousins et al., 1996; Salamone et al., 1994; Mott et al., 2010; Pardo et al., 
2012). Interestingly, the same doses of haloperidol had no effect on choice when 
both arms were blocked by barriers (Pardo et al., 2012); this observation 
confirms that the haloperidol-treated mice were capable of climbing the barrier, 
but chose not to when there was an alternative food source available that could 
be obtained with less effort. Again, in the T-maze, there were virtually no trials 
in which vehicle or haloperidol-treated animals failed to choose one of the two 
arms of the maze. Nevertheless, pre-fed animals showed a dramatic increase in 
omissions, and a relative indifference between the three options (high density 
selection, low density selection, omission) (Pardo et al., 2012). Thus, haloperidol 
did not display a pattern of effects that was consistent with a drug-induced 
reduction in appetite for food. 
Based on all these results a clear role for Nacb DA has been described on 
the activational aspect of motivation. It has been demonstrated that when 
animals have a choice between two options with different effort demands, they 
reallocate their instrumental response selection based upon the response 
requirements of the task, DA antagonists are able to redirect the behavior of 
animals towards the less effortful option, while leaving intact the orientation 
towards acquiring a reinforcer (see Salamone and Correa, 2002; Salamone et al., 
2009). This conclusion is in accordance with the present results. In the novel 
RW-Sucrose T-maze procedure the choice is between a reinforcer that requires 
high levels of activation (running in a wheel) or the consumption of sucrose, a 
much less energetic option.  
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It has been previously reported that a number of factors can influence 
wheel running activity, including environmental conditions (de Rijke et al. 2005; 
Cabeza de Vaca et al. 2007; de Visser et al. 2007), pharmacological or lesion 
manipulations (Iwamoto et al. 1999; Cabeza de Vaca et al. 2007) and genetic 
factors (Morishima-Yamato et al. 2005; de Visser et al. 2007). It is reasonable to 
argue that the intrinsic reinforcing value of voluntary activities, including not 
only lever pressing or barrier climbing, but also activities such as wheel running, 
are of critical importance for understanding several aspects of motivation and 
decision making (Salamone et al. 2009b). For example, Nacb DA depletions, 
which are known to suppress several types of spontaneous, novelty-induced, and 
schedule-induced behaviors in rats, also were shown to suppress schedule-
induced wheel running (Wallace et al. 1983).  
In summary, there have been numerous advances in the last few years 
that have helped to characterize the neural circuitry involved in behavioral 
activation and effort-related processes in rodents. Furthermore, a review of this 
literature suggests that there is a striking similarity between the brain 
mechanisms involved in behavioral activation and effort-related processes in 
rats, and those involved in energy-related disorders such as anergia, fatigue and 
psychomotor slowing seen in depressed humans (Salamone et al. 2007). As 
noted above, research on effort-related processes in rats can offer potential clues 
as to the neural systems involved in the regulation of physical activities such as 
wheel running. In fact, some of the brain systems that are known to be involved 
in behavioral activation and effort-related processes in rats also have been 
implicated in wheel running behavior. The present results are consistent with the 
idea that motivational and motor processes show considerable overlap in terms 
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of their neural mechanisms (Mogenson et al., 1980; Salamone et al., 1992; 
Salamone and Correa, 2002; Salamone et al., 2006). DA is particularly involved 
in preparatory or instrumental behavior, and activational aspects of motivation 
(Salamone et al., 1991).  Thus, it makes sense that running in a wheel, which 
requires considerable behavioral activation, is sensitive to disruption with DA 
depletion. In contrast, direct responses to a reinforcer that do not require much 
effort is not altered after DA manipulations. Our data and that of others (e.g. 
Cannon and Bseikri, 2004) suggest that hedonic value of reinforcers and the 
directional aspect of motivation are intact after DA function has been 
compromised.  
It has been noted that the biological basis of fatigue, energy and 
motivational impairments in depression is still unknown, although 
catecholamine systems have been implicated (Stahl, 2002). As D2 antagonism 
induces motor impairments as well as motivational impairments in effort-related 
choice procedures, it has been suggested that psychomotor slowing in depression 
may be functionally similar to the impairment in activational aspects of 
motivation that results from a suppression of DA activity in the brain (Salamone 
et al., 2007).  Several lines of evidence illustrate the mental health relevance of 
engaging in physical activity. Activity-related symptoms, such as psychomotor 
slowing, anergia and fatigue, are fundamental and debilitating symptoms of 
depression (Tylee et al. 1999; Salamone et al. 2006, 2007). Moreover, there is a 
substantial literature indicating that exercise in humans provides a variety of 
physical and mental health benefits. Some studies have indicated that exercise 
may help alleviate fatigue or other energy-related symptoms that are sometimes 
seen in parkinsonian patients (Friedman 2009), and research with animal models 
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indicates that exercise can have neurotrophic and neuroprotective effects 
(Dishman et al. 2006; Zigmond et al. 2009). Furthermore, substantial evidence 
suggests that a lack of physical activity could contribute to the development of 
depression (Lambert 2006). These observations have led many basic researchers 
and clinicians to suggest that exercise could be used as an intervention for the 
prevention of disease and the treatment of various neurological or psychiatric 
symptoms (Dishman et al. 2006), as well as drug abuse (Smith et al. 2008; 
Zlebnik et al. 2010). Of course, such an intervention would require that the 
person complies with the exercise plan and adheres to the specific program in 
place (Ekkekakis et al. 2008).  The choice to engage in voluntary physical 
activity is always undertaken in relation to the possible selection of other 
alternatives, such as sedentary behaviors or food consumption. For this reason, it 
is important to identify the factors that influence the choice to engage in physical 
activity.   
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CHAPTER 6: 
 
IMPACT OF DOPAMINE D2 RECEPTOR ANTAGONISM ON 
THE ACTIVATIONAL EFFECTS PRODUCED BY OLFACTORY 
CONDITIONED STIMULI ASSOCIATED TO VOLUNTARY SUCROSE 
CONSUMPTION. 
 
Abstract 
The present experiments explored dopaminergic involvement in the 
activational effects of stimuli associated with a natural reinforcer. In the first 
group of experiments, the DA D2 receptor antagonist haloperidol (0.025-0.1 
mg/kg) decreased spontaneous locomotion in a novel open field (OF). However, 
in the same dose range, haloperidol did not suppress free intake of sucrose, or 
sucrose preference relative to water, in animals with different levels of baseline 
motivation (i.e., water restricted or ad libitum available water). These results 
support previous findings indicating that although DA is involved in the 
regulation of locomotion, low doses of DA antagonists do not seem affect 
consumption of primary reinforcers such as sucrose. In the subsequent 
experiments, mice were individually presented for 30 minutes per day either 
with a bottle containing water or with a bottle containing a solution of 10% 
sucrose in a random order. Concurrently, every solution was always associated 
with the presentation of an olfactory conditioned stimulus (CS). The olfactory 
CS associated with the sucrose solution (CS+) was able to enhance locomotion 
in mice compared to the effect produced by the presentation of the stimuli 
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associated with water (CS-). This enhancement was observed in animals tested 
in different paradigms on measures of locomotion and exploration; in a running 
wheel, and also in horizontal and vertical exploration in a novel OF. These 
results show the energizing properties acquired by initially neutral stimuli when 
associated with an intrinsically reinforcing stimuli. However, the activational 
effects of the CS+ were blunted by a dose of haloperidol (0.05 mg/kg) that had 
demonstrated not to affect spontaneous vertical or horizontal locomotion in the 
first experiment and that did not affect vertical or horizontal locomotion in 
animals presented with the CS- in the OF. Moreover, because the CS was 
presented 15 cm above the floor and hanging from the walls of one of the 
quadrants, vertical locomotion in the group presented with the CS+ was mainly 
increased in the quadrant where this stimulus was placed, pointing at a targeted 
increase in exploration towards the CS+ stimulus. Horizontal locomotion was 
significantly enhanced in the CS+ containing quadrant, but also in the rest of the 
quadrants. The amount of sucrose consumption during the association days was 
not correlated with any of the parameters of locomotion in the OF. In summary, 
a dose of a D2 antagonist that did not have an effect on consummatory behavior, 
nor on spontaneous locomotion, reduced the invigorating properties of 
conditioned stimuli. This research allows for a better understanding of 
psychiatric symptoms such as psychomotor slowing, fatigue or anergia that can 
be observed in pathologies characterized by these symptoms such as depression.  
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INTRODUCTION 
Vigorous physical activity is a fundamental aspect of motivated behavior 
(Salamone 2010 a,b; Salamone et al. 2007, 2009). Animals foraging in the wild 
often cover wide areas of space, and surmount numerous obstacles, to gain 
access to motivationally relevant stimuli. Because organisms are separated from 
these significant stimuli by environmental constraints or obstacles (i.e., response 
"costs"), instrumental behaviors often are characterized by a high degree of 
vigor, persistence and work output. Thus, motivated behaviors are said to have 
an energetic or activational component (Salamone et al. 2007, 2009 b; Salamone 
2010 a).  
Nucleus accumbens (Nacb) dopamine (DA) is an important component 
of the neural circuitry that regulates the ability of organisms to overcome work-
related response costs in motivated behavior (Salamone et al. 2003, 2005, 2007, 
2009b; Robbins and Everitt 2007). This system is involved in several behavioral 
processes, including aspects of motivation, motor control, and learning 
(Bradberry 2007; Robbins and Everitt 2007; Salamone et al. 2007). Thus, Nacb 
DA is involved in behavioral activation (i.e., “motivational arousal”, or 
“response invigoration”; Salamone et al. 2007). Moreover, Nacb DA is one of 
the brain areas that has been most strongly implicated in the regulation of 
locomotor activity. DA depletions and DA receptor antagonists suppress 
spontaneous, novelty-induced, schedule-induced and stimulant-induced 
locomotor activity (Koob et al. 1978; Robbins and Koob 1980; Cousins et al. 
1993; Correa et al. 2002; Salamone et al. 2007; Collins et al., 2009; Pastor et al., 
2002).  
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The sweet taste of sucrose is strongly rewarding for animals such as 
rodents and primates (Bachmanov et al., 1997; Berridge, 2000; Steiner et al., 
2001; Levine et al., 2003; Yamamoto, 2003). Appetitive rewarding events are 
things that elicit approach reactions, serve as goals that direct voluntary 
behavior, and also as positive reinforcers. In appetitive learning, a primary 
reward is repeatedly paired with a neutral stimulus, until ultimately the 
conditioned stimulus (CS), reliably elicits a behavioral reaction similar to the 
reaction instigated by the primary reward. Thus, important components of the 
behavioral response are transferred from the primary reward to the conditioned, 
reward-predicting stimulus (Berridge and Robinson 2003). The CS induces 
similar preparatory approach behavior as to the primary reward itself, thus 
gaining some control over behavior (Flagel et al., 2007; Berridge and Robinson 
2003). A CS previously paired with a stimulus perceived as a reinforcer can 
evoke DAergic activity (Berridge and Schulkin, 1989; Bindra, 1974; Breslin et 
al., 1990; Delamater et al., 1986; Rozin and Schulkin, 1990; Toates, 1985; Wise, 
1982, 1985; Katner and Weiss, 1999; Weiss et al., 1993, 2000), particularly 
within the Nacb core (Day et al., 2007; Roitman et al., 2004). Moreover, cues 
paired with a preferred reward, (e.g. a CS+ paired with sucrose), have been 
shown to evoke greater DA responses than cues that predicted less preferred 
rewards (CS-, saccharin) (McCutheon et al., 2012). In addition, D1 and D2 
receptor adaptations underlie approach behaviors directed towards signals 
associated to rewards (Flagel et al., 2007). 
 Thus, in the present study we associate odor cues to a more preferred 
reward (CS+, sucrose) and different odor cues to a less preferred reward (CS-, 
water), and we tested if this CS+ has activational properties as measured by the 
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induction of locomotion in an open field (OF). We also evaluate if this activation 
is directed towards the CS predicting reward. In addition, haloperidol (a D2 
antagonist) was used to study the impact of DA manipulations on the putative 
activational effect of the CS+. Initially, we evaluated the impact of haloperidol, 
in a broad dose range, on spontaneous locomotion in the OF and in preference 
and consumption of sucrose. It was hypothesized that DA antagonism would 
affect behavioral activation while leaving the consumption of the primary 
reinforcer intact.  
 
MATERIALS AND METHODS 
Animals 
Swiss male mice (N=149) weighed 24-28 g at the beginning of the study 
(Janvier, France). Mice were housed in groups of three per cage, with standard 
laboratory rodent chow and tap water available ad libitum (see specific 
conditions for each experiment). Subjects were maintained at 22 + 2 ºC with 12-
h light/dark cycles. All animals were covered under a protocol approved by the 
Institutional Animal Care and Use Committee of Universitat Jaume I, and all 
experimental procedures complied with European Community Council directive 
(86/609/ECC). 
Pharmacological agents 
Haloperidol (Sigma Quimica C.O), a DA D2 receptor antagonist, was 
dissolved in a 0.2% tartaric acid solution (pH=4.0), which also was used as the 
vehicle control. Haloperidol was administered intraperitoneally (IP), 50 minutes 
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before testing started. Sucrose (Sigma Quimica C.O) was dissolved in tap water 
and used for oral self-administration.  
Apparatus and testing procedures 
Testing sessions started two hours after the colony lights were on. The 
behavioral test room was illuminated with a soft light, and external noise was 
attenuated. 
Water and Sucrose free consumption and preference. Different groups of 
mice had either ad libitum water or water restricted to 5.0 ml/day/mouse in their 
home cage. During one hour a day animals were individually exposed to a 
gradated tube containing 10% sucrose and another containing tap water. Each 
animal was exposed to these solutions for 2 weeks until after which a criterion of 
1 ml of sucrose minimum was consumed over three consecutive days in order to 
avoid floor effects in the study of DA antagonist effects. Sucrose and water 
intake were measured at the end of the test session by reading the meniscus of 
the solutions along the gradations.  
Association of olfactory stimulus with 10% sucrose and water. In the 
initial phase, animals were water restricted to 5.0 ml/day/mouse in their home 
cage during 4 weeks, after which ad libitum water was available in their home 
cages for the rest of the experiment (4 more weeks before testing session began). 
Conditioning sessions were performed for 30 minutes a day. Animals were 
individually placed in a different cage from the home cage with water or 10% 
sucrose access and an odorant located on the top of the cage was presented as the 
conditioned stimuli (CS). In order to avoid possible preferences for one of the 
two odors (papaya or strawberry), half of the animals had water associated with 
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odor A (CS-), and sucrose with odor B (CS+), while half had sucrose associated 
with odor A (CS+) and water with odor B (CS-). Every pair of stimuli (solution 
plus odor) was presented in a random order for 8 weeks, maintaining equal 
number of pairing sessions across weeks. The test day one of the odors was 
present either in the RW (experiment 3A) or in the novel OF (experiment 3B) 
and locomotion was assessed. Sucrose was never present during the test session. 
Running wheel (RW) locomotion. The automated RW consisted of a 
cage (32 x 15 x 13 cm) with a wheel (11 cm in diameter) inserted on top. 
Locomotor activity was registered by an electrical counter connected to the 
wheel. A completed turn of the wheel was registered as 4 counts. Animals 
placed in the cage had free access to the wheel. The session lasted 15 minutes.  
OF locomotion. The OF consisted of a Plexiglas cylinder with translucent 
walls (30 cm in diameter and 30 cm high) and an opaque floor divided into four 
equal quadrants by two intersecting lines. Locomotor activity was registered 
manually. Horizontal and vertical locomotion were simultaneously recorded. For 
horizontal locomotion an activity count was registered each time the animal 
crossed from a quadrant to another with all four legs. A count of vertical 
locomotion was registered each time the animal raised its forepaws in the air 
higher than its back, or rested them on the wall. Animals were placed in the 
center of the cylinder and immediately observed for 15 minutes. For experiment 
5, an odor was placed in one wall of the OF at a height of 20 cm from the floor. 
This odor acted as CS+ for half of the animals (was paired consistently with 
sucrose) and as CS- for the rest of animals (was paired consistently with water). 
Separate measurements were taken either for activity the quadrant where the CS 
(odor) was placed vs. the other 3 quadrants in this experiment.    
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Experiments 
Experiment 1: Effect of haloperidol on 10% sucrose and water 
preference and intake. Because water accessibility is a powerful motivational 
factor, and since animals in the conditioning experiment went through a period 
of restricted water access followed by a period of ad libitum access in the home 
cage, we evaluated these two housing conditions on preference and fluid 
consumption after haloperidol administration. Thus, mice (N=29, 15 for the 
water restricted experiment and 14 for the ad libitum experiment) received 
haloperidol (0.0, 0.025, 0.05 and 0.1 mg/kg) 50 minutes before the intake test 
started. A within-groups design was used. After testing began, there was one 
drug treatment day a week and 4 baseline days before the next drug day.  
Experiment 2: Effect of different doses of haloperidol on locomotion in 
the OF. In order to make experimental conditions similar to experiment 5, mice 
(N=45) were handled and weighted twice a week during 10 weeks after arriving 
to the laboratory. Animals were not pre-exposed to the OF paradigm. On the test 
day animals received one injection of haloperidol (0.0, 0.025, 0.05 or 0.1 mg/kg) 
50 min before being tested in the OF for 15 min. As in experiment 5, a between-
groups design was used.  
Experiment 3: Effect of olfactory CS associated with sucrose or water on 
measures of spontaneous locomotion. 
3.A. Effect of CS on locomotion in the RW. Mice (N=9) were trained to 
associate odor and fluid as described above, and 3 hours later were habituated to 
the RW during 30 minutes. A within-groups design was performed. During the 
test phase, mice were introduced in the RW cage with one of the CS placed on 
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top of the cage and RW counts were registered during 15 minutes. Additional 
training was done the following days and the effect of the other CS was 
evaluated one week later.   
3.B. Effect of CS on horizontal and vertical locomotion in the OF. Mice 
(N=35) were trained to associate odor and fluid as described above. No 
conditioned training was done the day of the testing session. To mimic 
experiment 4 conditions, animals were introduced in the OF with no odor, and 
15 minutes later one of the odors (CS+ or CS-) was introduced in the upper part 
of the OF attached to the wall, and centered in one of the quadrants. A between-
groups design was used. 
Experiment 4: Effect of haloperidol on horizontal and vertical 
locomotion in the OF in the presence of a CS. During the training phase, mice 
(N=66) were exposed to odor and fluid as described above. Animals did not 
receive conditioned training on the day of the testing session. Thirty five minutes 
after receiving haloperidol (0 or 0.05 mg/kg) mice were introduced in the OF 
with no odor, and 15 minutes later one of the odors (CS+ or CS-) was introduced 
in the upper part of the OF attached to the wall, and centered in one of the 
quadrants. Separate analyses were done for the quadrant where the CS was 
located and for the rest of quadrants. A between-groups design was used. 
Statistical analyses 
Different statistical analyses were used depending on the experiment. In 
experiments 1, and 3A, data were analyzed using repeated measures ANOVA. 
Experiments 2 and 3B were analyzed using a one-way simple ANOVA. In 
experiment 4 a two-way between-groups factorial ANOVA was used. When the 
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overall ANOVA was significant, non-orthogonal planned comparisons using the 
overall error term were used to compare each treatment with the control group 
(Keppel, 1991). The relationship between sucrose consumption and locomotor 
behavior was also examined using correlation tests with a 95% confidence 
interval. STATISTICA 7 software was used. All data were expressed as mean 
±SEM, and significance was set at p<0.05.  
 
RESULTS 
Experiment 1: Effect of haloperidol on 10% sucrose and water 
preference and intake. Previous to the haloperidol dose/response test phase, 
preference for 10% sucrose or water consumption was assessed by comparing 
the average volume consumed during the last four weeks before testing started. 
A Students t-test analyses comparing water vs sucrose, showed a significant 
effect (t (6)=77.66, p<0.01) among the animals with home cage restricted access, 
and also among the group of animals with ad libitum water access (t (6)=593.59, 
p<0.01). Animals in both groups consumed a significantly higher volume of 
sucrose compared to water (0.29 ± 0.04 ml of water, 2.62 ± 0.26 ml of sucrose in 
the deprived animals, and 0.15 ± 0.03 ml of water, 2.52 ± 0.09 ml of sucrose in 
the ad libitum group).  
For the drug testing phase (0.0, 0.025, 0.05 and 0.1 mg/kg haloperidol), 
the one-way ANOVA did not yield a statistically significant effect for either 
sucrose (F(3,39)=0.38, n.s) or water intake (F(3,39)=0.14, n.s) among non-
restricted animals. For the restricted group the one-way ANOVA for sucrose 
(F(3,42)=0.34, n.s) or water intake (F(3,42)=1.17, n.s) also did not yield a 
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statistically significant effect. Thus, haloperidol at this range of doses had no 
effect on intake under any condition tested. These data are shown in table 1.  
 
Table 1. Effect of haloperidol (0.0, 0.025, 0.05 and 0.1 mg/kg) on sucrose and 
water intake in non-deprived and water restricted animals. Mean (±SEM) ml 
consumed in 60 min. 
 
Experiment 2: Effect of different doses of haloperidol on locomotion in 
the OF. The one-way ANOVA for the haloperidol factor (0.0, 0.025, 0.05 or 0.1 
mg/kg) showed a significant effect of dose on horizontal locomotion (F 
(3,41)=85.63, p<0.01; Fig. 1A). Planned comparisons yielded significant 
differences between vehicle and the highest dose of haloperidol (p<0.01). For 
the vertical locomotion data (Fig. 1B) the ANOVA also showed a significant 
effect of haloperidol (F (3,41)=6.49, p<0.01). Planned comparisons revealed 
significant differences between vehicle and the lowest (p<0.05) and highest 
(p<0.05) doses of haloperidol. Thus, 0.1 mg/kg haloperidol consistently reduced 
spontaneous horizontal and vertical locomotion in a novel OF, while 0.05 mg/kg 
did not significantly affect any of the locomotion measurements. 
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Fig. 1. Effect of haloperidol (0.0, 0.025, 0.05 or 0.1 mg/kg) on A) horizontal 
locomotion and B) vertical locomotion. Mean (±SEM) number of counts in the 
OF during 15 minutes. *p<0.05 **p<0.01 significantly different from vehicle. 
 
Experiment 3: Effect of olfactory CS associated to sucrose or water on 
meassures of spontaneous locomotion. Figure 2 shows sucrose and water intake 
during the last conditioning sessions before locomotion tests started.  
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Fig 2.  Water and sucrose intake during olfactory conditioning sessions across 
the 4 weeks before locomotion tests started. Mean (±SEM) ml of water and 
sucrose consumed in 30 min. **p<0.01 significantly different from week 1.  
 
The repeated measures ANOVA showed no significant changes in water 
intake (F(3,204)=2.12, n.s) over four successive weeks of training. However, 
ANOVA yielded a significant effect on sucrose intake (F (3,204)=3.15, p<0.05) 
over weeks. Planned comparisons revealed significant differences on sucrose 
intake between first and last week (p<0.01). Students t-test analyses comparing 
the average volume consumed during the last four weeks water vs. sucrose yield 
a significant effect (t (6)=319.13, p<0.01). Mice preferred 10% sucrose over tap 
water.  
3.A. Effect of CS on locomotion in the RW. Repeated measures ANOVA 
yielded a significant effect of the CS (F(1,8)=5.79, p<0.05) on RW locomotion. 
Mean number (+SEM) of RW turns in 15 minutes when the CS- was present was 
780.3 ± 78.7, and when the CS+ was present; 840.2 ± 88.9 (see Fig. 3). Thus, 
mice habituated to running in the wheel showed an increase in wheel running 
when the CS+ was presented relative to wheel running when the CS- was present 
in the RW cage. 
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Fig. 3. Effect of CS+ or CS- on locomotion in the RW. Mean (±SEM) number of 
counts during 15 minutes. *p<0.05 significantly different from CS- condition.  
 
3.B. Effect of CS on horizontal and vertical locomotion in the OF. The 
Student t test comparing the two independent groups of mice presented with CS- 
or with CS+ demonstrated that there was a significant effect (t=5.90, df=33, 
p<0.05) of CS+ presentation relative to CS- presentation on both horizontal (Fig. 
4A) and vertical locomotion (Fig. 4B; t=9.03, df=33, p<0.01).  As in the RW 
experiment, the presence of the CS+ enhanced locomotion in both measures.  
 
A B 
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Fig. 4. Effect of CS+ or CS- on A) horizontal locomotion and B) vertical 
locomotion. Mean (±SEM) number of counts in the OF during 15 minutes. 
*p<0.05 **p<0.01 significantly different from CS-. 
 
Experiment 4: Effect of haloperidol on horizontal and vertical 
locomotion in the OF in the presence of a CS. A two-way factorial ANOVA of 
the conditioned stimulus factor (CS+ or CS-) and the haloperidol dose factor (0.0 
or 0.05 mg/kg) for horizontal locomotion in the CS quadrant (i.e., the quadrant 
in which the CS was located; Fig. 5A), showed no significant effect of stimulus 
condition (F(1,62)=8.22, n.s), a statistically significant effect of haloperidol 
(F(1,62)=8.25, p<0.01), and a significant stimulus x haloperidol interaction 
(F(1,62)=4.08, p<0.05). Planned comparisons yielded significant differences 
between CS+ and CS- groups in the vehicle condition (p<0.01), but not in the 
haloperidol condition. Moreover, haloperidol (0.05 mg/kg) significantly reduced 
horizontal locomotion in the CS+ group (p<0.01) but not in CS- group. Analysis 
of the vertical locomotion data for the CS quadrant (Fig. 5B), showed a 
significant effect of stimulus condition (F(1,62)=8.22, p<0.01), a statistically 
significant effect of haloperidol (F(1,62)=13.42, p<0.01), and a significant 
stimulus x haloperidol interaction (F(1,62)=13.05, p<0.01). Planned 
comparisons yielded significant differences between CS+ and CS- in the vehicle 
condition (p<0.01), but not the haloperidol condition. As with horizontal 
locomotion, haloperidol (0.05 mg/kg) also significantly reduced horizontal 
locomotion in the CS+ group (p<0.01) but not in CS- group.  
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Fig. 5. Effect of haloperidol (0.0 or 0.05 mg/kg) on locomotor effects induced by 
CS+ or CS- presentation on A) horizontal locomotion and B) vertical 
locomotion, in the quadrant where the CS was located. Mean (±SEM) number of 
counts in the OF during 15 minutes. **p<0.01 significantly different between 
doses in the same group; ##p<0.01 significant difference between CS+ and CS- 
at the same dose. 
 
Figures 6A and 6B show horizontal and vertical locomotion in the 
quadrants with no CS. A two-way factorial ANOVA with the two main factors 
(stimuli: CS+ or CS-) and haloperidol dose (0.0 or 0.05 mg/kg) for horizontal 
locomotion in the non-CS quadrants showed a significant effect of stimulus 
condition (F(1,62)=4.89, p<0.05), and of haloperidol treatment (F(1,62)=7.54, 
p<0.01), and also showed a significant stimulus x haloperidol interaction 
(F(1,62)=4.18, p<0.05). Planned comparisons yielded significant differences 
between CS+ and CS- in the vehicle condition (p<0.01), but not the haloperidol 
condition. Haloperidol (0.05 mg/kg) significantly reduced horizontal locomotion 
only in the CS+ group (p<0.01), and not in CS- group. Finally, the two-way 
factorial ANOVA of the vertical locomotion data in non-CS quadrants showed a 
significant effect of the stimulus factor (F(1,62)=6.80, p<0.05), but neither the 
A B 
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haloperidol factor (F(1,62)=3.97, n.s), nor the interaction (F(1,62)=2.46, n.s) 
were significant. These data indicate that the CS+ increased horizontal 
locomotion even in the areas of the chamber in which there was no CS, but in 
the case of vertical locomotion the results were less robust. There was a slight 
increase in vertical locomotion in animals exposed to the CS+, and the overall 
effect of haloperidol approached statistical significance (p<0.0507), but these 
actions were not enough to drive a significant interaction.   
 
Fig. 6. Effect of haloperidol (0.0 or 0.05 mg/kg) on locomotor effects induced by 
CS+ or CS- presentation on A) horizontal locomotion and B) vertical 
locomotion, in the rest of quadrants where no CS was present. Mean (±SEM) 
number of counts in the OF during 15 minutes. **p<0.01 significantly different 
between doses in the same group; ##p<0.01 significant difference between CS+ 
and CS- at the same dose. 
 
Additional analyses were performed to better understand the relation 
between consummatory behavior and activational effects of the CS. Thus we 
plotted the amount of sucrose consumed during the last 2 weeks previous to the 
OF test against locomotor measures in the OF. There were no significant 
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correlations between these two types of variables in any of the groups (see 
tables). 
Group: CS-/vehicle 
 
Group: CS+/vehicle 
 
Group: CS-/haloperidol 0.05 mg/kg 
 
Group: CS-/haloperidol 0.05 mg/kg 
 
Correlational analyses also were performed for sucrose intake averaged from the 
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two last weeks of training and locomotion measures obtained in the OF for the 
four experimental groups. The dependent variables are depicted in the far left 
column followed by the correlation coefficient (r) and the level of significance 
(P value). 
 
DISCUSSION 
The present results show that although DA D2 receptor antagonism was 
able to dose dependently was reduce measures of spontaneous horizontal and 
vertical activity in a novel OF in mice, it did not reduce total intake of sucrose 
and water, and did not alter sucrose preference. Our data are in agreement with 
previous results showing that Nacb DA has been clearly implicated in the 
regulation of spontaneous, novelty-induced, food-induced, and drug-induced 
locomotion (Kelley and Iversen, 1976; Koob et al., 1978; Ahlenius et al., 1987; 
McCullough and Salamone, 1992; Correa et al., 2002, 2004). However, 
consummatory behaviors remain intact after Nacb DA depletions or low doses of 
DA antagonists (Salamone et al., 2010). Moreover, directional aspects of 
motivation and emotional reactions to tastants are spared after DAergic 
antagonism, while activational aspects of motivation seem to be very susceptible 
to disruption by interference with DA transmission. Moderate doses of the D2 
receptor antagonist haloperidol do not modify the hedonic or aversive reactions 
to sucrose or quinine in rats (Treit and Berridge, 1990). Mice with DA 
deficiency show intact discrimination between saccharin, sucrose and water 
solutions, showing a clear preference for sucrose over the other two, and for 
saccharine over water (Cannon and Palmiter, 2003). Also, rats with DA 
depletions in the shell of the Nacb showed no alterations in preference for 
sucrose (Martinez-Hernandez et al., 2012). D2 or D1 receptor antagonists, 
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(raclopride and SCH23390) did not diminish the maximal lick rate of 10% 
sucrose achieved by rats (Cannon and Bseikri, 2004). The non-selective DA 
antagonist flupentixol injected in Nacb reduced speed to approach sucrose, but 
had no effect on final sucrose intake in rats (Ikemoto and Panksepp, 1996). 
Our results also indicate that an odor associated with sucrose presentation 
and consumption (Pavlovian conditioned stimulus, CS) was able to acquire 
properties that result in an increase of behavioral activation when the CS+ is 
presented. This potentiated activity is manifested in more running in a RW, as 
well as in increases of exploration in an OF a measured by increased horizontal 
locomotion and rearing. Horizontal locomotion was increased in all the areas of 
the OF, near the location of the CS+ but also in more distal areas, indicating a 
general increase in exploration. However, although vertical locomotion or 
rearing was substantially increased in proximity to the CS+, the stimulation of 
vertical activity by the CS+ in the other 3 quadrants was less robust. This pattern 
suggests that vertical activity was more focused in the direction of the location 
of the CS+.  Moreover, these increases in exploration are DA-dependent since a 
dose of haloperidol (0.05 mg/kg) that did not affect locomotion on its own (see 
fig 1 and also the CS- group in figures 6 and 7) was able to selectively decrease 
the effects of the CS+ in both measures of locomotion in the OF. Thus, the 
increases in both general and specific aspects of behavioral activation seem to be 
DA mediated. This conclusion seems to be supported by data showing that CSs 
evoke DA responses within the Nacb (Day et al., 2007; Roitman et al., 2004; 
McCutheon et al., 2012), and more specifically by results showing D1 and D2 
receptor adaptations underlying approach behaviors directed towards signals 
associated to rewards (Flagel et al., 2007). Some of the motivational functions of 
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mesolimbic DA represent areas of overlap between aspects of motivation and 
features of motor control, which is consistent with the well known involvement 
of Nacb in locomotion and related processes (Salamone et al., 1991, 1997, 2002, 
2003, 2005, 2007; Yurgelun-Todd et al., 2007; Barbano and Cador 2007; Niv et 
al., 2007; Phillips et al., 2007; Robbins and Everitt 2007). NAcb DA seems to be 
required for forward locomotion in response to novel stimuli and to stimuli 
associated with reward or punishment (Ikemoto and Panksepp, 1999). However, 
pavlovian associations do not specify fixed actions (Nicola, 2010). NAcb DA is 
required for CS to promote locomotor approach to the CS itself and to the 
reward (Di Ciano et al., 2001; Corbit et al., 2007; Lex and Hauber, 2008; Nicola, 
2010). Both stimuli (i.e., the unconditioned stimulus as well as CS) elicit 
activation, and DA manipulations can directly affect this activity, while the 
directional aspect of motivation is influenced by manipulations of other neural 
systems such as GABA systems in the brainstem, ventral pallidal systems where 
lesions produce aversion, or opioid systems in the nucleus accumbens shell 
(Berridge, 1996; Berridge and Peciña, 1995; Cromwell and Berridge, 1994; 
Peciña and Berridge, 1996a,b). In the present studies, the fact that the amount of 
sucrose consumption was not affect by DA antagonism and was not related to 
the amount of exploration, argues for a separation between the unconditioned 
reinforcing properties of sucrose and its predictive and invigorating properties. 
The CS does not elicit the same pattern of behavior in all animals. Thus, 
two different patterns of behavior have been described in an operant task in 
which a CS is presented before the food. Sign-trackers are animals that 
responded to the CS by approaching the CS and directly interacting with it (i.e. 
almost attempting to “consume” it). Goal-trackers are animals that responded to 
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the CS by approaching the location where the US (e.g. food or sucrose) would 
be delivered (Hearst and Jenkins, 1974; Boakes, 1977; Flagel et al., 2007, 2008, 
2009; Robinson and Flagel, 2009; Yager and Robinson, 2010; Morrow et al., 
2011). The present paradigm does not allow for the differentiation between 
animals directed towards the goal or towards the sign, since the goal was never 
present in the OF and the animals can not reach and grasp the sign. However, the 
present results demonstrate that the CS+ acquires activational properties, thus 
increasing active exploration in a novel area in which the unconditioned stimuli 
could be located, but also instigating more focused exploration towards the CS+, 
effects that were both blunted after DA antagonism.  
All these results suggest that DA activates and invigorates reward-
seeking behavior by allowing Pavlovian CSs to evoke general exploration of the 
environment and approach to potentially significant stimuli. It is important to 
characterize the neural correlates involved in behavioral activation and effort-
related processes in animals, since there is a striking similarity between the brain 
mechanisms involved in behavioral activation and effort-related processes in 
animals and energy-related disorders such as anergia, fatigue and psychomotor 
slowing seen in depressed humans (Salamone et al. 2007).  
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GENERAL CONCLUSIONS  
 
Along with previous data in the literature, a pattern of results that 
emerges across all the present studies is that DA mediates the willingness to 
exert effort for natural reinforcers (food or sucrose), and also mediates activation 
involved in exploratory behaviors. This conclusion is in agreement with the 
hypothesis that DA is involved in the activational component of motivation, 
rather than in the directional component. DA receptor antagonism or depletion 
does not change the preference for appetitive reinforcers, animals were still 
directed towards them, but they changed strategies in order to minimize the 
effort demands to obtain these reinforcers. When no effort was required, no 
change in behavior was observed. 
Work output in an instrumental task and locomotor exploration are 
components of naturalistic foraging behaviors to obtain food. Nacb DA does 
provide the neural substrate for this essential set of behaviors. This nucleus then 
acts as the interface between motor and motivated behavior. Nacb is part of a 
circuit that involves other striatal structures, that participate in the more pure 
motoric components, as well as in the stablisment of habitual responses, and also 
is modulated by other frontocortical and limbic structures. Moreover, 
neurochemical interactions between the DArgic system and the neuromodulator 
system adenosine are very important for the regulation of the energizing 
component of motivated behaviors. Thus, co-localization of adenosine and DA 
receptors, and the intracellular cascades that they initiate, regulates neural 
activity in the Nacb in a very precise way. The specificity of the receptor type is 
also key in this regulation, being D2- A2A interaction central for the types of 
behaviors studied in the present group of experiments. 
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CONCLUSIONS FROM THE EXPERIMENTAL CHAPTERS  
 
Chapter 1: Selection of sucrose concentration after DA depletion and 
selective DA antagonists depends on the effort required by the instrumental 
response: studies using tetrabenazine and D1, D2 and D3 antagonists.    
Control animals press the lever under a FR7 schedule to obtain the 
preferred 5% sucrose concentration while consuming little 0.3% sucrose volume.  
-       DA depletion by tetrabenazine as well as D1 and D2 antagonism 
produced a shift on the behavior; lever pressing was decreased and a significant 
increase in intake of free available sucrose was seen, effect that did not resemble 
those obtained after pre-exposing the animals to both sucrose solutions.  
-       D3 antagonism does not modify this behavior.  
-       DA antagonism does not affect sucrose consumption when no effort 
was required.  
-       Non-selective adenosine antagonists do not reverse the effects caused 
by D1 antagonism. However, theophylline attenuated the choice effects produced 
by D2 antagonism effects. 
  
Chapter 2: Dopaminergic modulation of effort-related choice 
behavior as assessed by a progressive ratio chow feeding choice task: 
Pharmacological studies and the role of individual differences. 
-       In each operant session, the PROG schedule represents a continuous 
challenge to work more and more to obtain preferred palatable food. This 
challenge is affected by the presence of freely available chow. Thus, more that 
with a FR schedule, PROG ratio forces animals to reach a break point after 
which they stop lever pressing and consume high quantities of the chow. This 
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characteristic of the task brings out individual differences in the amount of work 
output that the animals are willing to pay for the preferred food. 
-       The DA D2 antagonist haloperidol decreased number or lever presses, 
maximum ratio achieved, and active lever time. Haloperidol does not decrease 
chow intake, which indicates that primary food motivation is intact in 
haloperidol-treated rats. 
-        The A2A antagonist, MSX-3 increased number of lever presses and 
maximum ratio achieved, and also increased the amount of time that animals 
kept the lever active during the session. MSX-3 was observed to decrease chow 
consumption at the highest dose.  
-       Both DA and adenosine manipulations do not resemble the effects of 
pre-feeding the animals or the effects of appetite suppressants. Pre-feeding 
animals, to reduce food motivation and thereby devalue the food reinforcement, 
decreased number of lever presses and highest ratio achieved, and also 
substantially reduced chow consumption. CB1 receptor antagonist/inverse 
agonist AM251 produced similar effects to those resulting from pre-feeding. 
AM251 decreased number of lever presses, maximum ratio achieved, and chow 
consumption. 
-       The PROG/choice procedure is characterized by substantial 
individual variability. High responders did show greater DARPP-32 expression 
in Nacb core than low responders reflecting greater DA transmission in the 
animals working harder on the lever pressing component of the task. 
  
 274 
      Chapter 3: Effect of subtype-selective adenosine receptor 
antagonists on basal or haloperidol-regulated striatal function: studies of c-
Fos expression and motor activities in outbred and A2AR KO mice.  
-       D2 antagonism decreased behavioral activation in an OF.  
-       Non-selective adenosine antagonism was able to reverse the effects of 
D2 antagonism and this effect seems to be mediated by A2A receptors rather than 
A1 receptors. MSX-3, an A2A receptor antagonist completely reversed 
haloperidol effects while CPT, an A1 antagonist was not able to attenuate D2 
antagonism.  
-       KO mice for the A2A receptor showed resistance to haloperidol 
effects.  
-       Parallel results were obtained in the expression of the cellular marker, 
c-Fos, on Nacb and dorsal striatum.  
  
     Chapter 4: Adenosine A2A receptor antagonism and genetic 
deletion attenuate the effects of dopamine D2 antagonism on effort-based 
decision making in mice: Studies using a T-maze with barrier. 
-       In a T maze with barrier in the arm that has a high amount of food and 
free access on the other arm with a smaller quantity of the same type of food, 
control animals select to climb a barrier to obtain more food.  
-       D2 antagonism decreased HD arm selection redirecting the behavior 
towards the less effortful option. This effect does not resemble the results 
obtained after prefeeding the animals. Pre-fed animals do not shift behavior, they 
increase omissions. 
 275 
-       Theophylline as well as the selective A2A antagonist MSX-3, 
attenuated haloperidol effects, reaching control levels with the A2A antagonist. 
The A1 antagonist, CPT failed to reverse D2 antagonism.   
-       KO animals for the A2A receptor showed protection against D2 
antagonism on this task.  
-       Parallel results were obtained in the expression of the cellular marker 
c-Fos on Nacb and dorsal striatum.  
-       These data validate this effort based choice paradigm for mice used 
previously in rats. 
 
Chapter 5: DA D2 receptor antagonism modulates the preference for 
primary reinforcers based on their effort requirements: studies using 
running wheels and sucrose consumption in mice. 
-       Under control condition, mice showed a clear preference towards the 
RW and spend less time in contact with sucrose.   
-       D2 antagonism by haloperidol redirects the behavior towards the less 
effort demanding option, effect that did not resemble devaluation by pre-
exposition to both reinforcers.   
-       This new task allows the study of preference based on the activational 
costs of every reinforcer. 
 
     Chapter 6: Impact of DA D2 receptor antagonism on the 
activational effects produced by olfactory conditioned stimuli associated to 
voluntary sucrose consumption.  
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-   D2 antagonism at doses that reduce vertical and horizontal exploration 
in a novel OF, do not alter 10% sucrose or water intake and preference. 
-  An olfactory stimulus previously paired with sucrose presentation, 
increased locomotion in a RW and in the OF.  
-  Enhanced locomotion on a novel environment due to the presence of 
the CS+ was blocked after haloperidol at a low dose that did not alter by itself 
locomotion.  
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FUTURE DIRECTIONS 
 
In summary, the present results are consistent with the hypothesis that 
DA is involved in effort-related processes, and support the concept that 
adenosine A2A receptors interact with DA in modulating these functions. Future 
research should investigate the effects of additional genetic manipulations on 
effort-related choice behavior, including DA receptor knockouts as well as 
regionally-specific deletion of A2A receptors. Moreover, the search for individual 
differences in neural markers of Nacb activity in response to effort demanding 
tasks can be a new approach to understand this basic process. 
The present work also has clinical relevance. DA has been implicated in 
aspects of depression, including such fundamental symptoms as psychomotor 
slowing, anergia, feelings of listlessness, decreased energy levels and fatigue. It 
has been suggested that psychomotor slowing in depression may be functionally 
similar to the impairment in activational aspects of motivation that results from a 
reduction of DA activity in the brain. Thus, research on DA/adenosine 
interactions involved in effort-related processes may yield insights into the brain 
mechanisms involved in motivational symptoms of depression and other 
disorders. Future studies involving effort-based functions in genetically altered 
mice could prove to be a critical aspect of this research.   
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APPENDIX 
 
CONDITIONAL NEURAL KNOCKOUT OF THE ADENOSINE 
A2A RECEPTOR AND PHARMACOLOGICAL A2A ANTAGONISM 
REDUCE PILOCARPINE-INDUCED TREMULOUS JAW 
MOVEMENTS: STUDIES WITH A MOUSE MODEL OF 
PARKINSONIAN TREMOR. 
 
Abstract 
 Tremulous jaw movements are defined as a rapid vertical deflection of 
the lower jaw that resembles chewing but is not directed at any particular 
stimulus. In rats, tremulous jaw  movements can be induced by a number of 
neurochemical conditions that parallel those seen in human parkinsonism, 
including dopamine depletion, dopamine antagonism, and cholinomimetic 
administration. Moreover, tremulous jaw movements in rats can be attenuated 
using antiparkinsonian agents such as L‐DOPA, dopamine agonists, muscarinic 
antagonists, and adenosine A2A antagonists. In the present studies, a mouse 
model of tremulous jaw movements was established. The focus of these studies 
was to investigate the effects of adenosine A2A antagonism, and a conditional 
neuronal knockout of adenosine A2A receptors, on cholinomimetic‐induced 
tremulous jaw movements in mice. The muscarinic agonist pilocarpine 
significantly induced tremulous jaw movements in a dose dependent manner 
(0.25‐1.0 mg/kg IP). These movements occurred largely in the 3‐7.5 Hz local 
frequency range. Administration of the adenosine A2A antagonist MSX‐3 
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(2.5‐10.0 mg/kg IP) significantly attenuated pilocarpine‐induced tremulous jaw 
movements. Furthermore, adenosine A2A receptor knockout mice showed a 
significant reduction in pilocarpine‐induced tremulous jaw movements 
compared to litter‐mate controls. These results demonstrate the feasibility of 
using the tremulous jaw movement model in mice, and indicate that adenosine 
A2A receptor antagonism and deletion are capable of reducing 
cholinomimetic‐induced tremulous jaw movements in mice. Future studies 
should investigate the effects of additional genetic manipulations using the 
mouse tremulous jaw movement model. 
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INTRODUCTION 
Resting tremor is a cardinal symptom of Parkinson’s disease (PD), 
presenting in more than 70% of patients with idiopathic PD (Deuschl et al., 
2000). Moreover, tremor and other parkinsonian symptoms can be induced by 
various drugs, including dopamine (DA) antagonists (Marsden, 1984) and 
cholinomimetics (Ott and Lannon, 1992; Song et al., 2008). In recent years, 
adenosine A2A antagonists have emerged as a potential treatment of parkinsonian 
motor impairments, including tremor (Schwarzschild et al., 2006; Ferré et al., 
2008; LeWitt et al., 2008). Adenosine A2A receptors are highly expressed in 
neostriatum, and A2A antagonists exert motor effects in rodents and primates 
that are consistent with antiparkinsonian actions (Ferre et al., 1997, 2004; Chen 
et al., 2001; Morelli and Pinna, 2001; Wardas et al., 2003; Morrelli et al., 2007; 
Salamone et al., 2008; Collins et al., 2010). Human clinical reports have 
indicated that the adenosine A2A antagonists significantly improve motor 
deficits, reduce OFF time, and increase ON time in parkinsonian patients 
(LeWitt et al., 2008; Hauser et al., 2008; Factor et al., 2010). Given the potential 
utility of adenosine A2A antagonists for the treatment of parkinsonism, further 
investigations into their behavioral effects using animal models are critical. 
One model that has proven to be useful for assessing the role of 
adenosine A2A receptors in motor function is the tremulous jaw movement 
(TJM) model, an extensively validated rodent model of parkinsonian resting 
tremor (Simola et al., 2004; Miwa et al., 2009; Collins et al., 2010a, 2011; for 
reviews, see Salamone et al., 1998; Collins-Praino et al., 2011). TJMs are 
defined as rapid vertical deflections of the lower jaw that are not directed at any 
stimulus (Salamone et al., 1998), and occur in phasic bursts of repetitive jaw 
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movement activity, with multiple movements within each burst. TJMs have 
many of the neurochemical, anatomical, and pharmacological characteristics of 
parkinsonism, and thus meet a reasonable set of validation criteria for use as an 
animal model of parkinsonian tremor (Salamone et al., 1998; Collins-Praino et 
al., 2011). These movements can be induced by many conditions that are 
associated with parkinsonism, including neurotoxic or pharmacological 
depletion of striatal dopamine (DA; Jicha et al., 1991; Salamone et al., 2008a,b), 
and acute or subchronic administration of DA antagonists (Ishiwari et al., 2005; 
Betz et al., 2007; Salamone et al., 2008). TJMs also are induced by 
cholinomimetic drugs, including muscarinic agonists such as pilocarpine, 
arecoline and oxotremorine (Salamone et al., 1986, 1998; Collins et al., 2010), 
and the anticholinesterases physostigmine, tacrine, and galantamine (Salamone 
et al. 1998; Simola et al., 2004, 2006; Collins et al. 2011). As shown by studies 
using analyses of video recordings or electromyographic methods, TJMs occur 
largely within the 3-7 Hz frequency range that is characteristic of parkinsonian 
resting tremor (Finn et al., 1997; Ishiwari et al., 2005; Collins et al., 2010). TJMs 
also can be attenuated by several classes of antiparkinsonian drugs, including 
DA agonists and anticholinergics (Cousins et al., 1997; Salamone et al., 1998, 
2005; Betz et al. 2007). In recent years, several adenosine A2A antagonists have 
been shown to significantly reverse the TJMs induced by DA depletion, DA 
antagonism and cholinomimetic administration (Correa et al., 2004; Simola et 
al., 2004; Tronci et al., 2007; Salamone et al., 2008a; Betz et al., 2009; Collins et 
al., 2010; Pinna et al., 2010; Collins et al., 2011). 
With the rising importance of genetic manipulations in mice (i.e. 
transgenic, knockout, knockin, etc.) to the field of neuroscience, it is necessary 
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to investigate whether it is possible to extend well-validated behavioral 
paradigms currently being used in rats to mouse models. The TJM model is no 
exception. Although one previous study showed that mice with a knockout of 
muscarinic M4 receptors showed significantly fewer cholinomimetic-induced 
TMMs than wild type mice (Salamone et al., 2001), every other study of TJM 
activity has employed rats. Given the putative antiparkinsonian properties of 
adenosine A2A receptor antagonists, it is of great interest to determine if mice 
with a deletion of the adenosine A2A receptor show reduced levels of TJM 
activity compared to type mice. 
The present experiments sought to determine whether mice with a 
knockout of the adenosine A2A receptor would be resistant to the development of 
pilocarpine-induced TJMs compared to their wild type littermates. In order to 
investigate this research question, several preliminary experiments were 
necessary. The first experiment studied the ability of the muscarinic agonist 
pilocarpine (0.25 mg/kg – 1.0 mg/kg) to induce TJMs in the specific strain of 
mice being used for the knockout study (C57/BL6). In the second experiment, 
the local frequency range of the TJM “bursts” induced by pilocarpine was 
characterized using freezeframe video analysis. A third study investigated the 
ability of the adenosine A2A antagonist MSX-3 to attenuate pilocarpine-induced 
TJMs. Finally, in the fourth study, both wild-type and adenosine A2A receptor 
knockout mice were assessed for pilocarpine-induced TJMs. Based upon 
previous findings, it was hypothesized that A2A knockout mice would show 
fewer tremulous jaw movements than their wild type littermates. 
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MATERIALS AND METHODS 
Animals 
Male C57BL/6 mice (25; Harlan Laboratories, Indianapolis, IN) with no 
prior drug experience were used for the first 3 studies. For the final study, a total 
of 24 neuronal A2A receptor conditional knockout mice and their littermate 
controls (12 CaMKIIα-cre, A2A flox/flox and 12 non-transgenic [no cre] A2A 
flox/flox mice) congenic for the C57BL/6 background and with no prior drug 
experience were obtained from Massachusetts General Hospital (Boston, MA; 
see Bastia et al. (2006) and Xie et al., (2006) for details on the generation of 
these mice). Mice weighed 15-40 g throughout the course of the experiment and 
had ad libitum access to lab chow and water. The mice were group-housed in a 
colony that was maintained at approximately 23  C and had a 12-h light/dark 
cycle (lights on at 0700 h). These studies were conducted according to 
University of Connecticut and NIH guidelines for animal care and use. 
Pharmacological agents 
The muscarnic agonist pilocarpine was purchased from Sigma Aldrich 
Chemical (St. Louis, MO) and dissolved in 0.9% saline. The adenosine A2A 
antagonist MSX-3 ((E)-phosphoric acid mono-[3-[8-[2-(3-
methoxyphenyl)vinyl]-7-methyl-2,6-dioxo-1-prop-2-ynyl-1,2,6,7-
etrahydropurin- 3-yl]propyl] ester) was synthesized at the Pharmazeutisches 
Institut (Universität Bonn; Bonn, Germany; Hockemeyer et al., 2004), and was 
dissolved in 0.9% saline. MSX-3 is a pro-drug of the active adenosine A2A 
antagonist, MSX-2. In order to ensure that a similar dose was also appropriate 
for use in the mouse strain used for these experiments, extensive pilot work was 
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performed; the dose of 1.0 mg/kg pilocarpine used in experiments 2-4 was based 
upon the 
results of the first experiment. 
Apparatus and testing procedures 
Observations of mice took place in a 11.5 × 9.5 × 7.5 cm clear glass 
chamber with a plastic mesh floor, which was elevated 26 cm from the table top. 
This allowed for the viewing of the mouse from several angles, including 
underneath. TJMs were defined as rapid vertical deflections of the lower jaw that 
resembled chewing but were not directed at any particular stimulus (Salamone et 
al., 1998). Each individual deflection of the jaw was recorded using a 
mechanical hand counter by a trained observer, who was blind to the 
experimental condition of the mouse being observed. Separate studies with two 
observers demonstrated an inter-rater reliability of r = 0.98 (p<0.001) using 
these methods. 
Experiments 
Experiment 1: Ability of pilocarpine to induce tremulous jaw movements. 
A group of 11 male C57BL/6 mice was used to assess the effect of pilocarpine 
(0.25 mg/kg- 1.0 mg/kg) on TJMs. All mice received IP injections of either 1.0 
ml/kg saline or 0.25 mg/kg, 0.5 mg/kg, 0.75 mg/kg, or 1.0 mg/kg pilocarpine in 
a within-groups design, with all mice receiving all drug treatments in a randomly 
varied order (one treatment per week; no treatment sequences were repeated). 
Five min after IP injection, mice were placed in the observation chamber and 
allowed 5 min to habituate. Following this habituation period, TJMs were 
counted for 10 min. 
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Experiment 2: F reeze-frame video analysis of local frequency of the 
tremulous jaw movements induced by pilocarpine. Three male C57BL/6 mice 
received an IP injection of 1.0 mg/kg pilocarpine. Five min later, mice were 
placed in a flat bottom mouse restrainer (myNeuroLab.com, Richmond, IL) so 
that a consistent view of the orofacial area could be achieved. After habituating 
for 5 min, each mouse was videotaped for 15 min using a FlipVideo UltraHD 
(Cisco Systems, Farmington, CT). The sections of these video files that allowed 
for clear observation of the orofacial area were then subjected to a freeze-frame 
analysis (1 frame = 1/30 s), in which the observer went frame-byframe through 
each burst of jaw movements (i.e., each group of at least two jaw movements 
that were within 1.0 s of each other). The observer recorded the inter-movement 
interval for each pair of jaw movements within these bursts, which was defined 
as the number of frames between each point at which the jaw was fully closed 
during successive jaw movements. This information was then used to determine 
the local frequency within bursts of jaw movements. 
Experiment 3: Ability of the adenosine A2A antagonist MSX-3 to 
attenuate the tremulous jaw movements induced by pilocarpine. A group of 11 
male C57BL/6 mice was used to assess the effects of the adenosine A2A 
antagonist MSX-3 (2.5-10.0 mg/kg) on the tremulous jaw movements induced 
by administration of 1.0 mg/kg pilocarpine. A within-groups design was utilized 
for this study, with all mice receiving all drug treatments in a randomly varied 
order (one treatment per week; no treatment sequences were repeated). On test 
day each week, each mouse was given an IP injection of either 1.0 ml/kg saline 
or 2.5 mg/kg, 5.0 mg/kg, or 10.0 mg/kg MSX-3. Ten min later, all mice received 
an IP injection of 1.0 mg/kg pilocarpine to yield the following combined 
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treatment conditions: 1.0 mg/kg pilocarpine + saline vehicle, 1.0 mg/kg 
pilocarpine + 2.5 mg/kg MSX-3, 1.0 mg/kg pilocarpine + 5.0 mg/kg MSX-3, 
and 1.0 mg/kg pilocarpine + 10.0 mg/kg MSX-3. Five min after injections, mice 
were placed in the observation chamber and allowed 5 min to habituate, after 
which TJMs were counted for 10 min. 
Experiment 4: Ability of pilocarpine to induce tremulous jaw movements 
in mice with a knockout of the adenosine A2A receptor. A total of 24 male 
C57BL/6 mice (n = 12 postnatal neuronal A2A receptor conditional KO mice 
(A2A -/-); n = 12 litter mate controls (A2A +/+)) were used to assess the effect of 
the knockout of the adenosine A2A receptor on the induction of TJMs by 1.0 
mg/kg pilocarpine. For this experiment, only homozygous A2A KO mice and 
littermate controls were used. All mice received an IP injection of 0.1 mg/kg 
pilocarpine in a between-groups design. Five min after IP injection, mice were 
placed in a glass observation chamber and allowed 5 min to habituate. Following 
this habituation period, TJMs were counted for 10 min by an observer blind to 
the condition of the mouse (i.e. littermate control vs. A2A KO). 
Statistical analysis 
The behavioral data for the first two experiments were analyzed using a 
repeated measures analysis of variance (ANOVA). Average TJMs over the two 
five-min observation periods were calculated and then used in the ANOVA 
calculations. A computerized statistical program (SPSS 12.0 for Windows) was 
used to perform these analyses. When there was a significant ANOVA, planned 
comparisons using the overall error term were used to assess the differences 
between each dose and the control condition; the total number of comparisons 
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was restricted to the number of treatments minus one (Keppel, 1991). The 
behavioral data from the knockout experiment (Experiment 4) was analyzed 
using a Student’s independent samples t-test to contrast the knockout group with 
littermate controls. A computerized statistical program (SPSS 12.0 for 
Windows) was used to perform these analyses. 
 
RESULTS 
3.1 Experiments 1 and 2: Ability of pilocarpine to induce tremulous jaw 
movements. Figure 1A shows the effects of injections of pilocarpine (0.25 
mg/kg- 1.0 mg/kg) on the induction of TJM activity. Repeated measures 
ANOVA revealed that there was a significant overall effect of drug treatment on 
TJM activity (F(4, 40) =24.46; p < 0.001). Planned comparisons showed that all 
doses of pilocarpine were capable of significantly inducing tremulous jaw 
movements (p < 0.001) compared to mice treated with saline vehicle. Figure 1B 
displays the results of the freeze-frame analyses of videotaped samples of 
pilocarpine-induced jaw movement activity in three wild-type C57BL/6 mice. A 
total of 509 jaw movements were analyzed. 83.69% of these jaw movements 
took place within “bursts,” defined as a group of at least two jaw movements 
that were within 1.0 s of each other. Data are shown as the number of inter-
movement intervals (i.e., the number of 1/30 sec frames that elapsed from jaw 
closing through jaw opening to the next jaw closing during each movement) 
from jaw movements in bursts, assigned to four different frequency bins. To 
interpret these data in terms of frequencies (i.e. jaw movements per second), the 
reciprocal of the inter-movement interval was calculated (e.g. 10/30 frames per 
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second corresponds to 3 Hz; 4/30 frames per second to 7.5 Hz, etc.) The 
majority (77.60%) of the jaw movement activity took place in the 3.0-7.5 Hz 
frequency range. There were no jaw movements in the 1-3 Hz or > 10 Hz bins. 
 
Fig 1A, B. (A): Effects of different doses of pilocarpine (IP) on tremulous jaw 
movements. Mean (+SEM) number of jaw movements in mice (n = 11) treated 
with either saline vehicle or pilocarpine. **significant difference from vehicle 
control (p < 0.05). (B): This figure shows the results of the freeze-frame analysis 
of inter-movement intervals using the video analysis methods described above. 
Inter-movement times were determined by freeze-frame analysis of video 
obtained from 3 mice treated with 1.0 mg/kg pilocarpine, and were assigned to 
one of four local frequency bins. Distribution of the mean (+ SEM) number of 
inter-movement intervals within each frequency bin is shown. 
 
3.2 Experiments 3 and 4: Ability of the adenosine A2A receptor 
antagonism and knockout attenuate the tremulous jaw movements induced by 
pilocarpine. Co-administration of the adenosine A2A antagonist MSX-3 
attenuated the TJMs induced by a dose of 1.0 mg/kg pilocarpine (Figure 2A). 
Repeated measures ANOVA revealed that there was a significant overall effect 
of MSX-3 treatment on the induction of TJMs by 1.0 mg/kg pilocarpine (F(3,30) 
= 35.88; p < 0.001). Planned comparisons showed that the 2.5, 5.0 and 10.0 
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mg/kg doses of MSX-3 were capable of significantly reducing the TJMs induced 
by 1.0 mg/kg pilocarpine (i.e., compared to pilocarpine plus saline; p < 0.05). 
Figure 2B shows the effects of injection of 1.0 mg/kg pilocarpine on the 
induction of TJM activity in mice homozygous for neuronal knockout of the 
adenosine A2A receptor (A2A -/-) and littermate controls (A2A +/+). An 
independent samples t-test revealed that adenosine A2A neuronal knockout mice 
showed significantly fewer TJMs than the littermate controls (t (22) =2.45; p < 
0.05). 
 
Fig 2A,B. (A): Effect of the adenosine A2A antagonist MSX-3 on the tremulous 
jaw movements induced by 1.0 mg/kg pilocarpine. Mean (+ SEM) number of 
jaw movements in mice (n = 11) treated with pilocarpine plus vehicle 
(Veh/Pilo), and pilocarpine (Pilo) plus various doses (2.5, 5.0 and10.0 mg/kg IP) 
of MSX-3. *significant difference from pilocarpine plus vehicle control (p< 
0.05). (B): Effect of neuronal adenosine A2A receptor knockout on the tremulous 
jaw movements induced by 1.0 mg/kg pilocarpine. Mean (+ SEM) number of 
jaw movements in knockout mice (n = 12) and littermate controls (n = 12) 
treated with pilocarpine. *significant difference from littermate controls (p < 
0.05) 
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DISCUSSION 
The current studies describe the development of a mouse model of TJM 
activity. The first experiment investigated the ability of the muscarinic agonist 
pilocarpine to induce TJMs in C57BL/6 mice. Acute administration of 
pilocarpine has been well documented to induce TJMs in rats (Salamone et al., 
1986, 1998; Finn et al., 1997; Betz et al., 2007; Collins et al., 2010). Pilocarpine 
administration was able to induce TJM activity in C57BL/6 mice at all doses 
tested (i.e. 0.25-1.0 mg/kg). This is consistent with findings from a previous 
study indicating that administration of pilocarpine induced tremulous jaw 
movements in 129SvEv (50%) × CF1 (50%) mice (Salamone et al., 2001). Local 
frequency analysis of the pilocarpine-induced jaw movements in mice using 
freeze frame video analysis indicated that the TJMs induced by pilocarpine 
occurred largely in the 3-7.5 Hz frequency range, which is consistent with the 
findings from previous studies of the local frequency of TJMs induced by DA 
depletion, D2 antagonism, and administration of cholinomimetic drugs in rats 
(Finn et al., 1997; Ishiwari et al., 2005; Collins et al., 2010). Moreover, this 3-
7.5 Hz frequency range is similar to that reported during resting tremor in 
parkinsonian patients (Deuschl et al., 2000, 2001). These findings are consistent 
with the hypothesis that the oral motor movements induced by acute pilocarpine 
administration are potentially a useful mouse model of parkinsonian resting 
tremor.  
Taken together with previous studies, the finding that pilocarpine 
administration is capable of significantly inducing tremulous jaw movements in 
mice highlights the role that Ach plays in striatal motor functions related to 
parkinsonism. Cholinomimetic drugs, such as muscarinic agonists and 
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anticholinesterases used for the treatment of Alzheimer’s disease, have been 
shown to induce or exacerbate parkinsonian symptoms, including tremor, in 
humans (Ott and Lannon, 1992; Song et al., 2008; Collins-Praino et al., 2011). In 
addition, muscarinic receptor antagonists have been used as treatments for the 
motor symptoms of parkinsonism (Bezchlibnyk-Butler and Remington, 1994). 
Furthermore, several studies have implicated neostriatal muscarinic receptors in 
the regulation of TJM activity (Salamone et al., 1998; Betz et al., 2007, 2009). 
Tremor responds relatively poorly to most currently available 
antiparkinsonian medications, including L-DOPA (Bain, 2002). In recent years, 
adenosine A2A antagonists have emerged as a potential treatment of parkinsonian 
motor impairments. One clinical report suggested that tremor was particularly 
sensitive to the effects of adenosine A2A antagonism (Barra-Jimenez et al., 
2003). Adenosine A2A receptors are highly expressed in neostriatum, and A2A 
antagonists exert motor effects in rodents and primates that are consistent with 
antiparkinsonian actions (Ferre et al., 1997, 2004; Chen et al., 2001; Morelli and 
Pinna, 2001; Hauser and Schwarzschild, 2005; Morrelli et al., 2007; Salamone et 
al., 2008; Collins et al., 2010). For that reason, the final two experiments sought 
to investigate the ability of adenosine A2A receptor antagonism or genetic 
deletion to attenuate the TJMs induced by 1.0 mg/kg pilocarpine. In experiment 
3, the adenosine A2A antagonist MSX-3 significantly attenuated 
pilocarpineinduced TJMs, which is consistent with previous findings in rats 
(Correa et al., 2004; Simola et al., 2004; Tronci et al., 2007; Salamone et al., 
2008; Pinna et al., 2010; Collins et al., 2010, 2011). Furthermore, deletion of the 
adenosine A2A receptor also resulted in significantly lower levels of pilocarpine-
induced TJMs compared to wild-type mice. This is consistent with previous 
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research, which has shown that knockout of the adenosine A2A receptor is 
capable of reversing the catalepsy induced by the DA D2 antagonist haloperidol 
(Chen et al., 2001; El Yacoubi et al., 2001), the DA D1 antagonist SCH 23390 
(El Yacoubi et al., 2001), and the muscarinic agonist pilocarpine (El Yacoubi et 
al., 2001). Moreover, genetic deletion of the adenosine A2A receptor in mice has 
been shown to alter the locomotor response to adenosine antagonists (Yu et al., 
2008), and to affect amphetamine sensitization (Chen et al., 2003), drug self-
administration of cocaine and MDMA (Ruiz-Medina et al., 2011), aspects of 
cognition (Wei et al., 2011), and effort-related choice behavior (Pardo et al., 
2012). Furthermore, striatal adenosine A2A receptors appear to be required for 
the motor stimulating effects of adenosine A2A antagonists, because mice lacking 
these receptors showed an absence of motor stimulation in response to adenosine 
A2A antagonists (Yu et al., 2008; Wei et al., 2011). 
Taken together, these results demonstrate the feasibility of using the 
tremulous jaw movement model in mice, and indicate that adenosine A2A 
receptor antagonism and deletion are capable of reducing cholinomimetic-
induced TJMs in mice. The results of these experiments add to the growing body 
of evidence demonstrating that adenosine A2A function is involved in regulating 
motor functions in animals that are potentially related to parkinsonism. 
Additional studies will seek to more completely characterize the effect of 
adenosine A2A receptor deletion on motor function, and future research should 
investigate the effects of additional genetic manipulations using the mouse TJM 
model, including regionally-specific knockout of A2A receptors (e.g. Lazarus et 
al., 2011). 
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